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Hundreds of microRNAs are expressed in mammalian cells where they modulate gene 
expression by mediating transcript cleavage and/or regulation of translation. 
Functional studies to date have demonstrated that several of these microRNAs are 
important during development and disease. However, the role of microRNAs in the 
regulation of stem cell growth and differentiation is not well understood. It was 
shown, firstly, that microRNA (miR)-134 levels increase during retinoic acid- or 
N2B27-induced differentiation of mouse embryonic stem cells (mESCs). Secondly, 
elevation of miR-134 levels in mESCs enhances differentiation towards ectodermal 
lineages, an effect that is selectively blocked with a miR-134 antagonist. MiR-134’s 
promotion of mESC differentiation is due, in part, to its direct translational 
attenuation of Nanog, LRH1 and Sox2, known positive regulators of Oct4/POU5F1 
and mESC growth. Together, the data demonstrate that miR-134 alone can enhance 
the differentiation of mESCs to ectodermal lineages; additionally, they establish a 
functional role for miR-134 in modulating mESC differentiation through its potential 
to target and regulate multiple mRNAs.       
 
Experimental validation of rna22, a method for identifying microRNA binding sites 
and their corresponding heteroduplexes, is presented. rna22 does not rely upon cross-
species conservation, is resilient to noise, and, unlike previous methods, it finds 
putative microRNA binding sites in the sequence of interest before identifying the 
targeting microRNA. In a luciferase reporter screen, average repressions of 30% or 
more for 168 of 226 tested 3’UTR targets are obtained. The analysis suggests that 
some microRNAs may have as many as a few thousand targets, and that between 74% 
 i
and 92% of the gene transcripts in four model genomes are likely under microRNA 
control. 
 
Computational analyses by rna22 suggests that fairly extensive microRNA regulation 
may be effected through the 5′ untranslated regions (UTRs) and coding sequences 
(CDSs) of gene transcripts in animals, in addition to 3′UTRs. To explore the 
possibility of microRNA targeting outside the 3′UTR of a transcript, two distinct, 
non-overlapping rna22-predicted targets for miR-296 in the CDS of Nanog were 
pursued experimentally. Reporter assays, quantitative PCR, and Western blot analyses 
demonstrated that miR-296 post-transcriptionally regulates Nanog by acting 
independently on each of these two binding sites. Silent mutations at these sites 
abolish Nanog’s down-regulation by miR-296. To demonstrate that this is not an 
isolated incident of coding region targeting, similar experiments were performed to 
validate a single rna22-predicted target for miR-134 in the coding region of Sox2. 
Considered together, the results show that miR-296 and miR-134 repress the 
translation of Nanog and Sox2 mRNAs respectively via their interactions with 
specific CDS elements, and provide the first examples of animal microRNAs 
targeting genes in their coding regions. 
 
The combined data imply that, by controlling specific genesets, microRNAs have a 
powerful influence on how mESCs sense and respond to their environment. This is 
further highlighted by the observation that each microRNA may potentially target 
hundreds or even thousands of genes. Additionally, the existing number of 
microRNAs, coupled with the continual discovery of novel microRNAs, suggests that 
they may be involved in many aspects of post-transcriptional regulation in stem cells. 
 ii
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CHAPTER 1.  INTRODUCTION       
1.1   Embryonic stem cells 
1.1.1   History  
 
In the 1970s, the search for a cell culture platform to study early embryonic 
development led to the isolation of stem cells from teratocarcinomas. 
Teratocarcinomas are malignant gonadal tumors consisting of differentiated cell types 
from the three embryonic germ layers (endoderm, mesoderm and ectoderm), as well 
as a significant population of undifferentiated cells, termed embryonic carcinoma 
(EC) cells, which resemble early embryonic cells (Martin and Evans, 1975). EC cells 
could be expanded continuously in culture while retaining the capacity to differentiate 
into derivatives of all three germ layers (Kleinsmith & Pierce 1964, Martin & Evans 
1975). However, these cancer-derived EC cells have an aneuploid karyotype (Martin, 
1980), possibly due to uncontrolled selection pressures during tumour growth, and are 
thus incapable of undergoing meiosis to produce mature gametes (Smith, 2001).  
 
Nevertheless, studies with EC cells were of vital importance in establishing the 
technical expertise necessary for the derivation of embryonic stem cells (ESCs) 
(Evans and Kaufman, 1981; Martin, 1981; Stevens, 1970; Stevens et al., 1977; 
Stevens LC, 1978). A crucial insight was the discovery that EC cells thrived and 
maintained a high differentiation capacity when co-cultured with mitotically 
inactivated embryonic fibroblast cells (Martin et al. 1977; Martin & Evans, 1975), but 
did poorly when cultured in isolation. As these fibroblasts appeared to be providing 
some essential nutrient or trophic factor, they were described as feeder cells (Friel et 
al., 2005; Smith, 2001). 
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This discovery was instrumental in enabling the successful isolation and culture of 
ESCs from mouse blastocysts, described by two groups of scientists in 1981 (Evans 
and Kaufman, 1981; Martin, 1981). Embryos at the expanded blastocyst stage are first 
plated, either intact or after immunosurgical isolation of the inner cell mass (ICM), 
onto a layer of feeder cells (Smith, 2001). The mass of cells is dissociated and 
replated onto a fresh feeder layer several days later. Along with various types of 
differentiated colonies, colonies with a characteristic undifferentiated morphology 
arise that are individually dissociated, replated and expanded to establish ESC lines 
(Figure 1.1) (Robertson, 1987). 
 
 
Figure 1.1. Origin and differentiation potential of mESCs. 
 
 
1.1.2   Properties & Potential  
 
ESCs are pluripotent, ie. they possess the dual properties of unlimited self-renewal 
without senescence and the ability to differentiate into cell types of all three germ 
layers in vitro. Furthermore, tumours generated from ESCs contain endodermal, 
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ectodermal and mesodermal tissue and cell types (Evans and Kaufman, 1983); and 
ESCs (unlike EC cells) are able to participate fully in fetal development when 
reintroduced into an embryo (Smith, 2001).  
 
The drive to develop ESC-based systems stems from this potential of ESCs to 
differentiate into all cell types in the body. Although the clinical use of adult stem 
cells, which are present in multiple tissues in the mammalian body, is attractive due to 
the lack of allogenecity, adult stem cells are only able to differentiate into multiple 
cell types of a specific tissue, organ or physiological system (Erlandsson and 
Morshead, 2006; Mimeault and Batra, 2006; Serakinci and Keith, 2006). Aside from 
their limited differentiation potential, adult stem cells are also unable to self-renew 
indefinitely in culture and can be difficult to isolate (Erlandsson and Morshead, 2006; 
Mimeault and Batra, 2006; Serakinci and Keith, 2006). These properties limit their 
use as a scaleable, continous resource for generating multiple cell types for cell-based 
therapies.  
 
ESCs have been instrumental in enabling groundbreaking research into drug 
discovery facilitated by high throughput screening, and hold much promise for cell-
based therapy to treat a whole spectrum of degenerative diseases and injuries. 
Although the more recently-derived human ESCs (hESCs) are undisputedly a better 
disease model than mESCs, at the time this project began, the advantages of using 
mESCs as a model to elucidate the role and mechanisms of microRNAs in modulating 
pluripotency and differentiation outweighed those of hESCs. For example, mESCs 
can be used to generate gene knockouts which can be reintroduced into embryos to 
better elucidate the role of these genes of interest in development. They also have a 
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shorter doubling time, are more stable karyotypically, and do not require a feeder 
layer for indefinite self-renewal in culture. 
 
 
1.1.3   Maintaining Pluripotency: LIF, BMP & Wnt Signalling 
 
One of the major breakthroughs in ESC maintenance was reported in 1988, when 
leukemia inhibitory factor (LIF), a member of the IL-6 cytokine family, was identified 
as a major factor which enabled mESCs (mESCs) to self-renew indefinitely in an 
undifferentiated state without a feeder layer (Smith et al., 1988, Williams et al., 
1988). This enabled the feeder-free culture of mESCs in growth medium 
supplemented with serum and recombinant LIF. LIF stimulates mESCs by binding to 
a heterodimeric LIF receptor (LIFR)-gp130 signaling complex that activates two 
major signaling pathways,  the  canonical JAK-STAT (Janus-associated tyrosine 
kinase, signal transducer and activator of transduction) pathway and the Src homology 
2 (SHP2)-Erk pathway (Rao, 2004).   
 
Activation of the JAK-STAT pathway results in JAK-mediated phosphorylation of 
STAT3, leading to the formation of homodimers which subsequently translocate to 
the nucleus where they regulates transcription of genes involved in the self-renewal of 
ESCs (Niwa et al., 1998). This activation of STAT3 is necessary for LIF to maintain 
the self-renewal of mESCs (Niwa et al., 1998), and it alone is sufficient to prolong 
mESC self-renewal in the absence of LIF (Matsuda et al., 1999). Conversely, LIF-
induced activation of the SHP2-Erk pathway in mESCs is a promoter of 
differentiation, and may be a negative regulatory mechanism for STAT3 (Burdon et 
al., 1999; Cheng et al., 1998; Liu et al., 2006). In this context, the balance between 
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LIF-induced STAT3 activation and ERK signaling is a critical modulator of mESC 
self-renewal (Burdon et al., 1999). Intriguingly, LIF signaling is not required for the 
maintenance of hESC pluripotency. The report by Nichols et al. that LIFR gp130 -/- 
mouse embryos can develop and be used to establish ESC lines, coupled with the 
observation that LIF is unable to sustain mESCs in the absence of serum, suggests 
that other pathways may play a role in maintaining mESC pluripotency (Nichols et 
al., 2001; Pan and Thomson, 2007).  
 
The factor present in serum which is essential for mESC self-renewal is likely to be 
bone morphogenetic protein (BMP), a member of the transforming growth factor 
(TGF)-β superfamily (Liu et al., 2006). This is supported by a study by Ying et al. 
which demonstrated that successful derivation and maintenance of ESC lines was 
possible in serum-free medium supplemented with LIF and BMP (Wilson et al., 1995; 
Ying et al., 2003). BMP signaling activates cytoplasmic proteins called SMADs 
(mothers against dpp related), which subsequently induce the expression of Id 
(inhibitor of differentiation) genes. Id proteins antagonize neurogenic basic Helix-
Loop-Helix (bHLH) transcription factors and block neural differentiation of ESCs 
(Ying et al., 2003). Expression of Id1, Id2 or Id3 is able to compensate for the 
presence of BMP in mESC cultures supplemented with LIF (Ying et al., 2003). 
 
In addition to LIF and BMP signaling, recent studies have postulated a role for the 
Wnt pathway in the maintenance of ESC pluripotency. Wnt signaling is endogenously 
activated in mESCs, and is downregulated during differentiation (Sato et al., 2004). 
Sato et al. show that Wnt pathway activation by a specific pharmacological inhibitor 
of glycogen synthase kinase-3 (GSK-3), 6-bromoindirubin-3V-oxime (BIO), is able to 
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maintain ESCs in an undifferentiated state and sustain expression of the pluripotency 
markers Oct4, Rex1 and Nanog (Sato et al., 2004). Taken together, the contributions 
of the LIF, BMP and Wnt pathways to maintaining mESC pluripotency are suggestive 




1.1.4   Maintaining Pluripotency: Transcription Factors 
 
External signaling pathways such as the abovementioned LIF, BMP and Wnt 
eventually lead to the regulation of several genes that are critical for the maintenance 
of mESC self-renewal and pluripotency, such as Oct4, Sox2 and Nanog. The direct 
activation of these transcription factors have been found to influence ESC growth and 
differentiation. 
 
The Pit, Oct, Unc (POU)-domain transcription factor Oct4 (also known as Oct3), 
which is encoded by Pou5f1, is an important regulator of pluripotency in vivo (Pan et 
al., 2002). Oct4 expression, which begins at the four-cell stage during mouse 
embryogenesis, is restricted to totipotent and pluripotent cells and is downregulated in 
most adult tissues except the germ line (Pesce et al., 1998; Yeom et al., 1996). Mouse 
embryos lacking Oct4 do not have pluripotent ICM and thus cannot develop past the 
blastocyst stage (Nichols et al., 1998). This suggests that Oct4 is an essential 




Oct4 also acts as a gatekeeper for in vitro ESC pluripotency at the crossroads between 
self-renewal and lineage specification (Nichols et al., 1998; Stefanovic & Puceat, 
2007). Its expression is high in undifferentiated mESCs, and decreases during 
differentiation (Pan and Thomson, 2007). Precise levels of Oct4 are required for the 
maintenance of pluripotent ESCs: Reduction of Oct4 expression to 50% or less 
induces trophectodermal differentiation, while overexpression causes differentiation 
to primitive endoderm and mesoderm (Yeom et al., 1996; Niwa, 2001; Niwa et al., 
2000).  
 
Oct4 binds to the DNA octamer motif ATGCAAAT in the promoter or enhancer 
regions of numerous ESC-specific genes to regulate their transcription (Puceat, Han). 
Target genes of Oct4 that have been identified thus far include Fgf4, Hand1, Utf1, 
Opn, Rex1/ Zfp42, Fbx15, and Sox2 (Nishimoto et al., 1999; Tomioka et al., 2002; 
Zeng et al., 2004). Oct4 can cooperate with other transcription factors to activate or 
repress target genes (Guo et al., 2002; Yuan et al., 1995). One such transcription 
factor is the SRY-related HMG family member, Sox2 (Avilion et al., 2003).  
 
Sox2 is abundantly expressed in mESCs, where its knockdown induces differentiation 
into multiple lineages (Ivanova et al., 2006). Interestingly, Sox2 expression in vivo 
differs to that of Oct4, where its earliest detection is at the morula stage (E2.5), 
continutes in the ICM (E3.5), epiblast (E6.5), extraembryonic lineages and throughout 
the neural plate; before it becomes restricted to stem cells, neural, gut and germ cells  
(Graham et al., 2003; O’Shea, 2004). In addition,  Sox2-null embryos die immediately 
after implantation (Avilion et al., 2003). These data demonstrate that, similar to Oct4, 
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Sox2 plays an important role during development in vivo as well as in mESC 
pluripotency and differentiation.  
 
However, the expression of Oct4 alone does not prevent ESC differentiation in the 
absence of LIF, suggesting that other factors may be important regulators of ESC 
pluripotency (Pan and Thomson, 2007). In 2003, a novel factor that is instrumental for 
maintaining ESC pluripotency was identified (Chambers et al., 2003; Mitsui et al., 
2003). Nanog, a homeobox transcription factor named after the mythical land of the 
ever young Tir Na Nog, is expressed in mouse ES, EC and embryonic germ cells, is 
downregulated during differentiation, and is not expressed in adult tissues or 
differentiated cells (Chambers et al., 2003, Mitsui et al., 2003). Mouse ESCs 
overexpressing Nanog are able to self-renew in the absence of LIF, which suggests 
that Nanog may be a major regulator of pluripotency (Chambers et al., 2003, Mitsui et 
al., 2003). These two groups also found that although Nanog acts in concert with LIF, 
it does not modulate either the LIF or BMP signaling pathways. In addition, 
disruption of Nanog in ESCs causes differentiation into Gata-6 positive parietal 
endoderm-like cells (Mitsui et al., 2003).  
 
Nanog is also a critical regulator of cell fate in vivo: ICM cells in Nanog-null mice 
spontaneously differentiate into visceral and parietal endoderm (Mitsui et al., 2003). 
Nanog expression can be detected in the morula, ICM, early germ cells and proximal 




Genome-wide chromatin immunoprecipitation (CHIP), microarray expression 
profiling and RNA interference assays have identified numerous target genes of 
Nanog, Oct4 and Sox2 (Boyer et al., 2005, 2006; Ivanova et al., 2006; Loh et al., 
2006; Rao and Orkin, 2006). In mESCs, Loh et al. describe 1083 and 3006 binding 
sites for Oct4 and Nanog respectively, with substantial overlap between the two gene 
sets. The core downstream targets include genes related to pluripotency, self-renewal 
and cell fate determination such as Oct4, Sox2 and FoxD3 (Loh et al., 2006). Oct4, 
Nanog and Sox2 appear to regulate themselves, and each other, and form a 
transcriptional regulatory feedback circuit that is essential for the maintenance of ESC 
pluripotency (Boyer et al., 2005, 2006; Ivanova et al., 2006; Loh et al., 2006; Rao and 
Orkin, 2006). 
 
Although this transcriptional regulatory network is crucial for keeping ESCs in a 
undifferentiated state, other factors may also be important for the maintenance of 
pluripotency. One such example may be epigenetic processes such as the modification 
of DNA, histones or chromatin structure, as transcription factor activity is dependent 
on the accessibility of target genes (Jaenisch and Bird, 2003; Niwa et al., 2000; Mitsui 
et al., 2003; Chambers et al., 2003; Boyer et al., 2005; Niwa et al., 2005; Boyer et al., 
2006; Meshorer and Misteli, 2006). Chromatin modification factors such as histone 
deacetylases (HDACs), methyl-CpG-binding proteins (MECPs) and polycomb group 
proteins (PcG) are differentially expressed as ESCs differentiate, and may be crucial 
modulators of self-renewal and differentiation (Rao, 2004). 
 
Another factor which may be involved in maintaining the pluripotent state of ESCs is 
a class of recently-discovered small non-coding RNAs, microRNAs, which have been 
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shown to play vital roles in gene regulation (Bartel, 2004). Genome-wide CHIP 
analyses in mESCs by Loh et al. demonstrated that Nanog bound to sites within 30 kb 
of 5 microRNA genes, and that Oct4 and Nanog co-occupied sites near 2 of these 
genes (Loh et al., 2006). Boyer et al. showed that Oct4, Nanog and Sox2 were 
associated with 14 microRNA genes in hESCs, and  co-occupied the promoters of 2 
of these genes (Boyer et al., 2005). These results imply that microRNA genes are 
likely to be regulated by Oct4, Sox2 and Nanog in both mESCs and hESCs, and may 
thus be important regulators of pluripotency and self-renewal. Furthermore, the 
network of regulatory interactions that exists in ESCs as suggested by the CHIP data 
offers the intriguing possibility that these transcription factors may in turn be 
regulated by microRNAs, adding to the complexity of environmental sensing and 






1.2   MicroRNAs 
1.2.1   Function 
 
MicroRNAs, a family of small (~22 nucleotides long), noncoding RNAs similar to the 
siRNAs involved in RNA silencing, originate from stem-loop precursors in the 
genome. They have been shown to play important roles in diverse processes including 
apoptosis, fat metabolism, cancer, major signaling pathways, tissue morphogenesis 
and development.  
 
For example, Bantam and miR-14 have been implicated in programmed cell death in 
Drosophila. Bantam inhibits apoptosis by regulating the proapoptotic gene hid 
(Brennecke et al., 2003), while miR-14 suppressESC death by acting on a yet 
unknown cellular target (Xu et al., 2003). Intriguingly, miR-14 mutants are also 
phenotypically obese with elevated levels of triacylglycerol. This suggests that miR-
14 may be involved in fat metabolism (Xu et al., 2003). 
 
MicroRNA expression signatures are associated consistently with several types of 
cancers and cancer cell lines (McManus, 2003; Metzler et al., 2004; Takamizawa et 
al., 2004; Lu et al., 2005; Miska, 2005). Calin et al. demonstrated that the region on 
chromosome 13q14 containing miR-15 and miR-16 is deleted in the majority of 
chronic lymphocytic leukemia cases (Calin et al., 2002). Moreover, microRNA 
expression profiling in cancer patients has potential prognostic value as expression 
levels of miR-155 in B cell lymphoma patients and let-7 in lung cancer are indicative 
of patient survival (Kloosterman and Plasterk, 2006). 
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A number of microRNAs exhibit distinct spatial and temporal expression patterns 
during development (Aboobaker et al., 2005; Ason et al., 2006; Kloosterman et al., 
2006; Wienholds et al., 2005). Additionally, some microRNA expression patterns 
show species conservation, eg. miR-1 in muscles, miR-124 in the central nervous 
system and miR-10 in anterior-posterior patterning (Kloosterman and Plasterk, 2006). 
These observations indicate that microRNAs may be involved in the specification and 
maintenance of tissue identity and other facets of development. This is supported by 
studies which show that animals without mature microRNAs are not viable, eg. Dicer-
deficient mice die at embryonic day 7.5 and lack multipotent stem cells (Bernstein et 
al., 2003; Ketting et al., 2001; Wienholds et al., 2003). 
 
Studies in invertebrate model systems have identified lsy-6, the first microRNA found 
to play a role in neuronal patterning (Johnston and Hobert, 2003), and miR-9a, which 
ensures the generation of the precise number of neuronal precursor cells during 
development (Li et al., 2006). In vertebrate models, the restoration of a single 
microRNA (miR-430) in zebrafish modified to prevent production of endogenous 
microRNAs ameliorated deficits in neuroectodermal development and neuronal 
differentiation (Giraldez et al., 2005). MicroRNA regulation of Hox expression 
modulates developmental patterning processes to allow the generation of asymmetric 
morphology (Mansfield et al., 2004; Yekta et al., 2004).  
 
In mammals, specific microRNAs have been shown to regulate B cell differentiation 
(Chen et al., 2004), adipocyte differentiation (Esau et al., 2004), and insulin secretion 
(Poy et al., 2004). MicroRNAs have also been found to play key roles during neural 
differentiation in vitro (Krichevsky et al., 2006; Smirnova et al., 2005), and in 
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vertebrate central nervous system development (Giraldez et al., 2005; Krichevsky et 
al., 2004; Miska et al., 2004). In particular, miR-134 has been recently identified as a 
potential regulator of dendritic spine volume and synapse formation in mature rat 
hippocampal neurons in vitro through the localized repression of a protein kinase 
LimK1 (Schratt et al., 2006). The mouse homologue of miR-134, which demonstrates 
conservation across rodents and primates, was originally identified by cloning from 
the mouse cortex (Lagos-Quintana et al., 2002) and is located in a large imprinted 
microRNA gene cluster at the mouse Dlk1-Gtl2 domain (Seitz et al., 2004).  
 
Thus far, microRNAs have been found in diverse species including Arabidopsis 
thaliana, Caenorhabditis elegans, Drosophila melanogaster, Danio rerio, Mus 
musculus, Homo sapiens and even the Epstein Barr virus (miRBase; Griffiths-Jones, 
2006). As of December 2007, miRBase, a searchable database of published 
microRNA sequences and annotations, contained a total of 5395 entries. New 
microRNAs which have been identified and validated will be added to this repository. 
 
 
1.2.2   Identification 
 
Thus far, three approaches have been used successfully for microRNA discovery: 
forward genetics, the cloning and sequencing of size-fractionated cDNA libraries, and 
computational prediction. The first microRNA genes, lin-4 and let-7, were identified 
using forward genetics. Lin-4 was found to be responsible for a defective cell lineage 
in a Caenorhabditis elegans mutant (Lee et al., 1993). It had a large ~ 60 nt form 
which folded into a hairpin structure, and a small ~ 22 nt form which originated from 
the stem of the hairpin and repressed lin-14 gene expression via imperfect pairing 
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with its 3’ untranslated region (UTR) (Wightman et al., 1993). The discovery of let-7 
in C. elegans generated considerable interest in the microRNA field as it was 
conserved among a diverse range of phylogenetic taxa (Pasquinelli et al., 2000; 
Reinhart et al., 2000; Slack et al., 2000). This suggested that gene regulation by 
microRNAs may be more widespread and pervasive than previously thought. Four 
other microRNAs, bantam, miR-14, miR-278 and lsy-6, have also been identified by 
forward genetics (Brennecke et al., 2003; Johnston and Hobert, 2003; Teleman et al., 
2006; Xu et al., 2003). However, as a result of factors such as the small size of 
microRNAs, their tolerance to mutations and redundancy, forward genetics is a 
relatively inefficient method of discovering microRNAs (Abbott et al., 2005).  
 
Another approach useful for microRNA identification is the sequencing of size-
fractionated cDNA libraries. This protocol, which was originally used to clone small 
interfering RNA molecules (Elbashir et al., 2001), has been adapted by various 
groups for the successful identification of the majority of the microRNAs known 
today. Briefly, following size-fractionation of an RNA sample in a denaturing 
polyacrylamide gel, 5’ and 3’ adapters are added to the 20-25 nt fraction. RT-PCR is 
performed next, followed by the optional concatamerization of cDNAs into large 
fragments which increases the amount of sequence information obtainable (Berezikov 
et al., 2006, Lagos-Quintana et al., 2001; Lau et al., 2001; Pfeffer et al., 2003). These 
fragments are then cloned into vectors, sequenced and analyzed. However, 
microRNAs that have low, temporal or cell-type specific expression levels, and 
microRNAs that have specific sequence composition or post-transcriptional 
modifications may not be detected using this method (Luciano et al., 2004; Yang et 
al., 2006; Yang et al., 2006). 
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These cloning approaches provided enough information for scientists to recognize 
several distinctive properties of microRNAs, and begin to develop computer 
algorithms for microRNA prediction (Bentwich, 2005; Berezikov and Plasterk, 2005). 
All microRNA prediction approaches use secondary structure information as the 
hairpin loop is a defining microRNA characteristic. They also rely on one or more of 
the following: (1) Phylogenetic conservation of sequence and structure, (2) 
Thermodynamic stability of hairpins, (3) Similarity to known microRNAs in terms of 
sequence and structure, (4) Genomic location, as many microRNAs are found in 
clusters or in close proximity (Altuvia et al., 2005; Berezikov et al., 2006; Lau et al., 
2001; Seitz et al., 2004). All predicted candidate microRNAs need to be validated 
experimentally. Expression of the ~22 nt long mature microRNAs can be 
demonstrated using techniques such as northern blot analysis, primer extension, 
microRNA QUANTITATIVE PCR and/or in situ hybridization.  
 
 
1.2.3   Biogenesis 
 
Most mammalian microRNA genes (~70%) are found in defined transcription units, 
with about half of known microRNAs located in close proximity to other microRNAs 
(Lagos-Quintana et al., 2001; Lau et al., 2001; Mourelatos et al., 2002; Rodriguez et 
al., 2004). Many microRNAs are in the introns of protein-coding transcription units, 
while others are in the introns or exons of non-coding transcription units (Kim, 2005; 
Rodriguez et al., 2004). Although RNA polymerase (Pol) III was initially thought to 
mediate microRNA transcription as it transcribes most small RNAs, some microRNA 
precursors contain stretches of five or more uracils, which is a termination sequence 
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for Pol III (Lee et al., 2002). Increasing evidence suggests that microRNA gene 
transcription is mediated mainly by RNA Pol II: (1) Some microRNA precursors 
contain both cap structures and poly(A) tails; (2) MicroRNA transcription activity 
demonstrates sensitivity to conditions that specifically inhibit Pol II and not Pol I or 
III; (3) CHIP analyses show the physical association of Pol II with a microRNA 
promoter (Cai et al., 2004; Lee et al., 2004).  
 
MicroRNA transcription produces primary microRNA transcripts (pri-microRNAs), 
which contain a hairpin structure and may be up to several kilobases in length (Figure 
1.2) The nuclear RNase III enzyme Drosha cleaves the stem-loop to release precursor 
microRNAs (pre-microRNAs) (Lee et al., 2003). Drosha, a large protein which is 
evolutionarily conserved in animals, contains two RNase III domains (RIIIDs) and a 
double-stranded RNA-binding domain (dsRBD) that are essential for its function 
(Filippov et al., 2000; Fortin et al., 2002; Han et al., 2004; Wu et al., 2000). Drosha 
forms a complex with the double-stranded-RNA-binding protein DiGeorge syndrome 
critical region gene 8 (DGCR8, also known as Pasha in D. melanogaster and C. 
elegans) (Denli et al., 2004; Han et al., 2004; Gregory et al., 2004; Landthaler et al., 
2004). Gregory et al. have shown via knock-down in vivo and reconstitution in vitro 
studies that this Microprocessor complex is necessary and sufficient for the genesis of 
microRNAs from pri-microRNAs (Gregory et al., 2004). Drosha cleavage creates a 
short ~2 nucleotide overhang at the 3’ end, which is recognized by the downstream 
biogenesis factors and also generates one end of the mature microRNA (Lee et al., 
2003; Lund et al., 2004). 
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After Drosha processing, pre-microRNAs are exported out of the nucleus through 
nuclear pore complexes (Nakielny et al., 1999). Pre-microRNA export is mediated by 
exportin-5, a nuclear transport receptor, in a process requiring the hydrolysis of GTP 
to GDP (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 2003). Cullen et al. 
utilized mutational analyses to demonstrate that an RNA stem of more than 16 base 
pairs and a short 3’ overhang are important requirements for the export of pre-
microRNAs (Zeng and Cullen, 2004). 
 
 
Figure 1.2. MicroRNA biogenesis. See text for details. 
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Pre-microRNAs are next cleaved by the cytoplasmic RNase III enzyme Dicer, which 
is also involved in siRNA genesis, to produce ~22 nucleotide microRNA duplexes 
(Bernstein et al., 2001; Grishok et al., 2001; Hammond et al., 2000; Hutvagner et al., 
2001; ketting et al., 2001; Knight et al., 2001). Like Drosha, Dicer is highly 
conserved evolutionarily and contains two RIIIDs and a dsRBD. In addition, it 
contains a Piwi Argonaute Zwille (PAZ) domain which binds to the protruding 3’ 
ends of small RNAs (Lingel et al., 2004; Ma et al., 2004; Song et al., 2003).  
 
Dicer interacts with other proteins such as RDE-4 in C. elegans, R2D2 and FMR1 in 
D. melanogaster, and the PAZ domain-containing Argonaute (Ago) proteins (Caudy 
et al., 2002; Carmell et al., 2002; Hammond et al., 2001; Ishizuka et al., 2002; Jin et 
al., 2004; Tabara et al., 2002). These proteins may not be involved directly in the 
cleavage reaction, but are important for microRNA stability and effector complex 
formation and action (Kim, 2005; Liu et al., 2003; Zhang et al., 2004). Interestingly, 
they are also known to regulate mRNA stability and translation rates. For instance, 
Ago2 was originally described as a translation enhancer protein (Carmell et al., 2002). 
In the microRNA context, human AGO2 has been shown to function as the ‘slicer’ 
enzyme that mediates target mRNA cleavage (Meister et al., 2004; Song et al., 2004).  
 
After Dicer processing, one strand of the microRNA duplex is usually degraded while 
the other persists as a mature microRNA  (Kim, 2005). The strand that has a less 
thermodynamically stable 5’ end is thought to be incorporated into effector complexes 
called microRNA-containing RNA-induced silencing complexes (miRISCs) 
(Khvorova et al., 2003; Schwarz et al., 2003). These miRISCs recognize and bind to 
target mRNAs to modulate their expression. 
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1.2.4   Mechanism of action 
 
MicroRNAs modulate target expression in two different ways: by directing transcript 
degradation or inhibiting translation (Bartel, 2004) (Figure 1.3). In plants and very 
rarely in animals, microRNAs bind to highly complementary microRNA binding sites 
in target mRNAs to guide sequence-specific cleavage. This process is similar to RNA 
interference (Peters and Meister, 2007). In animals, microRNAs bind to partially 
complementary microRNA binding sites, usually in the 3’ UTRs of target mRNAs, 
and repress translation. This repression is achieved by interfering with translation or 
by guiding degradation processes that are initiated by mRNA deadenylation and 
decapping (Pillai et al., 2007). In contrast with sequence-specific RNA cleavage 
which is well characterized, the molecular mechanisms behind microRNA-mediated 
translational repression are poorly understood.  
 
 
Figure 1.3. Mechanism of microRNA action. MicroRNAs act via either 
translational control or transcript cleavage, depending on the degree of sequence 
complementarity between the microRNA and its mRNA target.  
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Recently, new insights into these mechanisms have been gained via the use of cell-
free in vitro systems (Mathonnet et al., 2007; Thermann and Hentze, 2007; Wakiyama 
et al., 2007; Wang et al., 2006). Wang et al. showed that microRNA-mediated 
translational inhibition requires a functional m7G-cap and a poly(A) tail (Wang et al., 
2006). Mathonnet et al. found that microRNAs inhibit ribosome recruitment to their 
target mRNA, and interfere with translational initiation by targeting the mRNA cap 
structure. They also suggest that inhibition of translation is an early event in 
microRNA-guided gene silencing that may be followed by mRNA degradation 
(Mathonnet et al., 2007). 
 
Ago proteins possess a highly conserved motif, containing two amino acids that 
specifically bind the m7G-cap, which is similar to the m7G-cap-binding motif of 
eIF4E. Kiriakidou et al. demonstrate that mutation of these two critical 
phenylalanines interferes with Ago2’s ability to interact with the m7G-cap, without 
affecting its ability to cleave target mRNAs (Kiriakidou et al., 2007). They propose a 
model in which Ago proteins and eIF4E compete for m7G-cap binding. eIF4E cannot 
access the cap once an Ago protein has bound to it. This results in repression of 
translational initiation (Kiriakidou et al., 2007). 
 
Intriguingly, Vasudevan et al. recently showed that human miR-369-3 activates 
translation by directing the association of Ago and fragile X mental retardation-
related protein 1 (FXR1) with AU-rich elements (AREs) (Vasudevan et al.,2007). 
They also demonstrate that two other microRNAs, Let-7 and the synthetic miRcxcr4, 
induce translation up-regulation of their target mRNAs on cell cycle arrest 
 21
(Vasudevan et al., 2007). These results provide the first evidence for microRNAs 
upregulating translation. 
 
Other studies in C. elegans and mammals have shown cosedimentation of microRNAs 
with polyribosomes, suggesting a role for microRNAs in regulating translational 
elongation (Maroney et al., 2006; Nottrott et al., 2006; Olsen and Ambros, 1999; 
Petersen et al., 2006; Seggerson et al., 2002). In addition, Petersen et al. reported that 
microRNA binding to the 3’UTR causes ribosomes to drop off mRNAs. This has led 
to a ribosome drop-off model of microRNA function (Petersen et al., 2006).  
 
Although there is increasing support for a model in which microRNAs regulate 
translational initiation, other evidence suggests that they may also function during the 
later steps of translation. MicroRNAs may also function in spatially and temporally 
distinct ways on different mRNAs.  
 
 
1.2.5   Target prediction 
 
Mature microRNAs regulate gene expression by binding to microRNA response 
elements (MREs) in their target mRNAs. Target prediction algorithms have been 
developed to identify microRNA targets, as target recognition is based partly on 
sequence complementarity between a microRNA and its MRE. However, at the time 
this study began, only a few such algorithms had been published, and only a small 
number of validated predictions had been reported (Table 1.1).  
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 Table 1.1. MicroRNA target prediction tools available when this study began.  
 
MicroRNA target prediction in plants is relatively straightforward as MREs, which 
are usually found in coding regions, have extensive complementarity to their 
corresponding microRNAs. Thus, comparatively simple bioinformatics screen have 
been sufficient to identify many plant microRNAs binding sites (Rhoades et al., 2002; 
Schwab et al., 2005). 
 
Prediction of animal microRNAs binding sites, which have been identified mostly in 
3’UTRs, has proven to be a significantly more challenging task as they usually exhibit 
imperfect complementarity with their mature microRNAs (Bentwich, 2005; 
Rajewsky, 2006; Segupathy et al., 2006). These microRNAs thus have the potential to 
be active against many mRNAs with little sequence homology. Although this 
ingenious mechanism allows the coordinate control of many genes, relatively 
complex algorithms will be required for prediction of these targets. 
 
 
In animals, the majority of target discovery approaches to date have focused almost 
exclusively on 3’UTRs as microRNA targets (Bentwich, 2005; Rajewsky, 2006). This 
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may be influenced by the fact that the founding members of the microRNA class were 
shown to act on the 3′UTRs of lin-14 and lin-41. 3’-UTRs of mRNAs also tend to be 
longer than 5’-UTRs, and are known to direct mRNA stability, translation efficiency 
and localization. However, the 5’-UTR also directs mRNA translation (Muckenthaler 
et al., 1998; Rouault, 2005; Thomson et al., 2005). No studies have yet been 
published on the targeting of endogenous 5’-UTR or coding regions by microRNAs in 
animals. However, it is interesting to note that other components of the post-
transcriptional machinery, the RNA-binding proteins (RBPs), are known to bind all 
along mRNAs and regulate their translation and degradation (George and Tenenbaum, 
2006). If the microRNA mode of action is reliant on incorporation in RBP-mRNA 
complexes, then one may surmise that microRNAs may exhibit activity along most of 
a mRNA, not just its 3’UTR. 
 
To date, despite the considerable effort expended on developing prediction 
algorithms, the number of confirmed heteroduplexes remains small. The number of 
target sites that have been validated in vivo under endogenous conditions and by 
mutagenesis is even smaller (Chen and Rajewsky, 2007). There is also little overlap 
between predictions made by various algorithms (Rajewsky 2006). These 
observations underscore the challenging nature of this field. Undoubtedly, 
breakthroughs in microRNA target prediction and validation will be instrumental in 
advancing our understanding of microRNA function and potential therapeutic 
applications.   
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1.3   MicroRNAs in ESCs 
 
In the context of mESCs, the loss of mature microRNAs in Dicer1 null mESCs results 
in a failure of mESCs cells to differentiate (Kanellopoulou et al., 2005). Furthermore, 
DGCR8, an RNA-binding protein involved in microRNA processing, is essential for 
microRNA biogenesis and silencing of mESC self-renewal (Wang et al., 2007). These 
data highlight the importance of regulated microRNA expression in controlling ESC 
growth and differentiation.  
 
ESC-specific microRNAs have been identified in murine and human ESCs (Houbaviy 
et al., 2003; Suh et al., 2004), however, their functional significance has not been 
evaluated (Table 1.2). The expression patterns of microRNAs in ESCs can be 
classified into five groups (1) microRNAs that are expressed in ESCs as well as in 
embryonic carcinoma (EC) cells, which may have conserved roles in mammalian 
pluripotent stem cells (2) microRNAs expressed specifically in ESCs but not in other 
cells including EC cells. These may have functions specific to ESCs (3) microRNAs 
that are rare in ESCs and increase upon differentiation, which may be involved in the 
differentiation process (4) microRNAs that are present in ESCs and remain at a 
constant level during differentiation. These may be involved in general aspects of cell 
physiology (5) microRNAs that increase or decrease transiently during ESC 
differentiation. These may module ESC differentiation into specific cell types. 
 
MicroRNAs were first identified in ESCs using cDNA cloning (Table 1.2 and 1.3). 
Houbaviy et al. describe 53 microRNAs in mESCs, of which 15 are novel (Houbaviy 
et al., 2003). Although the levels of many previously described microRNAs remain 
constant or increase upon differentiation, eight of the novel microRNAs (miR-290, 
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miR-291s, miR-291as, miR-292, miR-292as, miR-293, miR-294, miR-295) appear to 
be ESC or early embryo specific by four criteria: (1) their sequences are distinct from 
those of previously described microRNAs, including microRNAs cloned from adult 
mouse organs; (2) they cannot be detected in adult mouse organs by Northern 
analyses; (3) they are repressed during ESC differentiation in vitro, (4) all ESTs that 
map within the cluster are derived from ESCs or preimplantation embryos (Houbaviy 
et al., 2005).  
 
MiR-290 to miR-295 is a cluster of partially homologous pre-microRNA hairpins 
encoded by genomic loci clustered within 2.2kb of each other (Houbaviy et al., 2003). 
This entire Early Embryonic microRNA Cluster (EEmiRC) is spanned by a spliced, 
capped and polyadenylated primary transcript, and transcription is directed by a 
conserved promoter element containing a TATA box. Sequence analysis shows that 
the EEmiRC transcription unit  is  remarkably  variable  and  can  only  be  identified  
bioinformatically in placental (eutherian) mammals (Houbaviy et al., 2005). The only 
conserved regions within the locus are the pre-microRNA hairpins and the putative 
minimal promoter. The number and precise sequences of the pre-microRNAs, their 
distance from the promoter and the polyadenylation sites, the regions flanking the 
hairpins, and the types, positions and numbers of repetitive element insertions vary in 
species belonging to different mammalian orders (Houbaviy et al., 2005).  
 
Experimental support for the in silico prediction of an EEmiRC counterpart in the 
human genome was provided by the cDNA cloning of the corresponding microRNA 
homologs (miR-371, miR-372, miR-373 and miR-373*) from hESCs (Suh et al., 
2004). Although mouse and human EEmiRC microRNAs are sufficiently different 
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from each other to warrant different numerical designations, multiple sequence 
alignment reveals related sequences both within each cluster and across species. 
Furthermore, sequence conservation extends beyond the mature microRNAs to the 
entire pre-microRNA hairpin sequences (Houbaviy et al., 2003). 
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The miR-371 to miR-373* cluster is located within a 1050 bp region on chromosome 
19 (Suh et al., 2004). Intriguingly, they are also highly expressed in cancer cell lines, 
and miR-372 and miR-373 have the ability to protect cells from oncogenic stress and 
transform primary human cells (Kim, 2005; Voorhoeve et al., 2006). This suggests 
that they may operate key regulatory networks conserved in pluripotent stem cells and 
cancer cells, and serve as molecular markers for undifferentiated hESC and specific 
cancers. Suh et al. report another cluster of eight highly related microRNAs (miR-
302b, miR-302b*, miR-302c, miR-302c*, miR-302a, miR-302a*, miR-302d and miR-
367) located within a ~700bp region on chromosome 4. MiR-302b, miR-302c and 
miR-302d appear to be the close homologues of miR-302 that was cloned from 
mESCs. Although these are the most abundant microRNAs in hESCs, their murine 
homologue miR-302 appears to be less abundant (Suh et al., 2004). 
 
It is intriguing that two microRNA clusters are conserved and specifically expressed 
in both mouse and human ESCs. Although the variation in the numbers and sequences 
of the homologues may implicate divergence of the conserved regulatory pathways, 
these conserved microRNAs are likely to play central roles in the regulation of 
mammalian ESCs. Aside from these two clusters, there are considerable differences 
between the microRNAs cloned from human and mESCs. This may imply 
fundamental differences between the regulatory networks in hES and mESCs, or may 
simply be due to the cloning techniques employed, which may not be sensitive 
enough to identify the complete set of microRNAs in these cell lines. This limitation 
has been overcome by recently developed microRNA microarray techniques which 
have enabled global microRNA expression profiling. Microarray analysis of 124 
mammalian microRNAs has identified 6 additional microRNAs, miR-214, miR-134, 
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miR-25, miR-182, miR-204, miR-132, which demonstrate mESC-specific expression 
(Thomson et al., 2004). 
 
Despite the relative abundance of expression data, at the time this study began, 
comparatively few microRNAs have been functionalized in ESCs (Tables 1.2, 1.3). 
Thus, more comprehensive expression profiling, in conjunction with in-depth 
functional studies, will enhance current knowledge about microRNAs and should also 
increase our capacity to manipulate and develop ESCs as therapeutics for regenerative 
medicine. 
 
MicroRNA Type of differentiation Function Reference 
Let-7a-3 Neural  Lee et al., 2005 
miR-9/9* Neural 
Affects neural lineage 
differentiation, may 
act in the STAT3 
signaling pathway 
Krichevsky et al., 2006 
miR-21 Embryoid body formation (+/- RA)  Houbaviy et al., 2003 
Embryoid body 
formation (+/- RA) Houbaviy et al., 2003 miR-22 
Neural 
 
Krichevsky et al., 2006 
miR-124a Neural 
Affects neural lineage 
differentiation, may 
act in the STAT3 
signaling pathway 
Krichevsky et al., 2006 




Krichevsky et al., 2006 
 
Table 1.3. Some of the microRNAs that are upregulated during mESC 
differentiation. 
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CHAPTER 2.  STATEMENT OF AIMS 
 
Due to the paucity of knowledge about the functions of microRNAs in ESCs and the 
limited target prediction algorithms available at the time of this study, the two initial 
aims were to identify and characterize additional microRNAs which may be involved 
in the modulation of ESC pluripotency and differentiation, and to aid the development 
of a robust and sensitive microRNA prediction algorithm with higher positive 
predictive rates than those previously available. 
 
Chapter 3 describes work to identify putative microRNAs whose attenuation or 
overexpression may induce ESC differentiation, and to determine if these microRNAs 
are able to modulate specific lineage differentiation.  
 
Chapter 4 will describe briefly a microRNA target prediction algorithm, rna22, 
developed by our collaborator Isidore Rigoutsos, and experimental validation of 226 
rna22-predicted targets. Several of these will be further investigated to determine 
whether they mediate the effect of microRNAs in modulating mESC differentiation. 
 
As results from chapter 3 suggest that miR-134 may modulate in vitro mESC 
differentiation towards neural lineages, chapter 5 will investigate the expression 
profile in vivo of miR-134, and provide preliminary evidence of possible mechanisms 
by which miR-134 may modulate neural differentiation in vivo.  
 
Chapter 6 challenges the dogma that animal microRNAs only target the 3’UTRs of 
genes. This will be investigated in the context of microRNAs targeting the coding 
regions of transcription factors which are important regulators of pluripotency. 
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CHAPTER 3.  MICRORNAS MODULATE MESC DIFFERENTIATION 
3.1   Introduction 
 
MicroRNA expression profiling in mESCs has been performed previously by 
Houbaviy et al. by cloning and sequencing size-fractionated cDNA libraries of 
undifferentiated and differentiated mESCs. As most sequences (73%) were observed 
only once, Houbaviy et al. surmised that their dataset was probably not representative 
of the complete pool of microRNAs present in undifferentiated and differentiated 
mESCs (Houbaviy et al., 2003). Additionally, as mentioned earlier, this method of 
detection may not detect microRNAs that have low expression levels, specific 
sequence composition or post-transcriptional modifications (Luciano et al., 2004; 
Yang et al., 2006; Yang et al., 2006).  
 
A later study by Krichevsky et al. describes microRNA expression profiling during 
mESC-derived neurogenesis in vitro with probes specific for 135 microRNAs 
(Krichevsky et al., 2005). They showed that a number of microRNAs are 
simultaneously co-induced during the differentiation of neural progenitor (NP) cells to 
neurons and astrocytes. Seventy of the 135 vertebrate microRNAs tested showed a 
greater than two-fold change between any two stages of the five-step neural 
differentiation protocol. MiR-124a and miR-9, which are almost exclusively 
expressed in the brain, affect neural lineage differentiation of the mESC cultures. 
Krichevsky et al. hypothesize that early overexpression of miR-124a in NPs prevents 
gliogenesis whereas miR-9 expression contributes to neurogenesis (Krichevsky et al., 
2005). These data demonstrate a functional role for distinct microRNAs in the 
determination of neural fates during ESC differentiation. 
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The microarray analysis by Krichevsky et al. profiled microRNA expression during a 
defined 5-stage protocol that induces neural differentiation of mESCs. Differentiation 
of mESCs can be induced in many ways, including embryoid body (EB) formation, 
induction with retinoic acid (RA), culture in serum-free medium containing N2 and 
B27 supplements, co-culture with specific tissues or cell lines, promoter trapping and 
the forced expression of certain developmental control genes (Bain et al., 1995; 
Barberi et al., 2003; Finley et al., 1999; Friedrich and Soriano, 1991; Fujikura et al., 
2002; Leahy et al., 1999; Niwa et al., 2005; Okada et al., 2004; Ying et al., 2003).  
 
EBs, cell aggregates formed from ESCs grown in suspension, are useful models of 
gene expression and differentiation in early development as they resemble the early 
postimplantation embryo in size, differentiation capacity and gene expression profile 
(O’Shea, 2004). EBs have been shown to differentiate into derivatives of all three 
germ layers (Leahy et al., 1999). As such, many differentiation protocols start with 
several days of EB formation in the absence of LIF (Doetschman et al., 1985; Kanai-
Azuma et al., 2002; Lickert et al., 2002; Martin and Evans, 1975; Ying et al., 2003).  
 
Treatment with RA is another commonly used and robust method of mESC 
differentiation.  RA is an important morphogen which is required during development 
of the central nervous system, lung, and kidneys, and during proximodistal patterning 
and limb generation (Aliotta et al., 2005; Burrow, 2000; Maden, 2001; Yashiro et al., 
2004). In the absence of LIF, RA enhances both neural differentiation and 
caudalization of mESCs in a concentration-dependent manner (Bain et al., 1995; 
Okada et al., 2004). Furthermore, certain concentrations of RA have been shown to 
enhance cardiomyocyte differentiation from mESCs (Wobus et al., 1997). 
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In an attempt to obtain a more comprehensive profiling of microRNA expression 
during mESC differentiation that was not restricted to any particular lineage, 
microarray analysis was performed using chips containing probes for 461 
microRNAs. For this study, the two methods of differentiation used were EB 
formation and RA induction. 
 
 
3.2   Identification of microRNAs modulated    
   during mESC differentiation 
 
To examine the relative changes in microRNA expression during mESC 
differentiation, microarray analysis was performed on two sets of samples: Total RNA 
isolated from E14 mESCs subject to EB differentiation for 0, 3, 6, 9, 12 and 15 days, 
and total RNA isolated from mESCs ± RA (100 nM) at 0, 2, 4 and 6 days post-
treatment. The difference in time durations selected was due to the fact that RA 
induction results in more rapid mESC differentiation than EB formation.  
 
Out of the 461 microRNAs probed, 201 were differentially expressed during EB 
differentiation; the expression pattern of several of these is shown in Figure 3.1A and 
B. Additionally, 134 microRNAs that were differentially expressed following RA 
treatment were identified; the expression pattern of several of these is shown after 
four days of RA treatment (Figure 3.2A, B). Northern blot analysis was performed to 
confirm the microarray profiling for a representative sample of these differentially 




Microarray analysis also demonstrates that members of the miR-290 to 295 
microRNA cluster are highly expressed in undifferentiated mESCs and decrease 
during both EB and RA differentiation (Figure 3.1A, 3.2B) This is consistent with the 
previous report by Houbaviy et al. and affirms the reliability of the cell culture and 




Figure 3.1. MicroRNA expression levels change during EB differentiation of mESCs 
(A,B) The expression levels of representative microRNAs which (A) decreased or (B) 
increased during EB differentiation compared to day 0 mESCs. Total RNA extracted from 
mESCs (control) or EBs (day 3 to day 15) was size fractionated and hybridized to microRNA 
specific probes on a microarray as described in methods. The total array profile has MIAME 




Figure 3.2. MicroRNA expression levels change during RA-induced mESC 
differentiation (A,B) The expression levels of representative microRNAs which (A) 
increased or (B) decreased with RA treatment (day 4) compared to day 0 mESCs. Total RNA 
extracted from mESCs (control) ± 100 nM RA (day 0 to day 4) was size fractionated and 
hybridized to microRNA specific probes on a microarray as described in methods. The total 
array profile has MIAME accession number E-MEXP-977. 
 
 
Figure 3.3. Northern blot validation of microRNA microarray expression profiles (A,B) 
Northern blot analyses demonstrating (A) upregulation or (B) downregulation of 
representative microRNAs by RA treatment (day 0 to day 4) of E14 mESCs, confirming the 
data obtained from the microRNA microarray analysis (C) Expanded Northern blot analyses 
of miR-134 upregulation during RA-induced mESC differentiation to demonstrate probe 
specificity. 
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3.3   MicroRNAs can modulate Oct4 and Nanog   
   promoter activity  
 
Next, the effect of dysregulation of these differentially expressed microRNAs on self-
renewing mESCs in the presence of serum and LIF was investigated. The 
transcription factors Oct4, Sox2 and Nanog are known to play a central role in ESC 
maintenance and differentiation, and the levels and activity of these transcription 
factors are indicators of ESCs’ pluripotent- or differentiation-status (Loh et al., 2006). 
Constructs containing either the Oct4 promoter or the Nanog promoter that contain 
Oct4/Sox2 binding sites driving transcription of a luciferase reporter gene were used 
to measure the transcription activity of these promoters and provide a sensitive 
method to detect loss of pluripotency and onset of differentiation (Figure 3.4A, B). A 
stringent threshold of p<0.0001 was set based on the luciferase readout for each 




Figure 3.4. Schematic representations of pOct4-Luciferase and pNanog-Luciferase 
constructs (A) Schematic representation of pOct4-Luciferase plasmid reporter construct, 
which was used as a measure of Oct4 promoter activity. pOct4-Luciferase comprises 3 kb of 
the human Oct4 promoter, where the Oct4-Sox2 binding site is indicated (DE, distal 
enhancer; PE, proximal enhancer; PP, proximal promoter), upstream of the transcription start 
site (TSS) for Photinus pyralis luc (firefly luciferase) (ATG, translation start codon; TGA, 
translation stop codon; PolyA, polyadenylation signal) (B) Schematic representation of 
pNanog-Luciferase plasmid reporter construct, which was used as a measure of Nanog 
promoter activity. pNanog-Luciferase comprises 500 bp of the mouse Nanog promoter, where 
the Oct4-Sox2 binding site is indicated. 
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Anti-miR™ microRNA inhibitors (Anti-miRs) or Pre-miR microRNA™ precursors 
(Pre-miRs) from Ambion were used to repress or overexpress the selected 
microRNAs. An experiment was first carried out in 293T cells to demonstrate the 
efficacy of these synthetic oligomers. As the effectiveness of target repression by a 
microRNA is dependent on the degree of sequence complementarity it has with its 
target sequence, it would exhibit maximal repression of a perfectly complementary 
target. The reverse complements (RCs) of miR-291-5p and miR-291-3p were cloned 
downstream of a luciferase reporter to serve as the readouts for this experiment.  
 
Relative to the Scrambled oligomer control transfection, transfection of Pre-miR-291 
resulted in a very significant repression of luciferase activity of both 291-5p and 291-
3p RC targets (Figure 3.5). This was not affected by the co-transfection of the non-
complementary Anti-miR 19b (Figure 3.5). Transfection of Pre-miR-22 did not 
repress the luciferase activity of the 291-5p RC target relative to Scrambled control 
transfection (Figure 3.5). These results indicate that Pre-miRs are processed within 
transfected cells to yield mature microRNAs which are able to act specifically on their 
mRNA targets. 
 
This luciferase reporter assay was also used to investigate the effectiveness of Anti-
miRs. As depicted in Figure 3.5, the co-transfection of Pre-miR-291 (which generates 
both miR-291-5p and miR-291-3p) and Anti-miR-291-5p was able to specifically 
rescue the effect of Pre-miR-291 on the 291-5p RC target but not the 291-3p target, 
demonstrating that the Anti-miRs were functional as microRNA inhibitors in the cell 
culture platform used (Figure 3.5). 
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Figure 3.5. Luciferase assay demonstrating the efficacy of Anti-miRs and Pre-
miRs. Graph showing the effect on luciferase activity in 293T cells of the listed Pre-miR and 
Anti-miR cotransfections with the respective reverse complement (RC) target. Luciferase 
experiments were performed in quadruplicate thrice (n=12), where error bars denote standard 
error. 
 
In addition to the luciferase assays, Northern blots were also performed after 
transfection of Pre-miRs and Anti-miRs into mESCs. Anti-miR-293 was able to 
reduce the amount of the abundantly expressed miR-293 in mESCs (Figure 3.6B).  
Other studies have also reported a reduction in microRNAs with Anti-miR treatment, 
however, the mechanism remains unknown (Flynt et al., 2007). Furthermore, Pre-
miR-134 was processed to generate mature miR-134, which could be sustained for at 
least 5 days post-transfection (Figure 3.6D). 
 
Having confirmed the efficacy of both Anti-miRs and Pre-miRs, they were next co-
transfected with the Oct4-luciferase reporter construct in mESCs to provide an initial 
screen for microRNAs which may modulate the loss of mESC pluripotency. In all 
experiments, co-transfection of E14 and D3 mESCs with Oct4 RNAi (positive 
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control) and the Oct4-luciferase reporter resulted in at least a 60% reduction in 
promoter activity (Figure 3.6A, C, E).  
 
For the microRNAs that were downregulated during differentiation, the Oct4-
luciferase reporter was co-transfected with Anti-miRs to ascertain whether reduction 
in the levels of these microRNAs alone could result in a loss of mESC pluripotency. 
However, compared to the Scrambled control transfection, transfection of any one of  
the Anti-miRs did not result in any significant change in luciferase activity across the 
2 mESC-lines tested (Figure 3.6A). It is possible that the simultaneous 
downregulation of several of these microRNAs may be needed to observe a 
significant effect.  
 
For the microRNAs that were upregulated during differentiation, the Oct4-luciferase 
reporter was co-transfected with Pre-miRs to ascertain whether upregulation in the 
levels of these microRNAs alone could result in a loss of mESC pluripotency. Of the 
eleven microRNAs tested, only miR-134 resulted in a significant reduction in Oct4-
promoter activity (Figure 3.6C) relative to the Scrambled oligomer control in both 
E14 and D3 mESCs.  
 
To further investigate whether miR-134 could induce mESC differentiation as 
quantified by a decrease in transcription activity of a pluripotency marker, Pre-miR-
134 was next co-transfected with the Nanog-luciferase reporter. Consistent with the 
Oct4-luciferase reporter results, this also resulted in significantly reduced Nanog-




Figure 3.6. Overexpression of miR-134 downregulates Oct4 and Nanog promoter 
activities (A) Relative to the Scr control transfection, none of the Anti-miRs transfected were 
able to induce a significant downregulation in Oct4 promoter activity in E14 or D3 mESCs 
(C,E) Relative to the Scr control transfection, PmiR-134 transfection induced a significant 
downregulation in Oct4 promoter (C) and Nanog promoter (E) activities in both E14 and D3 
mESCs. Experiments were performed in triplicate thrice (n=9), where error bars denote 
standard error, and asterisk (*) denotes significance of difference to scrambled RNA oligomer 
control at p<0.0001 (B,D) Northern blot analyses showing that Anti-miR-293 transfection 
into E14 mESCs led to reduced levels of mature miR-293 (B), while PmiR-134 transfection 
led to enhanced levels of mature miR-134 (D), relative to non-transfected control  (where 0 
denotes no transfection, D1 to D5 denote day 1 through 5 post-transfection). Experiments 
were performed in triplicate twice (n=6), and a representative blot is shown. 
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3.4   Expression profile of miR-134 during mESC differentiation 
 
As the results of the Oct4 and Nanog promoter screens suggested that miR-134 may 
be able to modulate mESC differentiation, its expression during mESC differentiation 
was explored more thoroughly. Quantitative PCR analyses corroborated the 
microarray data which demonstrated that miR-134 expression increases during RA 
differentiation, reaching a peak at day 4 before subsiding by day 6 (though still 
remaining at an elevated level relative to undifferentiated mESCs) (Figure 3.7). 
 
When a less heterogeneous neuroectodermal lineage differentiation promoting regime 
(N2B27) was used (Aiba et al., 2005; Ying et al., 2003), the levels of endogenous 
miR-134 increased significantly within two days (3 times greater induction compared 
to RA), and again the levels of miR-134 subsided over the time course but remained 
elevated above control (Figure 3.7). Interestingly, and consistent with the microarray 
data, miR-134 levels did not change during EB formation (Figure 3.5).  
 
 
Figure 3.7. Expression profile of miR-134 during mESC differentiation. MicroRNA 
quantitative PCR analyses showing that, relative to expression in untreated E14 mESCs, miR-
134 expression increases during both RA and N2B27 treatment of E14 mESCs, and not EB 
differentiation. Experiments were performed in duplicate thrice (n=6), where error bars 
denote standard error, and asterisk (*) denotes significance of difference to day 0 at p<0.0001. 
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3.5          MiR-134 modulates mESC differentiation   
   even in the presence of LIF 
 
To further investigate the possible role of miR-134 in modulating mESC 
differentiation, the effect of miR-134 alone on changes in the mRNA levels of key 
marker genes associated with pluripotency and differentiation was examined. 
Quantitative PCR of total RNA samples taken from E14 and D3 mESCs 3 days post-
transfection with Pre-miR-134 showed that the Oct4 mRNA level was significantly 
reduced, consistent with the reduction of promoter activity (Figure 3.8.). Nanog 
transcript levels were reduced significantly in D3, but not E14, mESCs transfected 
with Pre-miR-134. Sox2 levels were reduced significantly in both D3 and E14 mESCs 
after Pre-miR-134 transfection. Additionally, elevated expression levels of early 
primitive ectoderm marker (Fgf5), neuroectoderm marker (Nestin) were observed, 
with no change or a down-regulation of endoderm (Gata4, Sox17) and mesoderm 
(Bmp4, Nkx2.5) markers (Figure 3.8.). These findings indicate that elevated miR-134 
levels alone in undifferentiated mESCs promote a transcriptional expression profile 




Figure 3.8. miR-134 modulates the transcript levels of lineage-specific biomarkers, even 
in the presence of LIF. Relative to Scr control transfection, transfection of PmiR-134 into 
E14 and D3 mESCs led to an appreciable upregulation of ectodermal markers Nestin and Fgf5 
after 3 days, with a concomitant reduction in endodermal, mesodermal and pluripotency-
associated markers. Experiments were performed in triplicate thrice (n=9), where error bars 
denote standard error, and significance of difference to scrambled RNA oligomer control at 
p<0.001 are denoted as asterisk (*) and hex (#) for E14 and D3 mESCs respectively. 
 
As transcript level is not always an accurate indication of the amount of a particular 
protein present, the effect of miR-134 on the protein levels of several pluripotency 
and differentiation markers was also explored. Western blot analyses showed that 
miR-134 elevation consistently resulted in a significant downregulation of Oct4, 
Nanog and Sox2 proteins in both E14 and D3 mESCs, relative to Scr control, during 
the second and third day following transfection with Pre-miR-134 (Figure 3.9A). 
Importantly, this effect was completely abolished by co-transfection of Pre-miR-134 
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with Anti-miR-134, miR-134’s antagonist, thus demonstrating the specificity of miR-
134 in the downregulation of these proteins (Figure 3.9A). Concomitant with changes 
in mRNA levels in E14 mESCs, Pre-miR-134 transfection led to increased protein 
levels of Nestin and decreased protein levels of BMP4. Gata4 protein levels were not 
affected (Figure 3.9B).   
 
Having demonstrated at the molecular level that miR-134 induces mESC 
differentiation, miR-134’s effect on mESCs at the cellular level was next investigated.  
E14 mESCs transfected with the scrambled RNA oligomer (Scr) maintained the 
characteristic domed colony structures of mESCs with no morphological changes for 
up to 4 days post-transfection (Figure 3.9C). However, transfection with Pre-miR-134 
alone induced visible morphological changes in these cells within 4 days post-
transfection (Figure 3.9C), with the cells acquiring a flattened epithelial-like 
morphology typical of differentiation. This data is consistent with reduced alkaline 
phosphatase activity in Pre-miR-134 treated mESCs (Figure 3.9C), where alkaline 






Figure 3.9. miR-134 downregulates protein levels of pluripotency markers and induces 
changes in mESC morphology indicative of differentiation, even in the presence of LIF 
(A) Western blot analyses showing that PmiR-134 induced significant downregulation of 
Nanog, Oct4 and Sox2 protein levels relative to Scr control in E14 and D3 mESCs. This 
effect was blocked by Anti-miR-134, over three days post-transfection. Experiments were 
performed in triplicate twice (n=6), and a representative blot is shown (B) Western blot 
analyses showing that PmiR-134 induced significant upregulation of Nestin protein relative to 
Scr control in E14 mESCs. Experiments were performed in triplicate twice (n=6), and a 
representative blot is shown (C) Photographs showing the morphology (left panel) and 
alkaline phosphatase (AP) staining (right panel) of E14 mESCs four days post-transfection 
with PmiR-134 or Scr control; where PmiR-134, unlike Scr, induced visible phenotypic 
changes to a flattened, epithelial-like morphology, and reduced AP activity relative to Scr 
control. Scale bar = 10 microns. 
 
 
Colony forming unit assays, which involve the replating of mESCs 2 days post-
transfection  with Pre-miRs, Anti-miRs, Scrambled or water onto mEF feeder layers, 
were also performed. The number of secondary colonies obtained is a measure of the 
pluripotent state of the respective cultures. Colony formation assay results  
demonstrated that there was an ~30% decrease in the ability of mESCs treated for 2 
days with Pre-miR-134 to form mESC colonies compared to mock transfection 
control (Table 3.1). This provided further evidence that miR-134 alone could 




Table 3.1. Overexpression of miR-134 reduces the colony forming efficiency of mESCs. 
Colony formation assay results demonstrating that relative to mock transfection control, 
transfection of PmiR-134 into E14 mESCs significantly reduced the proportion of 
undifferentiated, colony forming mESCs in the cell population. This effect was effectively 
blocked by Anti-miR-134. The data is expressed as mean number of colony forming units ± 
standard error. Experiments were performed in triplicate thrice (n=9). 
 
 
3.6   The mRNA expression patterns between    
   RA-treated and miR-134-transfected mESCs   
   demonstrate a high degree of correlation 
 
As quantitative PCR and Western blot analyses suggested that miR-134 may enhance 
ectodermal differentiation, the effect of miR-134 during RA-induced differentiation of 
mESCs was next investigated by comparing the microarray profile of mESCs treated 
with Pre-miR-134 to that of RA treatment alone.  
 
For RA-induced differentiation, total RNA was collected from untreated mESCs, and 
from mESCs after two and four days of RA treatment (in the absence of LIF); 
whereas for Pre-miR-induced differentiation, total RNA was collected three days after 
transfection of mESCs (in the presence of LIF) with Pre-miR-134, water only (mock 
transfection, MT), Scrambled oligomer, or Pre-miR-Let-7i, a microRNA that neither 
induces mESC differentiation nor is induced by RA. RNA samples were labeled, 
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hybridized to Illumina microarray chips and heat maps were generated to compare the 
spectrum of transcript levels altered by RA or Pre-miR-134 treatment.  
 
There was a high degree of correlation between the expression pattern of genes 
altered after 4 days of RA treatment in mESCs and all Pre-miR-134 responsive genes 
(Figure 3.10A, B). Prior to Pearson correlation analysis, the intensity data were log2 
transformed and subtracted from the medium intensity. The mean Pearson correlation 
coefficient between these two expression profiles (and replicates) was ~ 0.57, whereas 
the mean Pearson correlation coefficient between Pre-miR-134 transfection/4 days of 
RA treatment and other treatments (ESC/MT/Scr/Pre-Let-7i) was ~ -0.36. When 
comparing the means of the above Pearson correlation coefficients between RAd4 and 
miR-134 to the corresponding means between miR-134/RAd4 and ESC/MT/Scr/Pre-
Let-7i, all p-values were < 0.001.  
 
Analysis of mRNAs upregulated in response to either RA or Pre-miR-134 indicated 
increased levels of transcripts associated with ectodermal differentiation (Figure 
3.10C) (Choi et al., 2005; Hay et al., 2004; Palmqvist et al., 2005; Luo et al., 2006; 
Tolkunova et al., 2006; Yamada et al., 2002), supporting the evidence presented in 
Figure 3.8. In contrast, levels of non-ectoderm markers were not significantly altered 
by either RA or Pre-miR-134 (Choi et al., 2005; Hay et al., 2004; Palmqvist et al., 
2005; Luo et al., 2006; Tolkunova et al., 2006; Yamada et al., 2002). Transfection of 
Pre-Let-7i resulted in a very different pattern of gene expression compared with Pre-





Figure 3.10. miR-134 induces a subset of genes similar to that induced by RA treatment 
of mESCs (A) Heat map depicting the expression profile of all genes with changes ≥2 fold 
after 4 days of RA treatment (left panel). The RAd4 dataset was ordered based on descending 
average intensity and the expression profile of these genes in the PmiR-134-treated dataset is 
shown in the same order (right panel) (B) Dendrogram obtained from hierarchical sample 
clustering showing the relatedness of all the samples profiled in (A) (C) Heat map depicting 
the expression profile of ectoderm, endoderm and mesoderm markers from RA-treated versus 
PmiR-134 transfected datasets. Each of the lineage markers genes are mean-centered 
separately in the PmiR-134 and RA-treated datasets and ordered based on the fold change in 
the RA-treated dataset. 
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3.7   MiR-134 enhances RA- and N2B27-mediated   
   mESC differentiation 
 
This microarray data which suggested that overexpression of miR-134 alone could 
induce the expression of a subset of genes similar to that induced by RA treatment of 
mESCs led to a study of whether Pre-miR-134 could enhance the RA-induced 
ectodermal differentiation of mESCs. In E14 mESCs, transfection of Pre-miR-134 
into RA-treated cells resulted in accelerated acquisition of the early primitive 
ectoderm marker, FgF5, and the neuroectoderm markers Nestin, and Neurogenin2 
(Figure 3.11A), with a concomitant increase in Sox1, a promoter of neurogenesis 
(Ying et al., 2003), relative to RA-treated cells transfected with Scrambled oligomer. 
The enhancement of these mRNAs by RA was blocked by Anti-miR-134 (Figure 
3.11A). Pre-miR-134 enhanced the RA-induced decrease in the pluripotent marker 
Oct4, however, unlike the neuroectoderm markers, this effect was not blocked by 
Anti-miR-134 (Figure 3.11A). There were no major changes in the transcript levels of 
mesendoderm (Gata4, Bmp4) markers during these experiments (Figure 3.11A). 
MESCs co-treated with both Pre-miR-134 and RA exhibited lower protein levels of 
Oct4, Sox2 and Nanog, compared to treatment with Scrambled, Anti-miR-134 or 





Figure 3.11. miR-134 enhances the effect of RA on mESCs (A) Transfection of PmiR-134 
into RA-treated E14 mESCs led to an appreciable upregulation of ectodermal markers, with a 
concomitant reduction in the pluripotency associated marker Oct4, above that induced by 
transfection of Scr control into RA-treated E14 mESCs. Transcript levels of biomarkers were 
normalized to internal β-actin and expressed relative to day 0 control levels. Experiments 
were performed in triplicate thrice (n=9), where error bars denote standard error, and 
significance of difference to scrambled RNA oligomer control on RA day 2 at p<0.001 are 
denoted as asterisk (*) and hex (#) for PmiR-134 and Anti-miR-134 respectively (B) Western 
blot analyses showing that PmiR-134 enhances the RA-induced downregulation of Nanog, 
Oct4 and Sox2 protein levels relative to Scr control in E14 mESCs. Experiments were 
performed in triplicate twice (n=6), and a representative blot is shown. 
 
 
As miR-134 expression also increased during N2B27 differentiation, the effect of Pre-
miR-134 in the presence of N2B27 medium was tested next. Mouse ESCs were 
subject to Pre-miR-134 transfection for one day before N2B27 treatment for three or 
five days. Cell cultures transfected with Pre-miR-134 contained a larger percentage of 
cells positive for the neuronal marker β-III-Tubulin relative to scrambled control 
(Figure 3.12A, B). In addition, Cellomics analysis determined that the intensity of β-
III-Tubulin immunostaining was significantly stronger in neuronal cell bodies and 
neurites in Pre-miR-134 treated cultures relative to Scr treated control cultures (Figure 
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Figure 3.12. miR-134 enhances the effect of N2B27 medium on mESCs (A) 
Immunostaining of β-III-tubulin 4 and 6 days after the transfection of PmiR-134 into N2B27-
treated E14 mESCs depicting that PmiR-134 transfection increases the number of β-III-
tubulin positive cells compared to the Scr control transfection. Scale bar = 50 microns (B) 
Quantification of the immunostaining depicted in (C). Data shown are presented as the ratio 
of the respective readings for PmiR-transfected cells / Scr transfected cells, and are an 
average of values from 16 random fields from 3 replicate wells in two independent 
experiments. Error bars denote standard error, and asterisk (*) denotes significance of 




3.8   Discussion  
This study has provided a comprehensive profiling of microRNA expression during 
both EB and RA-induced mESC differentiation. Although a large number of 
microRNAs are either up or downregulated during the differentiation of mESCs by 
these two methods, overexpression or reduction of expression of most of these 
microRNAs did not result in any significant phenotype change in mESCs. This may 
be explained by the hypothesis that the majority of microRNAs function in vertebrates 
by subtly modulating cell types instead of being inducers or regulators of 
differentiation (Flynt et al., 2007). 
 
Of all the microRNAs tested, miR-134 was found to have the most significant effect 
on mESCs. MiR-134 was identified as one of many microRNAs upregulated during 
RA- and N2B27-induced neural differentiation of mESCs. Interestingly, the data 
showed that miR-134 was not upregulated during EB differentiation. As EB formation 
results in a random differentiation of ESCs to endodermal, mesodermal and 
ectodermal lineages, the heterogeneity of cell types present in EBs may explain why 
an overall increase in miR-134 levels was not detected, even though its expression 
may increase in the population of cells differentiating towards ectoderm. This data 
also suggested that upregulation of miR-134 and its effect on target mRNAs is not an 
absolute requirement for mESC differentiation into lineages from all three germ 
layers, but may have a role in modulating neural lineage differentiation.  
 
Significantly, miR-134 was the only one of the microRNAs tested that on its own 
modulated differentiation of mESCs, as determined by the profiling of pluripotency 
and differentiation markers at both transcript and protein levels, and cellular assays 
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such as colony forming efficiency and alkaline phosphatase staining. Furthermore, 
miR-134 was able to enhance RA and N2B27-induced transition of mESCs to neuro-
ectodermal lineages, as measured by microarray profiling, transcript analysis and 
immunostaining. The observation that Anti-miR-134 was able to attenuate the RA-
induced changes in Sox1, Nestin and Neurogenin2 mRNA levels highlights the 
specificity of the results obtained and lends further support to the hypothesis that 
miR-134 is an enhancer of ectodermal lineage specification. However, Anti-miR-134 
could not attenuate the RA-induced Oct4 mRNA downregulation, suggesting that the 
elevation of miR-134 is not an absolute requirement for differentiation. 
 
The data thus far showed that miR-134, a microRNA which was upregulated during 
RA- and N2B27-induced neural differentiation of mESCs, was able to modulate the 
differentiation of undifferentiated mESCs and enhance RA and N2B27-induced 
ectodermal lineage specification. These observations led to an investigation into the 












CHAPTER 4.  MICRORNA TARGET PREDICTION 
4.1   Introduction 
To investigate the potential mechanisms through which miR-134 modulates mESC 
differentiation, it is necessary to identify potential targets which may mediate its 
action. As mentioned previously, the prediction of animal microRNAs binding sites, 
which usually exhibit imperfect complementarity with their mature microRNAs, has 
been a challenging task (Bentwich, 2005; Rajewsky, 2006; Segupathy et al., 2006). 
Furthermore, at the time this study was conducted, there were only a few target 
prediction algorithms available. The number of validated predictions that had been 
reported was also small, and there was little overlap between predictions made by 
various algorithms (Rajewsky, 2006). 
 
Thus, to further the dual objectives of identifying miR-134 targets which may aid in 
elucidating its mechanism of action, and to contribute to the development of a robust 
and sensitive microRNA prediction algorithm, we worked with collaborators at IBM, 
led by Isidore Rigoutsos, who were in the process of developing rna22, a method for 
identifying microRNA binding sites and their corresponding heteroduplexes.  
 
rna22 does not rely upon cross-species conservation, is resilient to noise, and, unlike 
previous methods, it first finds putative microRNA binding sites in the sequence of 
interest, then identifies the targeting microRNA. Computationally, the Rigoutsos lab 
has shown that rna22 is able to predict most of the currently known heteroduplexes. A 
schematic depicting the various steps of rna22 is presented in Figure 4.1. 
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4.2   Validation of rna22,       
   a microRNA target prediction algorithm 
 
Figure 4.1. Flowchart depicting the various steps of the target prediction method used 
(adapted from Figure 1 of Miranda et al., 2006). 
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To provide experimental support for the in silico predictions generated by rna22, 
luciferase-reporter assays were used to evaluate randomly selected rna22-predicted 
microRNA binding sites. This was selected as the method of choice due to its high 
sensitivity, robustness and amenability to scale-up for high-throughput screening. 
 
Each predicted microRNA binding site, also known as microRNA response element 
(MRE), was inserted as a single copy directly downstream of a Renilla luciferase open 
reading frame (ORF) (Figure 4.2.) Examining one predicted target at a time was an 
important component of the stringent evaluation approach so that any reduction in 
luciferase activity could be attributed to a single source. The relative luciferase 
activity of the control transfection (Luciferase-MRE plasmid co-transfected with 
scrambled RNA oligo or empty plasmid vector – represented as 100%) was compared 
to the corresponding activity when the cognate microRNA was added.  
 
 
Figure 4.2. Schematic representation of pLuc-MRE plasmid reporter construct. 
Predicted MREs and binding heteroduplexes are also depicted. 
 
 
In addition to miR-134, two other murine microRNAs were selected for target 
valdiation: miR-375 and miR-296. MiR-375 was included as its human homolog was 
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characterized and shown to regulate insulin secretion by binding to myotrophin (Poy 
et al., 2004). MiR-296 was included due to its possible role in ESC differentiation. 
Requiring a minimum of M = 14 matching base pairs between the microRNA and a 
target, at most G = 1 unpaired bases in the seed region, and binding energies ( E = -22 
Kcal/mol for the microRNA/mRNA complex, 2292, 271 and 2318 3’UTR targets 
were predicted for miR-375, miR-296 and miR-134 respectively. Of these 3’UTR 
targets, 44 predicted sites for miR-375, 24 for miR-296, and 158 for miR-134 were 
randomly subselected for validation in vitro with luciferase assays.  
 
As the level of target repression is related to the degree of sequence complementarity 
between a microRNA and its target mRNA, the reverse complement of each targeting 
microRNA served as a positive control. None of these three microRNAs were 
predicted to target the reverse complement of miR-21, so this served as a negative 
control. Based on the observed standard deviation about the mean (100%) of 
luciferase activity for negative controls, 30% repression was determined to be the 
minimum requirement for a positive microRNA target (Figures 4.3C and 4.4A). 
 
Figures 4.3A, B and 4.4B show the results of these assays for miR-375, miR-296 and 
miR-134 respectively. Luciferase activity was suppressed by at least 30% for 168 out 
of the 226 tested predictions; in fact, suppression ranged between 40% and 80% for 
more than half of the predictions tested. Appendices 7.1-3 list the ENSEMBL ids and 
sequences for the 226 tested predictions. These results suggest that a high proportion 
of the rna22 predicted targets may be post-transcriptionally regulated by microRNAs, 
























































































































































































































































































































































































































































































































































































































































































































































































4.3   MiR-134 targets Nanog and LRH1, amongst other genes  
Having verified rna22’s effectiveness, its target predictions for miR-134 were 
examined in greater detail. The relationship between miR-134 and the expression 
profile of all its predicted mRNA targets in mESCs was investigated using gene 
expression analysis. This revealed that 1,051 of the genes potentially targeted by miR-
134 were expressed in mESCs (Figure 4.5A and B). Of these, approximately 50% 
were upregulated, 20% remained unchanged and 30% were downregulated relative to 
water only (mock transfection) and Scrambled oligomer control transfections. This 
suggested that miR-134 had different effects, direct or indirect, on target mRNAs, 




Figure 4.5. Expression analysis of all rna22-predicted miR-134 target genes (A) Heat map 
depicting the expression profile of all rna22-predicted miR-134 targets in both the PmiR-134 
dataset (left panel) and the RA-treated dataset (right panel) (B) Dendrogram obtained from 
hierarchical sample clustering showing the relatedness of all the samples profiled in (A). 
 
 
Interestingly, the expression profile of predicted target genes after Pre-miR-134 
transfection was highly correlated with their corresponding expression profile after 4 
days of RA treatment (Figure 4.5A and B). The mean Pearson correlation coefficient 
between these two expression profiles was 0.51, whereas the mean Pearson 
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correlation coefficient between predicted target gene expression in Pre-miR-134 
transfection or after 4 days of RA treatment and other treatments (ESC/MT/Scr/Pre-
Let-7i) was ~ -0.39. These data implied that miR-134’s effect on mESCs may be 
mediated, at least in part, by modulation of the transcript levels of its target mRNAs.  
 
In order to begin to understand the role of miR-134 in the post-transcriptional 
regulation of its potential direct targets, four predicted mRNA targets were next 
selected for further characterization. Upon Pre-miR-134 treatment, LRH1, Gαo and 
Nanog mRNA levels do not change and FADD mRNA levels increase. The predicted 
MREs in the 3’UTRs of these four genes are depicted in Figure 4.2.  
 
The orphan nuclear receptor liver receptor homologue 1 (LRH1, also known as 
NR5A2), is a transcription factor that binds to the PE and PP regions of the Oct4 
promoter (Figure X) and regulates its expression (Gu et al., 2005), it is also known to 
modulate cell proliferation through its interaction with β-catenin (Botrugno et al., 
2004). LRH1 is an important modulator of stem cell fate and is required for 
maintaining Oct4 expression in the epiblast of the embryo; loss of LRH1 leads to 
early embryonic lethality (Gu et al., 2005). Gαo (Guanine nucleotide binding protein, 
alpha o) and FADD (Fas-associated via death domain) have been shown to play key 
roles in neurite extension (Nakata et al., 2005), apoptosis (O’Flaherty et al., 2006) and 
embryo development (Yeh et al., 1998).  
 
For these four targets, miR-134 elicited a significant decrease in luciferase activity 
(Figure 4.6A). No effect was observed with Pre-miR-124a, Pre-miR-21, or Scrambled 
oligomer control that were not predicted to target these genes. Secreted frizzled 
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receptor protein 2 (Sfrp2) is shown as an example of a predicted MRE that was 
affected by Pre-miR-134 by a negligible amount (Figure 4.6A). Luciferase activity of 
miR-134 reverse complement (RC) sequence was suppressed almost completely by 
Pre-miR-134 (Figure 4.6A), confirming Pre-miR-134 activity in this assay.  
 
Pre-miR-134 could specifically suppress luciferase activity when the entire Nanog 
3’UTR was cloned within the 3’UTR of the Renilla luciferase reporter, verifying that 
the use of a single copy MRE is indicative of a microRNA’s effect on the 3’UTR of a 
gene (Figure 4.6B). Moreover, the effect of miR-134 on Nanog’s 3’UTR was 
abolished when its predicted MRE was mutated specifically while maintaining the 
integrity of the rest of the 3’UTR (Figure 4.6B and C). This demonstrates that this site 




Figure 4.6. LRH1, FADD, Gαo and Nanog are potential targets of miR-134 (A) Graph 
showing the effect on luciferase activity in 293T cells of PmiR and Scr control transfections 
against five predicted miR-134 MREs. Relative to Scr control, PmiR-134 reduced luciferase-
MRE activity of 4 of the 5 constructs, but not PmiR-21 or PmiR-124a. These unrelated PmiRs 
were used to detect any false positives. The PmiRs were also tested with luciferase-MRE 
constructs containing the perfect reverse complements of miR-134 (134 RC) and miR-21 (21 
RC) as positive and negative controls respectively (B) Graph showing the effect on luciferase 
activity in 293T cells of PmiR and Scr transfections against the entire Nanog 3’UTR. Relative 
to Scr control, PmiR-134 reduced luciferase-UTR activity, but not PmiR-21 or PmiR-296. All 
luciferase experiments were performed in quadruplicate thrice (n=12), where error bars 
denote standard error, and asterisk (*) denotes significance of difference to scrambled RNA 
oligomer control at p<0.0001 (C) Sequences and binding heteroduplexes of the predicted 







After confirming the effect of miR-134 on Nanog, LRH1, Gαo and FADD at the 
luciferase level, its effect on the endogenous protein levels of these four selected 
positive targets in E14 mESCs was explored next (Figure 4.7A, B). Transfection with 
Pre-miR-134 downregulated the endogenous protein levels of LRH1 (lanes 2 and 4), 
Gαo (lanes 10 and 12) and Nanog (lanes 14 and 16), both in the presence and absence 
of RA. Consistent with the induction of miR-134 by RA, RA alone also 
downregulated the endogenous protein levels of LRH1 (lanes 1 and 3), Gαo (lanes 9 
and 11) and Nanog (lanes 13 and 15). Importantly, and for all three tested targets, 
protein downregulation was not associated with a concomitant down-regulation in 
mRNA levels (Figure 4.7C), suggesting that miR-134 acted, at least in part, by 
translationally inhibiting these mRNAs in E14 mESCs.   
 
An intriguing finding was that miR-134 on its own led to an increase (+50%) in 
FADD mRNA levels (Figure 4.7C), whereas FADD protein levels decreased (-80%) 
(Figure 4.7A, lanes 5 and 6). RA induced a significant increase in FADD mRNA 
(+100%) and enhanced the effect of Pre-miR-134 (+250%) (Figure 4.7C; lanes 7 and 
8), with concomitant increase in FADD protein (Figure 4.7A and B; lanes 7 and 8). 
This highlights that miR-134 on its own can affect mRNA levels and that its effect on 
protein levels can be context dependent. RA- or N2B27-mediated changes on other 
components of the post-transcriptional machinery (Harris et al., 2004) may alter the 
mechanism of action by which miR-134 affects FADD translation. 
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Figure 4.7. miR-134 reduces the protein levels of predicted pluripotency-associated 
targets LRH1, Gαo and Nanog without altering their mRNA levels (A) Western blot 
analyses showing that PmiR-134 transfection of E14 mESCs, relative to Scr transfection, led 
to a reduction in the endogenous protein levels of LRH1, FADD, Gαo and Nanog. 
Experiments were performed in triplicate twice (n=6), and a representative blot is shown (B) 
Graph showing quantification of the western blots in (A) (C) Graph showing percentage 
change in mRNA levels of LRH1, FADD, Gαo and Nanog in PmiR-134 transfected E14 
mESCs ± RA relative to Scr transfection without RA-treatment. Experiments were performed 
in triplicate thrice (n=9), where error bars denote standard error. 
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4.4   Knockdown of miR-134 targets     
   induces mESC differentiation 
If these genes were bona fide targets of miR-134 that could mediate its effect, 
downregulation of their expression in mESCs should promote differentiation. To 
investigate this, FADD, LRH1, Gαo and Nanog levels were perturbed by RNA 
interference (RNAi) and their effects on mESC differentiation were examined. 
Quantiative PCR demonstrated that the respective RNAi were effective in 
significantly reducing transcript levels of LRH1, FADD, Gαo and Nanog (Figure 
4.8A).  
 
Knockdown of Nanog, LRH1 and Gαo resulted in differentiation of mESCs as 
determined by the reduction in Oct4 promoter activity (Figure 4.8B). To compare the 
effects of miR-134 and target genes RNAi on mESC differentiation, the levels of 
transcript markers associated with pluripotency (Oct4, Sox2) and differentiation 
(Nestin, Otx2, Fgf5, Sox17, Bmp4; Figure 4.8C) were measured. RNAi against LRH1, 
Gαo and Nanog decreased Oct4 and Sox2 with concomitant elevation of ectoderm-
associated Fgf5, but had variable effects on Nestin, Otx2, Sox17 and Bmp4 (Figure 
4.8C).  These data indicated that although Nanog, LRH1 and Gαo were all able to 
induce some degree of mESC differentiation, none of them were able to completely 
replicate the effect of miR-134. This suggests that they may be partial mediators of 
miR-134 activity, and supports the hypothesis that miR-134 acts via modulation of 





Figure 4.8. Knockdown of Nanog, LRH1 and Gαo results in differentiation of mESCs. 
(A) Graph showing that transfection of gene-specific RNAi in mESCs resulted in a reduction 
in target mRNAs relative to non-silencing shRNA control (CTL). No reduction was observed 
in target mRNAs with vector only transfection. The expression of each gene was normalized 
to internal β-actin, and expressed as the relative percentage change to their respective gene in 
the CTL. Experiments were performed in triplicate thrice (n=9), where error bars denote 
standard error, and asterisk (*) denotes significance of difference to non-silencing vector 
control at p<0.0001 (B) Graph showing changes in Oct4 promoter activity in E14 mESCs 
induced by RNAi to LRH1, FADD, Gαo, Nanog, and Oct4, relative to the non-silencing 
shRNA control (CTL). RNAi to LRH1, Gαo, Nanog and Oct4 elicited reductions in Oct4 
promoter activity. To correct for transfection efficiency, firefly luciferase activity was 
normalized to Renilla luciferase activity, and expressed as relative percentage change to that 
of the CTL. Experiments were performed in quadruplicate thrice (n=12), where error bars 
denote standard error, and asterisk (*) denotes significance of difference to non-silencing 
vector control at p<0.0001 (C) Graph showing transcript changes in pluripotency and 
differentiation markers induced by PmiR-134 and RNAi against LRH1, FADD, Gαo and 
Nanog relative to non-silencing shRNA control (CTL). Experiments were performed in 
triplicate thrice (n=9), where error bars denote standard error, and asterisk (*) denotes 
significance of difference to non-silencing vector control at p≤0.001. 
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4.5   Discussion 
In the last few years, diverse computational methods for predicting microRNA 
binding sites have been published (Table 1.3). One approach is ‘signature-based’, and 
relies on a model in which target MREs posses exact complementarity to the first 6 to 
8 bases from the 5’ end of the mature microRNAs. This signature is referred to as the 
‘seed’ region (Krek et al., 2005; Lewis et al., 2003, 2005; Rajewsky and Socci, 2004). 
Another approach (Enright et al., 2003; John et al., 2004; Kiriakidou et al., 2004) 
utilizes variants of the dynamic programming solution to the ‘‘local suffix alignment’’ 
problem (Gusfield, 1997). Other algorithms make use of hidden Markov models to 
find seed matches (Stark et al., 2003), or calculate binding interactions for every 
offset of the microRNAs target sequence and subselect the relative placements that 
are significant based on an energy-based statistical measure (Rehmsmeier et al., 
2004). Although these computational methods can be applied to individual genomes 
in isolation; multiple species conservation of a potential binding site at orthologous 
positions has typically been used to filter results. 
 
At a time when it was thought that each microRNA only targeted a few genes (Lewis 
et al., 2003), one of the most significant findings in this study was that a single 
microRNA could have numerous targets. Luciferase results in 293T cells for miR-134 
and miR-375 showed at least 30% repression for 81.7% and 61.4% of the tested 
MREs respectively. If this ratio of success, obtained by testing randomly selected 
targets, is representative of the entire datasets then it follows that a large number of 
the predicted miR-134 and miR-375 targets may be true. In other words, miR-134 
may have more than 129/158*2318 = ~1,890 targets, and miR-375 may have more 
than 27/44*2292 = ~1,400 targets.  
 68
If these two microRNAs are not exceptions in this regard, it is probable that many  
other microRNAs have numerous targets. This hypothesis is in congruence with the 
average number of transcripts that rna22 estimates are targeted by a single 
microRNA: focusing on 3’UTR targets alone, the numbers range from several tens of 
targets in the worm to about a thousand in the human genome (Miranda et al., 2006).  
 
Furthermore, the experiments here were only performed in a single cell line. Based on 
the fact that post-trancriptional mechanisms can vary from cell type to cell type (Han 
et al., 2000; Sammarco et al, 2007), it is a possibility that some microRNAs may only 
bind to certain targets in specific cell types. If this is true, then experiments in single 
cell lines may not encompass the entire spectrum of endogenous targets of a particular 
microRNA. This will be explored further in the next chapter.  
 
With regards to miR-134, there were 2,318 rna22-predicted mRNA 3’UTR cis-
element targets in the mouse genome for miR-134, of which 129 out of 158 were 
confirmed as positive (>80%). Over one thousand genes expressed in mESCs 
comprised miR-134 potential targets. This implies that the mechanism by which miR-
134 post-transcriptionally regulates mRNA to enhance mESC differentiation is 
complex.  
 
This hypothesis is supported by the microarray data, which demonstrated that miR-
134 is able to induce the global modulation of transcript levels of its potential target 
mRNAs. Interestingly, RNAi of any single target of miR-134 was not sufficient to 
replicate the Pre-miR-134 induced changes in mESC transcript levels, again 
suggestive of a wide-ranging miR-134 target network. Together, these data indicate 
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that RA-induced elevation of miR-134, or exogenously elevated levels of miR-134 
alone may promote mESC differentiation through the co-ordinate post-transcriptional 
regulation of a potentially large target-gene pool, that includes the pluripotency-
associated target genes such as Nanog, LRH1 and Gαo. Interestingly, the sequences of 
the predicted miR-134 target sites in LRH1 and Gαo are conserved in mouse, rat and 
human; and mouse, rat, human, dog and chicken respectively. 
 
Nanog and LRH1 are known regulators of mESC self-renewal where their interaction 
with specific promoter regions is integral to the transcriptional regulation of many 
genes, including Oct4 (Loh et al., 2006). Although Nanog mRNA levels remained 
unchanged in E14 mESCs during Pre-miR-134 treatment over 3 days, but decreased 
in D3 mESCs, this may reflect subtle differences across cell types, or that D3 mESCs 
may be more sensitive to elevated levels of Pre-miR-134 than E14 ESCs. 
 
Gene expression analysis demonstrated clearly that amongst the constellation of genes 
responding to RA treatment in mESCs, a subset of genes responded in the same 
manner to Pre-miR-134 transfection. Antagonists to miR-134 ablated the effects of 
miR-134. The data add to growing evidence that miRs function not only by 
translational inhibition of target mRNAs, but can influence changes in levels of non-
target mRNAs. Recent reports show that RNAi can lead to an upregulation of target 
mRNAs in some cases (Li et al., 2006). Intriguingly, miR-134 on its own led to an 
increase in FADD mRNA levels, whereas FADD protein levels decreased. RA 
induced a significant increase in FADD mRNA and enhanced the effect of PmiR-134, 
with concomitant increase in FADD protein. As RA induces multiple changes in 
ESCs, this highlights that the effect of a microRNA may be context dependent.  
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Thus far, the predicted targets studied have shed some light on the mechanism by 
which miR-134 modulates mESC differentiation. However, results in chapter 3 also 
suggested that miR-134 was able to enhance the differentiation of mESCs into neural 
lineages. As the validated targets thus far could not explain this phenomenon, this led 
to the hypothesis that miR-134’s effect on neural differentiation was mediated by 
additional targets that had not been identified yet.  
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CHAPTER 5.  MIR-134 IN NEURAL DEVELOPMENT 
5.1   Introduction 
 
Aside from this study, the only reported results that describe a functional role for 
miR-134 were reported by Schratt et al. They found that miR-134 was brain-specific 
and localized to the synaptodendritic compartment of rat hippocampal neurons, where 
it negatively regulated the size of dendritic spines. This effect was mediated by miR-
134 inhibition of the translation of Limk1, a protein kinase that controlled dendritic 
spine development. Exposure of neurons to extracellular stimuli such as brain-derived 
neurotrophic factor was able to relieve miR-134 inhibition of Limk1 translation, and 
may contribute to synaptic development, maturation and/or plasticity (Schratt et al., 
2006). 
 
These findings indicated that miR-134 regulated synapse formation in mature, 
postnatal, rat hippocampal neurons.  However, its role in neural cell differentiation at 
earlier stages had not been investigated. To gain better insight into this phenomenon, 
a list of genes that have been implicated in neural differentiation and development 
were selected from the list of 2,800 rna22-predicted miR-134 targets for experimental 
validation. Additionally, as experiments thus far had been performed in mESCs, a 
model for studying early development in vitro, an investigation of miR-134’s 
expression profile during early mouse development in vivo was also performed. 
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5.2   MiR-134 may target Chrdl and Dcx, amongst other genes 
 
In order to begin to understand the potential role that miR-134 may play in neural 
differentiation, 47 out of the 2318 mRNA targets predicted by rna22 were selected for 
validation using the luciferase-based reporter assay. These genes were chosen based 
on their known involvement in neural differentiation and/or development.  
 
Of these 47 MREs, located in a total of 41 genes, luciferase activity was suppressed 
by at least 30% for 17 of the targets tested (See Appendix 10.4). Figure 5.1A shows 
the results of these assays in 293T cells for 8 MREs which demonstrated significant 
repression of luciferase activity when co-transfected with Pre-miR-134. No effect was 
observed with Pre-miR-296 or Scrambled oligomer that were not predicted to target 
these genes. Chordin-like-1 MRE 4 (Chrdl1-4) is an example of a predicted MRE that 
was affected by Pre-miR-134 by a negligible amount (Figure 5.1A). Luciferase 
activity of miR-134 reverse complement (RC) sequence was suppressed almost 
completely by Pre-miR-134 (Figure 5.1A), confirming Pre-miR-134 activity in this 
assay.  
 
To examine the effect of miR-134 on these neural MREs in a more biological context, 
the luciferase screen was repeated in Neuro2As, a mouse brain neuroblastoma cell 
line. Appendix 10.4 lists all 47 targets tested and the corresponding luciferase 
activities respective to Scr control in both cell lines. For the majority of the 47 MREs 
tested, the luciferase activities after Pre-miR-134 transfection relative to their 
respective Scr control transfection were strikingly similar across both 293Ts and 
Neuro2As. This result suggests that 293Ts are indeed a valuable model system in this 
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context, and that results obtained in this cell line are likely to be representative of 
bona fide microRNA:target interactions.  
 
Figures 5.1A and B depict the 8 MREs which demonstrated significant repression of 
luciferase activity when co-transfected with Pre-miR-134 in both 293Ts and 
Neuro2As respectively (Figures 5.1A and B). These 8 MREs are found in the 6 genes 
BMP8b (1 site), Chordin-like 1 (Chrdl1, 3 sites), Doublecortin (Dcx, 1 site), Deltex-4  
(Dtx4, 1 site), Hoxc10  (1 site) and Tcf12  (1 site). Dcx is a microtubule-associated 
protein that is highly expressed by migrating and differentiating neurons (Cohen et 
al., 2008; Francis et al., 1999; Gleeson et al., 1999). It is a reliable marker of 
neurogenesis and neuronal precursors, and is necessary for neuronal migration, a 
pivotal step during the development of brain architeacure and function (Hwang et al.; 
Kawauchi and Hoshino, 2008; Verwer et al., 2007). Dcx may also function in glia-to-
neuron communication in the adult human neocortex (Verwer et al., 2007). Dcx 
knockout mice exhibit severe morphological defects in the rostral migratory stream, 
delayed neuronal migration and have a fractured pyramidal cell layer in the 
hippocampus (Corbo et al., 2002; Koizumi et al., 2006). 
 
Bmp8b is a member of the TGFbeta superfamily of growth factors, which promotes 
primordial germ cell differentiation from mESCs (Kee et al., 2006). A secreted 
protein with significant homology to Chordin, Chrdl1, is hypothesized to be an 
important regulator of BMP signaling for the differentiation of mesenchymal cells and 
the development of specific neurons (Nakayama et al., 2001). Dtx4, a mouse homolog 
of Drosophila Deltex, encodes a modulator of the Notch pathway that may be 
involved in the regulation of neurogenesis (Kishi et al., 2001). It has been reported to 
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promote oligodendrogliogenesis from progenitor cells and oligodendrocyte precursor 
cell differentiation (Cui et al., 2004) and repress neural fate (Ramain et al., 2001). 
Hoxc10 is expressed in the lumbar spinal cord, and mutations in this gene have been 
shown to affect motor neuron patterning (Choe et al., 2006). It is thus conceivable 
that regulation of any or several of these genes may modulate neural differentiation. 
   
 
Figure 5.1. BMP8b, Chrdl1, Dcx, Dtx4 and Hoxc10  are potential targets of miR-134 
(A,B) Graph showing the effect on luciferase activity in (A) 293T and (B) Neuro2A cells of 
PmiR and Scr control transfections against nine predicted miR-134 MREs. Relative to Scr 
control, PmiR-134 reduced luciferase-MRE activity of 8 of the 9 constructs, but not PmiR-
296. This unrelated PmiR was used to detect any false positives. The PmiRs were also tested 
with the luciferase-MRE construct containing the perfect reverse complement of miR-134 
(134 RC) as a positive control. All luciferase experiments were performed in quadruplicate 
thrice (n=12), where error bars denote standard error. See Appendix 10.4 for the entire list of 
47 targets tested and the corresponding luciferase activities respective to Scr control in both 
cell lines. 
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5.3   Expression profiling of miR-134     
   in embryos and adult tissues 
To gain further insight into the possible role of miR-134 in neural differentiation in 
vivo, quantitiative PCR was used to examine the temporal and spatial expression 
patterns of miR-134 in mouse embryos and adult tissues (Figure 5.2A). During mouse 
embryogenesis, miR-134 expression was detected in embryonic day (E)7.5 whole 
embryos at relatively low levels. This increased between E7.5 and E15.5 and 
decreased towards E17.5 (Figure 5.2A). MiR-134 expression was highest from E11.5 
through E15.5, which coincides with major phases of spinal cord neurogenesis, 
neuronal differentiation, cell migration, gliogenesis, and motor neuron cell death 
(Choe et al., 2006).  
 
Spatial distribution of miR-134 at E12.5 indicated that miR-134 levels were highest in 
the midbrain compared to the cortex, hindbrain and hippocampus (Figure 5.2B). 
Levels of brain-specific miR-124a were lower than miR-134 in the embryonic brain. 
Interestingly, this pattern was reversed in the adult (postnatal day 60) brain where 
miR-124a levels were higher in all brain regions relative to miR-134, although the 
latter’s levels remained comparably higher in the midbrain (Figure 5.2C). Although 
the significance of this switch from miR-134 to miR-124a predominance is not 
understood, it may represent a change in maturation from fetal to adult tissue. 
Intriguingly, the overexpression of several microRNAs in adult cardiomyocytes was 
able to reactivate fetal genes (van Rooij et al, 2006; van Rooij et al,  2007).  
 
Screening of various adult tissues was also performed. This demonstrated that miR-
134 expression was notably enriched in brain and spinal cord (as with miR-124a), 
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Figure 5.2. miR-134 expression increases during embryogenesis and is present in several 
adult tissues (A) MicroRNA quantitative PCR analysis demonstrating that miR-134 
expression increases during mouse embryogenesis and is present in various adult mouse 
tissues, notably the brain and spinal cord. miR-16 expression was used as a loading control 
(B,C) MicroRNA quantitative PCR analysis showing miR-134 expression in various parts of 
the (B) embryonic and (C) adult brain. miR-16 expression was used as a loading control. 
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MiR-134 and miR-124a distribution were also examined by in situ hybridization 
(Figure 5.3). A diffuse miR-134 expression was observed throughout the E11.5 
embryo, although there was significant enrichment in caudal and ventral brain 
regions. This was consistent with quantitative PCR measurements, showing 
significant miR-134 expression in hindbrain (Hb) and the ventral telencephalon / 




Figure 5.3. Distribution of miR-134 expression in the E11.5 embryo. Whole mount and 
section in situ hybridization depicting miR-134, miR-124a and β–actin expression during 
mouse embryogenesis. Diffuse miR-134 expression was observed throughout the E11.5 




5.4   Discussion 
The preliminary evidence presented here suggests that beyond its role in enhancing 
the differentiation in vitro of mESCs towards neural lineages, miR-134 may also be 
involved in modulating neural differentiation in vivo or development. This may 
involve the following rna22-predicted targets that have been implicated in these 
processes and have been validated at the luciferase level: BMP8b, Chrdl1, Dcx, Dtx4, 
Hoxc10 and Tcf12.  
 
The presence of 4 predicted MREs in Chrdl1, of which 3 showed very significant 
luciferase repression across both cell lines tested, was especially fascinating. To date, 
although multiple target sites in a single mRNA by a specific microRNA have been 
reported in plants (Arteaga-Vázquez et al., 2006), similar findings have not been 
described in animals.  
 
Another putative miR-134 target which demonstrated dramatic luciferase repression 
across both cell lines tested is Dcx. Intriguingly, reduced expression of Dcx in 
dendrites resulted in reduced branch points, total length and complexity (Cohen et al., 
2008). This finding appears to be consistent with Schratt et al.’s finding that miR-134 
negatively regulated dendritic spine size in hippocampal neurons via Limk1 (Schratt et 
al., 2006), and suggests that miR-134 may have more substantial effects on neuronal 
maturation that may be cell type and/or context dependent.  
 
In addition, in situ hybridization and quantitative PCR analysis indicate that the peak 
of miR-134 expression in vivo coincides with major phases of spinal cord 
neurogenesis, neuronal differentiation, cell migration, gliogenesis, and motor neuron 
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cell death (Choe et al., 2006). Although at a preliminary stage, it is hoped that this 
combination of expression analysis and validation of neural target genes will serve as 
a useful launchpad to extend the developmental role for miR-134 prior to that of spine 
formation in terminally differentiated neurons.  
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CHAPTER 6.  MICRORNAS TARGETING OUTSIDE THE 3’UTR 
6.1   Introduction 
 
It has long been established that RBPs are essential components of translation and 
mRNA degradation processes, and that these RBPs bind across all regions of mRNAs 
(George and Tenenbaum, 2006). Therefore, as microRNAs are part of the post-
transcriptional regulatory machinery, it would not be surprising that they should 
probably be active across all regions of a mRNA where they act in conjunction with 
RBP complexes. 
 
In this final chapter, the computational evidence generated by rna22 suggesting that 
microRNAs may target genes outside their 3’UTRs is revisited. rna22 is not biased in 
favor of 3’UTRs as its starting point is microRNA sequences, not 3’UTR sequences. 
Application of rna22 to the analysis of the worm, fruit fly, mouse and human 
genomes resulted in the predictions that between 31% and 53% of the known 5’UTR 
sequences contained one or more targets, and that almost every amino acid coding 
sequence contained one or more targets (Appendix 10.4).  
 
Although it is unclear whether rna22’s low rate of false positives for 3’UTRs 
predictions can be extrapolated to predictions in 5’UTR and CDS regions, the sheer 
number of predictions raises the distinct possibility that fairly extensive microRNA 
regulation may occur via the 5’UTRs and CDSs of gene transcripts in animals, in 
addition to 3’UTRs. To investigate this, the interactions of microRNAs with the 
transcription factors Nanog and Sox2 were explored. 
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6.2   MiR-296 targets the coding region of mouse Nanog 
 
To explore the possibility of microRNAs targeting outside the 3′UTR of a transcript, 
rna22 was first used to determine which of the 380 murine microRNAs in Release 9.1 
of miRBase (Griffiths-Jones, 2006) formed heteroduplexes in Nanog’s 5′UTR, coding 
sequence (CDS) or 3′UTR. The settings for the three parameters of rna22 were as 
follows: the number of unmatched bases in the seed region was set to G=0; the 
minimum number of paired-up bases was set to M=12; and, the maximum allowed 
folding energy was set to E=-20Kcal/mol. The above choices for M and E were 
substantially more lenient than those used for 3’UTR predictions – this was an 
intentional choice meant to allow a broader exploration of the space of rna22’s 
predictions.  
 
MiR-296 was predicted to target the CDS of Nanog at two distinct non-overlapping 
locations starting at positions 235 and 493 respectively from the translation start site. 
These were full-length binding sites, i.e. each predicted heteroduplex extended well 
beyond the span of the microRNA seed. These two sites were in close proximity and 
flanked the region that coded for Nanog’s homeobox domain (Figure 6.1). However, 
the significance of this arrangement is unclear. rna22 predicted no miR-296 binding 
sites in either the 5′UTR or the 3′UTR of Nanog. 
 
Considering the leniency of parameter settings, the fraction of correct predictions in 
this set will likely be lower than the 75-80% obtained earlier for the 3’UTR 
predictions. Even considering a reduced rate of correctly predicted binding sites and 
the fact that microRNA expression exhibits temporal and tissue-specific aspects, the 
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sheer number of predicted heteroduplexes will likely represent a substantial obstacle 
to attempts at elucidating the full extent of Nanog’s control by microRNAs. 
 
Figure 6.1. Nucleotide sequence of Nanog’s CDS region, codons and the corresponding 
amino acid translation. The homeodomain is marked with a red border whereas the two 
predicted binding sites for miR-296, starting at positions 235 and 493 respectively from the 
start of translation, are shown in cyan background. Note the symmetric placement of the two 





Luciferase-reporters were used to test the predicted putative MREs. Each MRE was 
inserted as a single copy directly downstream of a Renilla luciferase open reading 
frame (ORF) as described earlier. Each MRE was examined separately in order to 
ensure that any reduction in luciferase activity could be attributed to a single source. 
The relative luciferase activity of the control transfection (Scr, scrambled RNA 
oligomer – represented as 100%) was compared to the activity observed after addition 
of the cognate microRNA. The reverse complement of miR-296, labeled 296 RC, 
served as a positive control whereas microRNAs miR-21 and miR-134, which are not 
predicted to target Nanog-235p or Nanog-493p, served as negative controls.  
 
Figure 6.2A shows that the luciferase activity of both MREs is significantly repressed 
in the presence of Pre-miR-296 but remains unchanged when Pre-miR-21 or Pre-miR-
134 were transfected (negative controls). Notably, the amount of observed repression 
is different for Nanog-235p and Nanog-493p, suggesting that each of these MREs 
likely acts as an independent binding site for miR-296 in the CDS of Nanog. 
 
Nanog’s full length 5′UTR and 3′UTR were next cloned into the luciferase vector 
generating two different reporters. As rna22’s prediction that miR-134 targets 
Nanog’s 3′UTR had been validated in chaper 4, and it is not predicted to target 
Nanog’s 5′UTR, it was used as a negative control for the 5′UTR assay and as a 
positive control for the 3′UTR assay. The results in Figure 6.2B show that there is 
effectively no change in luciferase activity upon co-transfection of Pre-miR-296 with 
the Nanog 5′UTR and 3′UTR reporters, in agreement with the computational 
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Figure 6.2. Nanog-235p and Nanog-493p are potential targets of miR-296 (A) Graph 
showing the effect on luciferase activity in 293T cells of Pre-miR and Scr control 
transfections against the Nanog-235p and Nanog-493p MRE constructs. Relative to Scr 
control, Pre-miR-296 reduced luciferase-MRE activity of both these constructs, but not Pre-
miR-21 or Pre-miR-134. These unrelated Pre-miRs were used to detect any false positives. 
The Pre-miRs were also tested with a luciferase-MRE construct containing the perfect reverse 
complements of miR-296 (296 RC) as a positive control (B) Graph showing the effect on 
luciferase activity in 293T cells of Pre-miR and Scr transfections against the entire Nanog 
5’UTR and 3’UTR constructs. Relative to Scr control, Pre-miR-296 did not reduce luciferase 
activity, thus suggesting the absence of binding sites for this microRNA in Nanog’s 5′UTR 
and 3′UTR. All luciferase experiments were performed in quadruplicate thrice (n=12), where 
error bars denote standard error, and asterisk (*) denotes significance of difference to 




To explore the impact of miR-296 on endogenous Nanog in mESCs, Western blotting 
of mESCs transfected with Pre-miR-296 was performed. This showed a marked 
decrease in Nanog protein expression (Figure 6.3A). However, no change was 
observed when Scrambled oligomer or Pre-miR-181a were transfected. Quantitative 
PCR showed only a slight decrease of Nanog mRNA in the presence of Pre-miR-296, 
compared to the pronounced reduction in its protein level (Figure 6.3C). These results 
suggest a mode of action whereby miR-296 induces posttranscriptional down-






Figure 6.3. Transfection of Pre-miR-296 reduces the amount of endogenous Nanog 
protein in mESCs and the amount of exogenous Nanog protein in 293T cells (A) Western 
blot analysis of mESCs transfected with control Scrambled RNA oligomer (Scr), Pre-miR-
296 or Pre-miR-181a (B) Western blot analysis of 293T cells co-transfected with control Scr, 
Pre-miR-296 or Pre-miR-181a and 0.2μg of Nanog CDS (C) Quantitative PCR analysis of 
mESCs transfected with control Scr, Pre-miR-296 or Pre-miR-181a, and 293T cells co-
transfected with control Scr, Pre-miR-296 or Pre-miR-181a and 0.2μg of Nanog CDS, 
together with the quantitation of the corresponding Western blots in (A) and (B). 
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Earlier work has suggested the possibility of a complex regulatory interconnection 
involving miR-296, Nanog, Oct4 and possibly other transcription factors (Loh et al., 
2006). To ensure that the above findings were not the result of a complex interplay of 
the numerous proteins involved in the regulation of mESC pluripotency, Nanog was 
also studied in an environment shielded from such interactions. Western blot analysis 
confirmed that Nanog protein is absent from 293T cells (Figure 6.4A) thus making the 
latter a suitable platform for this purpose. This experiment was further optimized by 
transfecting various amounts of plasmid and harvesting cells at different time points. 
The most significant effect was observed with 0.2 μg of plasmid construct, and when 
cells were harvested 24 hr post-transfection, so these conditions were used for 
subsequent experiments (Figure 6.4). 
 
 
Figure 6.4. Selection of 293T cells as a suitable cell line to study exogenous Nanog (A)  
Western blot analysis of 293T cells co-transfected with water, control Scr, or Pre-miR-296 
and 1.5 μg of empty vector or Nanog CDS. Cells were harvested 48 hr post-transfection.  (B) 
Western blot analysis of 293T cells co-transfected with control Scr, or Pre-miR-296 and 0.2 
or 0,4 μg of Nanog CDS. Cells were harvested 24 hr post-transfection. 
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Following co-transfection of Pre-miR-296 and the Nanog-CDS construct in 293T 
cells, quantitative PCR showed a slight decrease of Nanog mRNA in the presence of 
Pre-miR-296, whereas Western blotting showed a rather pronounced decrease in 
Nanog protein expression (Figure 6.3B and C). This is consistent with observations in 
mESCs. When the Nanog-CDS construct was co-transfected with either Scr or Pre-
miR-181a (negative controls), quantitative PCR and Western blots revealed no change 
in Nanog mRNA or protein levels (Figure 6.3B and C).  
 
Given that the construct we employed in 293T cells comprised only the CDS of 
Nanog, these findings show that miR-296 acts on Nanog’s CDS region and induces 
post-transcriptional repression of exogenous Nanog mRNA in these cells. Even 
though our data suggests that this repression is predominantly through translation 
repression, we cannot rule out the possibility that miR-296 somehow induces an 
increase in Nanog protein turnover; we examine this last point next. 
 
In order to corroborate the hypothesis that the effect of miR-296 is predominantly 
through translation repression of Nanog mRNA via binding to the Nanog-235p and 
Nanog-493p sites, silent mutations to each of these sites were introduced and studied . 
Since these mutations result in no amino acid changes to the Nanog protein, the 
observed miR-296 effects could viewed purely in the context of either translation 
repression or mRNA degradation.  
 
Mutational studies involved luciferase reporter assays for the MRE mutants, and 
quantitative PCR and Western blot analysis of 293T cells that were co-transfected 
with Pre-miR-296 and mutant versions of Nanog-CDS. Several Nanog-CDS mutants 
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were designed as follows: a) silent mutations in the Nanog-235p site only and with the 
Nanog-493p site intact; b) silent mutations in the Nanog-493p site only and with the 
Nanog-235p site intact; and, c) simultaneous silent mutations at both the Nanog-235p 
and the Nanog-493p sites. 
 
Figure 6.5A shows the results for the reporter assays and the mutant MREs containing 
the silent mutations: the mutant MREs have been listed and numbered in order of their 
increasing ability to disrupt the binding of miR-296. Five mutants of the Nanog-235p 
MRE and eight mutants of the Nanog-493p MRE were analyzed. With the exception 
of mutant Nanog-493p/m1 that contained a single-nucleotide silent mutation, all other 
mutant MREs contained mutations at two or more nucleotide locations. Figure 6.5B 
shows the sequence for each mutant MRE. As can be seen, in all cases the silent 
mutations disrupted miR-296’s ability to suppress luciferase activity. 
 
Figure 6.6 shows results from the Western blot and quantitative PCR analysis of 293T 
cells that were co-transfected with Pre-miR-296 and wild-type or mutant constructs of 
Nanog’s CDS. Again, Scr and 296RC served as negative and positive control 
respectively. We used four Nanog-CDS mutants in these experiments. The mutants’ 
labels are the same as in Figure 6.5, i.e., 235-m4 denotes the Nanog-CDS mutant 
whose Nanog-235p MRE has been replaced by the mutant-MRE labeled m4 in Figure 




Figure 6.5. Several MRE mutants are able to rescue the miR-296 induced reduction in 
luciferase activity of Nanog-235p and Nanog-493p (A) Luciferase results for co-
transfection of Pre-miR-296 with various luciferase-MRE mutant constructs; values for each 
construct are presented relative to their respective Scr control transfection. Results are shown 
for five mutants of the Nanog-235p MRE and for eight mutants of the Nanog-493p MRE (B) 
Sequences corresponding to the silent mutations we introduced in each mutant MRE – red 
letters show the modified nucleotides.  
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In concordance with the reporter assays, silent mutations to either one of the binding 
sites disrupted miR-296’s ability to repress the translation of the mutant Nanog-CDS 
in 293T cells. Furthermore, introduction of silent mutations at both the Nanog-235p 
and Nanog-493p sites simultaneously (235-m4 and 493-m2) abolished the 
downregulation effect of miR-296 on Nanog (Figure 3.23). It is evident that these 
silent mutations disrupted miR-296’s ability to down-regulate Nanog, thus showing 
that miR-296’s effect on Nanog protein levels is not through altered protein turnover 
states. This observation in conjunction with the lack of changes in mRNA levels 
demonstrates that the miR-296 effects are predominantly through translation 
repression of Nanog mRNA via miR-296’s interaction with specific CDS elements. 
 
 
Figure 6.6. The 235-m4/493-m2 double mutant is able to rescue the miR-296 induced 
reduction in Nanog protein levels (A) Western blot analysis of 293T cells co-transfected 
with control Scrambled RNA oligomer (Scr) or Pre-miR-296, and 0.2μg of Nanog-CDS wild-
type and mutant constructs (B) Quantitative PCR analysis of 293T cells co-transfected with 
Pre-miR-296, and 0.2μg of Nanog-CDS wild-type and mutant constructs, together with the 
quantitation of the corresponding Western blots; values for each construct are presented 
relative to their respective Scr control transfection. 
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6.3     MiR-296 modulates mESC differentiation 
 
As Nanog is a known regulator of mESC pluripotency (Chambers et al., 2003, Mitsui 
et al., 2003), these results suggested that miR-296-modulated repression of Nanog 
protein levels may modulate mESC differentiation. To investigate this, miR-296 
expression during mESC differentiation was profiled. Quantitative PCR analyses 
demonstrated that miR-296 expression increased during the differentiation of E14 
mESCs. During RA induction, its expression relative to day 0 increased to about 
650% after 4 days, with subsidence by day 6 (100% of day 0 expression, Figure 
6.7A). During EB formation, its expression relative to day 0 increased to about 900% 
after 10 days, with subsidence by day 15 (400% of day 0 expression, Figure 6.7A).  
 
It was next determined whether miR-296 could elicit phenotypic effects. E14 mESCs 
transfected with scrambled RNA oligomer (Scr) maintained the domed colony 
structures characteristic of mESCs and expressed high levels of alkaline phosphatase 
(Figure 6.7B). Alkaline phosphatase is expressed at higher levels in pluripotent ESCs 
compared to differentiated cells. However, transfection with Pre-miR-296 alone 
induced visible morphological changes in these cells, with the cells acquiring a 
flattened epithelial-like morphology typical of differentiation and expressing reduced 
levels of alkaline phosphatase (Figure 6.7B). Furthermore, colony forming unit assays 
demonstrated that there was a ~50% decrease in the ability of mESCs treated for 2 
days with Pre-miR-296 to form mESC colonies compared to scrambled RNA 
oligomer treated controls (Figure 6.7C). This provided additional support to the 




Figure 6.7. miR-296 is upregulated during mESC differentiation, and reduces the 
alkaline phosphatase activity and colony forming efficiency of mESCs (A)  
MicroRNA quantitative PCR analyses showing that, relative to expression in untreated E14 
mESCs, miR-296 expression increases during both RA and EB differentiation of E14 mESCs. 
Experiments were performed in duplicate thrice (n=6), where error bars denote standard error, 
and asterisk (*) denotes significance of difference to day 0 at p<0.0001 (B) Photographs 
showing alkaline phosphatase (AP) staining of E14 mESCs three days post-transfection with 
Pre-miR-296 or Scr control; where Pre-miR-296, unlike Scr, induced visible phenotypic 
changes to a flattened, epithelial-like morphology, and reduced AP activity relative to Scr 
control (C) Colony formation assay results demonstrating that relative to Scr control, 
transfection of Pre-miR-296 into E14 mESCs significantly reduced the proportion of 
undifferentiated, colony forming mESCs in the cell population. Let-7i is an example of a 
microRNA that does not affect ESC differentiation. The data is expressed as mean number of 
colony forming units ± standard error. Experiments were performed in triplicate thrice (n=9). 
 
 
The effect of miR-296 alone on cell phenotype as determined by changes in the 
mRNA and protein levels of key marker genes associated with pluripotency and 
differentiation was determined next. Quantitative PCR of total RNA samples taken 
from E14 mESCs three days post-transfection with Pre-miR-296 was performed. 
Compared to scrambled RNA oligomer treated control, transfection of Pre-miR-296 
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into undifferentiated E14 mESCs increases expression of the early primitive ectoderm 
marker, Fgf5, neuroectoderm marker, Sox1, endoderm marker, MixlI, and mesoderm 
marker Kdr (Figure 6.8A).  
 
Transfection of Pre-miR-296 in RA-treated E14 mESCs resulted in accelerated 
acquisition of the early primitive ectoderm marker, FgF5, and neuroectoderm markers 
Sox1 and Otx2 (Figure 6.8A) relative to RA-treated cells transfected with the Scr 
control oligomer. Pre-miR-296 also enhanced the RA-induced decrease in the 
pluripotent marker Nanog, (Figure 6.8A), but did not elicit any significant changes in 
Oct4 or Sox2 mRNA levels. These results suggest that an elevated level of miR-296 in 
undifferentiated mESCs promotes a transcriptional expression profile that is 
indicative of differentiation, and enhances the differentiation of mESCs treated with 
RA.  
 
As discussed previously, Western blot analyses of Pre-miR-296 transfected E14 
mESCs showed that relative to Scr control oligomer control transfection, cells 
transfected with Pre-miR-296 express significantly decreased amounts of Nanog 
protein (Figure 6.8B and C). Oct4 and Sox2 protein levels do not change significantly 
after Pre-miR-296 transfection (Figure 6.8B and C). The quantitative PCR and 
western blot results suggest that the observed effect of miR-296 on mESC 
differentiation is not due to direct regulation of Oct4 or Sox2, at either transcript or 




Figure 6.8. miR-296 modulates the transcript levels of lineage-specific biomarkers in 
mESCs (A) Relative to Scr control transfection, transfection of Pre-miR-296 into 
undifferentiated E14 mESCs led to an appreciable upregulation of the early primitive 
ectoderm marker, Fgf5, neuroectoderm marker, Sox1, endoderm marker, Mix1I, and 
mesoderm marker Kdr. Relative to RA-treated Scr control transfection, transfection of Pre-
miR-296 in RA-treated E14 mESCs resulted in accelerated acquisition of the early primitive 
ectoderm marker, FgF5, and neuroectoderm markers Sox1 and Otx2. Experiments were 
performed in triplicate thrice (n=9), where error bars denote standard error, and significance 
of difference to scrambled RNA oligomer control at p<0.001 are denoted as asterisk (*).(B) 
Western blot analyses showing that Pre-miR-296 induced significant downregulation of 
Nanog protein levels, but not Oct4 or Sox2 protein levels, relative to Scr control in E14 
mESCs. Experiments were performed in triplicate twice (n=6), and a representative blot is 







As Nanog is an essential regulator of mESC pluripotency, the next question asked was 
whether the 235-m4/493-m2 double mutant Nanog, which had silent mutations 
introduced in both miR-296 binding sites but should function in the same way as 
wild-type Nanog, was able to rescue the observed effects of Pre-miR-296 on mESC 
differentiation. For these experiments, two independent clones of the 235-m4/493-m2 
double mutant Nanog (Ng-DM1 and DM2) were used to increase the reliability of  the 
results obtained.  
 
Earlier results indicated that transfection of Pre-miR-296 into undifferentiated E14 
mESCs increased expression of Fgf5, Sox1, MixlI, and Kdr (Figure 6.8A). These 
markers, together with Couptf, are consistently upregulated when Pre-miR-296 is co-
transfected with the empty vector control (Figure 6.9A). Relative to this empty vector 
control, transfection of either Ng-DM1 or DM2 into undifferentiated E14 mESCs was 
able to rescue the Pre-miR-296 induced upregulation of Fgf5, Sox1, Mixl1 and Couptf 
(Figure 6.9A). However, both Ng-DM1 and DM2 were unable to rescue the Pre-miR-
296 induced upregulation of Kdr, suggesting that this may not be modulated by its 
targeting of Nanog via its CDS. 
 
Furthermore, Western blot analyses showed that transfection of Ng-DM1 or DM2 into 
mESCs was able to rescue the Pre-miR-296 induced downregulation of Nanog protein 
(Figure 6.9B). Interestingly, overexpression of the wild-type Nanog CDS construct 
was able to elevate Nanog protein levels in the presence of Pre-miR-296 to a 
significantly higher level than that seen when Pre-miR-296 alone is transfected 
(Figure 6.9B). This may explain the observation that co-transfection of wild-type 
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Nanog CDS and Pre-miR-296 is able to partially rescue the Pre-miR-296 induced 
upregulation of Fgf5, Sox1, Mixl1 and Couptf transcripts (Figure 6.9A).  
 
Ng-DM1 and DM2 were also able to partially rescue the Pre-miR-296-induced visible 
phenotypic changes and reduced AP activity in mESCs (Figure 6.9C). Taken together, 
these results suggest that miR-296’s effect on ESCs is largely mediated via its 




Figure 6.9. 235-m4/493-m2 double mutants are able to rescue miR-296-modulated 
mESC differentiation (A) Relative to the empty vector control, transfection of either of two 
independent clones of the 235-m4/493-m2 double mutant (Ng-DM1 and DM2) into 
undifferentiated E14 mESCs was able to rescue the Pre-miR-296 induced upregulation of 
Fgf5, Sox1, Mixl1 and Couptf. Experiments were performed in triplicate thrice (n=9), where 
error bars denote standard error (B) Western blot analyses showing that transfection of Ng-
DM1 or DM2 into mESCs was able to rescue the Pre-miR-296 induced downregulation of 
Nanog protein (C) Photographs showing alkaline phosphatase (AP) staining of E14 mESCs 
three days post-transfection; where Ng-DM1 and DM2 were able to partially rescue the Pre-
miR-296-induced visible phenotypic changes and reduced AP activity in mESCs. 
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6.4   MiR-134 targets the coding region of mouse Sox2 
 
To demonstrate that the targeting of Nanog’s CDS by miR-296 was not an isolated 
incidence of microRNAs targeting genes in their coding regions, five distinct, full-
length rna-22 predicted targets for miR-134 in the CDS of mouse Sox2 were explored 
next. Previously, the results in chapters 3 and 4 have shown that miR-134 modulates 
the differentiation of mESCs, partly via the 3’UTR targeting of Nanog and LRH1.  
 
The 5′UTR and 3′UTR of Sox2 did not contain any rna-22 predicted miR-134 binding 
sites. Luciferase reporter assays show that for the Sox2-637p site, luciferase activity is 
significantly repressed in the presence of Pre-miR-134 but remains unchanged when 
transfected with Pre-miR-181a (negative control) (Figure 6.10A). For the other four 
predicted CDS target sites tested, luciferase activity in Pre-miR-134 transfected cells 
was not significantly different from the luciferase activity in Scrambled oligomer or 
Pre-miR-181a transfectants (Figure 6.10A). 
 
As shown previously, Western blot analyses of mESCs transfected with Pre-miR-134 
showed a marked decrease in endogenous Sox2 protein expression (Figure 6.10B, left 
panel). However, no change was observed when the Scrambled oligomer or Pre-miR-
181a (negative control) were transfected. Quantitative PCR showed a decrease of 
Sox2 mRNA in the presence of Pre-miR-134, although this decrease was less 
pronounced than the decrease in protein expression (Figure 6.10B, left panel). No 
decrease in the amount of Sox2 mRNA was observed when Scrambled oligomer or 
Pre-miR-181a were transfected. These results suggest a mode of action whereby miR-
134 induces posttranscriptional down-regulation of endogenous Sox2 in mESCs.  
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Figure 6.10. Sox2-637p is a potential target of miR-134 (A) Graph showing the effect on 
luciferase activity in 293T cells of Pre-miR and Scrambled oligomer (Scr) control 
transfections against five predicted Sox2 MRE constructs. Relative to Scr control, Pre-miR-
134 reduced luciferase-MRE activity of Sox2-637p, but Pre-miR-181a did not. This unrelated 
Pre-miR was used to detect any false positives. Luciferase experiments were performed in 
quadruplicate thrice (n=12), where error bars denote standard error, and asterisk (*) denotes 
significance of difference to scrambled RNA oligomer control at p<0.0001 (B) Quantitative 
PCR analysis of mESCs transfected with control Scr, Pre-miR-134 or Pre-miR-181a, and 
293T cells co-transfected with control Scr, Pre-miR-134 or Pre-miR-181a and 0.2μg of Nanog 
CDS, together with the quantitation of the corresponding Western blots in (C). (C) Western 
blot analysis of mESCs transfected with control Scrambled RNA oligomer (Scr), Pre-miR-
134 or Pre-miR-181a (bottom left panel), Western blot analysis of 293T cells co-transfected 




Western blot analysis confirmed that Sox2 protein is absent from 293T cells (data not 
shown). Following co-transfection of Pre-miR-134 and a Sox2-CDS construct in 
293T cells, quantitative PCR showed a slight decrease of Sox2 mRNA in the presence 
of Pre-miR-134, whereas Western blotting showed a significant decrease in Sox2 
protein expression (Figure 6.10B, right panel). When the Sox2-CDS construct was co-
transfected with either Scrambled oligomer or Pre-miR-181a (negative controls), 
quantitative PCR and Western blots revealed no change in Sox2 mRNA or protein 
(Figure 6.10B, right panel). Given that the construct we employed with 293T cells 
comprised only the CDS of Sox2, these findings show that miR-134 acts on Sox2’s 
CDS region and induces post-transcriptional repression of exogenous Sox2 mRNA in 
these cells.  
 
Silent mutations, which result in no amino acid changes to the Sox2 protein, were 
next introduced to the Sox2-637p site. As discussed previously for miR-296 targeting 
Nanog CDS, we utilized: a) luciferase reporter assays for the MRE mutants, and b) 
quantitative PCR and Western blot analysis of 293T cells that were co-transfected 
with Pre-miR-134 and mutant versions of Sox2-CDS. Figure 6.11A shows the results 
for the reporter assays and the mutant MREs containing the silent mutations: the 
mutant MREs have been listed and numbered in order of their increasing ability to 
disrupt the binding of miR-134. We analyzed four mutants of the Sox2-637p MRE. 
The table in Figure 6.11A shows the sequence for each mutant MRE. The MRE 
labeled 134RC was the reverse complementary sequence of miR-134 and served as a 
positive control. All four silent mutations disrupted miR-134’s ability to suppress 
luciferase activity, with mutant 637-m4 being the most effective (Figure 6.11A). 
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Figure 6.11B shows results from the Western blot and quantitative PCR analysis of 
293T cells that were co-transfected with Pre-miR-134 and wild-type or mutant 
constructs of Sox2’s CDS. The two Sox2-CDS mutants 637-m3 and 637-m4, which 
demonstrated the most significant rescue of Pre-miR-134 induced repression at the 
luciferase level were used in these experiments. The mutants’ labels are the same as in 
Figure 6.11A, i.e. 637-m4 denotes the Sox2-CDS mutant whose Sox2-637p MRE has 
been replaced by the mutant-MRE labeled m4 in Figure 6.11A and so on. In 
concordance with the reporter assays, the 637-m3 mutant disrupted slightly miR-
134’s ability to repress the translation of the mutant Sox2-CDS in 293T cells, and the 
637-m4 mutant abolished completely the downregulation effect of miR-134 on Sox2 
(Figure 6.11B). Furthermore, for the 637-m4 mutant, Sox2 mRNA levels after Pre-
miR-134 co-transfection did not change relative to the Scr co-transfection. These 
observations demonstrate that miR-134’s effect on Sox2 protein is predominantly 
through translation repression of Sox2 mRNA via interaction with a specific CDS 
element, and provides an additional example of microRNAs targeting genes in their 







Figure 6.11. The 637-m4 mutant is able to rescue the miR-134 induced reduction in Sox2 
protein levels (A) Luciferase results for co-transfection of Pre-miR-134 with various 
luciferase-MRE mutant constructs; values for each construct are presented relative to their 
respective Scrambled oligomer (Scr) control transfection. The table shows sequences 
corresponding to the silent mutations introduced in each mutant MRE (B) Quantitative PCR 
analysis of 293T cells co-transfected with Pre-miR-134, and 0.2μg of Sox2-CDS mutant 
constructs, together with the quantitation of the corresponding Western blots in (C); values 
for each construct are presented relative to their respective Scr control transfection (C) 
Western blot analysis of 293T cells co-transfected with Scr or Pre-miR-134, and 0.2μg of 
Sox2-CDS mutant constructs. 
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6.5   Discussion 
 
 
Luciferase assays, Western blots and quantitative PCR analyses showed that miR-296 
post-transcriptionally downregulates the expression of Nanog by binding to two non-
overlapping sites that are located in the CDS region of Nanog. The targeting of 
Nanog’s CDS by miR-296 was shown to be true for both endogenous (mESCs) and 
exogenous (293T cells) Nanog. Separate reporter assays using Nanog’s full length 
5′UTR and 3′UTR supported the absence of any interaction between miR-296 and 
Nanog’s UTRs. Additionally, any of a number of silent mutations introduced in each 
of the two CDS binding sites was able to disrupt miR-296’s activity. Finally, 
simultaneous silent mutations at both binding sites succeeded in abolishing miR-296’s 
activity. The impact of silent mutations on miR-296’s activity was supported by 
reporter assays, qPCR and Western blots, and suggests that miR-296 acts on Nanog 
predominantly through translational repression.  
 
These findings lend experimental support to rna22’s statistically-significant 
computational evidence that animal microRNA binding sites must exist along the 
entire length of messenger RNAs, and show this to be true for the CDS region of a 
murine mRNA. This suggests the possibility of an expanded sphere of activity for 
animal microRNAs. It is likely that natural microRNA binding sites exist beyond the 
confines of a 3′UTR, which would imply a substantially more complex picture of 
microRNA-based regulation than previously estimated. Notably, in the miR-
296/Nanog case that we discussed, the microRNA does not appear to act on the 
5′UTR or 3′UTR region of the transcript, which suggests that CDS-only microRNA-
targeting may also be a possibility.  
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The above analysis also showed that the two non-overlapping binding sites act 
independently of one another and are targeted by the same microRNA. Indeed, in 
order to abolish Nanog’s down-regulation by miR-296, silent mutations had to be 
introduced simultaneously at both sites to disrupt miR-296’s binding.  
 
Even though a definite statement cannot be made based on the available data, it is 
nonetheless conceivable that the presence of a second binding site for the same 
microRNA may serve to provide a necessary degree of redundancy, especially 
considering the importance of Nanog for mESCs. Interestingly, rna22 has predicted 
two or more binding sites in Nanog’s mRNA for 158 microRNAs, thus suggesting 
that this redundancy hypothesis may apply to many of the microRNAs that target 
Nanog. Finally, it is worth noting that a single point mutation at Nanog-493p (Nanog-
493p/m1) is sufficient to disrupt miR-296’s activity in a very substantial manner. This 
provides yet another clear demonstration of the remarkable impact that single 
nucleotide polymorphisms can have on the binding of microRNAs (Abelson et al., 
2005; Clop et al., 2006).  
 
As discussed earlier, Nanog is known to be a major regulator of mESC pluripotency 
(Chambers et al., 2003, Mitsui et al., 2003). MiR-296’s ability to modulate post-
transcriptional repression of Nanog via its CDS region thus led to an investigation of 
the effect of miR-296 on mESC differentiation. The results demonstrated that miR-
296 was upregulated during RA and EB differentiation, and was able to modulate 
mESC differentiation as determined by reduced alkaline phosphatase activity, reduced 
colony forming efficiency and increased expression of differentiation marker 
transcripts. As transcript and protein levels of Oct4 and Sox2 did not change 
 105
significantly with miR-296 overexpression, the data suggests that the effect of miR-
296 on mESCs is mainly mediated by post-transcriptional regulation of Nanog. 
Furthermore, transfection of Nanog constructs which had silent mutations abolishing 
miR-296 binding was able to significantly rescue the miR-296-modulated 
differentiation of mESCs. This provides further evidence that miR-296’s effect on 
ESCs is largely mediated via its repression of Nanog via the two sites in its CDS. 
 
Finally, to demonstrate that the targeting of Nanog’s CDS by miR-296 is not an 
isolated incidence of microRNAs targeting genes in their coding regions, the 
interaction between miR-134 and its five rna-22 predicted targets in the CDS of 
mouse Sox2 was explored. The data suggested that miR-134 post-transcriptionally 
down-regulates the expression of Sox2 by binding to a single site located in the CDS 
region of Sox2. The targeting of Sox2’s CDS by miR-134 was shown to be true for 
both endogenous (mESCs) and exogenous (293T cells) Sox2. Additionally, a number 
of silent mutations introduced in the CDS binding site were able to disrupt miR-134’s 
activity. The impact of silent mutations on miR-134’s activity was supported by 
reporter assays, qPCR and Western blots, and suggested that miR-134 acts on Sox2 
predominantly through translation repression via interaction with a specific CDS 
element.  
 
Taken together, these data demonstrating that miR-296 and miR-134 modulate post-
transcriptional repression of Nanog and Sox2 respectively provide the first examples 
of animal microRNAs targeting genes in their coding regions and suggest that the 
sphere of microRNA influence on gene regulation in animals extends beyond the 
3’UTR. 
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CHAPTER 7. CONCLUSION       
 
The importance of the complex transcriptional regulatory network including Nanog, 
Oct4 and Sox2 for the maintenance of ESC pluripotency and self-renewal has been 
well documented.  Mounting evidence over the past few years, from this study and 
others, suggests that microRNAs may act as an additional layer of gene regulation in 
these cells. This is likely to be partially mediated via the reciprocal regulation of 
important ESC factors and microRNAs. Additional support for this hypothesis has 
emerged from a rather unexpected source.  
 
In a recent publication, Yu et al. demonstrate that the four factors Oct4, Sox2, Nanog 
and Lin28 are sufficient for the reprogramming of human somatic cells to induced 
pluripotent stem (IPS) cells exhibiting the essential characteristics of ESCs (Yu et al., 
2007). These IPS cells are karyotypically normal, express hESC pluripotency markers 
and possess the ability to differentiate into derivatives of all three primary germ layers 
(Yu et al., 2007). While Oct4, Sox2 and Nanog have been studied extensively in 
ESCs, comparatively little is known about Lin28. It is a highly conserved protein that 
is expressed in mouse embryos, ESCs, EC cells and subsequently downregulated 
during development in vivo and the neuronal differentiation of EC cells (Moss and 
Tang, 2003; Sempere et al., 2004; Yang and Moss, 2003).  
 
The mammalian orthologs of C. elegans Lin28, which is repressed by lin-4 in worms 
via 3'UTR targeting, contain conserved predicted MREs in their 3'UTRs for miR-
125b (a lin-4 ortholog), Let-7a, and miR-218 (Sempere et al., 2004). The 
downregulation in Lin28 expression during RA-induced EC cell differentiation 
parallels the concomitant upregulation of miR-125b, let-7a, and miR-218, suggesting 
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that these events may be linked (Sempere et al., 2004). The expression of mouse miR-
125b is also observed to increase during RA-induced mESC differentiation (Figure 
3.2A). Furthermore, human miR-125b and its homolog miR-125a have been shown to 
target Lin28 via two conserved sites in its 3’UTR (Wu and Belasco, 2005). Taken 
together, these data suggest a direct role for several microRNAs in the regulation of 
Lin28, a heterochronic gene recently implicated in reprogramming and pluripotency. 
 
The results of this study present further evidence for microRNA-mediated modulation 
of ESC pluripotency via the targeting of important regulators of pluripotency and self-
renewal. In summary, three significant findings are presented herein.  
 
Firstly, the previously uncharacterized role of miR-134 in mESCs is described. By 
combining microRNA identification and expression, functional analyses and 
validation of microRNA-mRNA heteroduplexes, data is presented that suggests a role 
for miR-134 in modulating differentiation of mESCs, where this promiscuous 
microRNA exerts its effects through post-transcriptional regulation of multiple 
mRNAs, including translational attenuation of Nanog and LRH1 via their 3’UTRs. 
Upregulation of miR-134 also enhances the ectodermal differentiation of mESCs 
treated with RA or N2B27, where it augments the RA- and N2B27-induced elevation 
of ectodermal markers (ß-III-tubulin, Nestin, Neurogenin2, Sox1). These results will 
aid in the understanding of microRNA function in ESCs, and facilitate our ability to 
inhibit or enhance the differentiation of ectodermal lineages. 
 
Secondly, experimental validation is provided for 168 of 226 rna22-predicted 
microRNA targets at the luciferase level. This is significant as aside from this study, 
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the number of validated predictions that have been reported thus far is small 
(Rajewsky, 2006). These experimental validations were also invaluable in enabling 
the refinement of rna22, a microRNA target prediction algorithm. Assuming that the 
luciferase results for a subset of randomly selected targets are representative of the 
entire dataset, the analysis suggests that some microRNAs may have more than a 
thousand targets. This hypothesis challenged the prevailing opinion in the field at the 
time that each microRNA only targeted a few genes. 
 
Thirdly, 3′UTRs have been the focus of virtually all animal microRNA/mRNA studies 
to date, both from a computational and from an experimental standpoint. Although 
Kloosterman et al demonstrated functional targeting of let-7 sites in the CDS or 
5’UTR in zebrafish, this study did not identify any endogenous target sites as it 
utilized a fragment of the lin-41 3'-UTR containing two let-7 target sites inserted into 
a gfp reporter gene (Kloosterman et al, 2004). Thus, the results of this study 
demonstrating that miR-296 and miR-134 modulate post-transcriptional repression of 
Nanog and Sox2 via 2 sites and 1 site in their respective coding regions provide the 
first examples of animal microRNAs regulating gene expression via endogenous CDS 
target sites.  
 
This suggestion that the sphere of microRNA influence on gene regulation in animals 
may be far wider than currently thought is supported by several recent publications. 
Lytle et al reported that the translational efficiency of luciferase reporters containing 
let-7 microRNA complementary sites derived from the C. elegans lin-41 3' UTR was 
repressed in human HeLa cells, which express endogenous Let-7a (Lytle et al, 2007). 
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Although this study did not identify any endogenous 5’UTR microRNA binding sites, 
it raises the possibility that such targeting may be functional in mammalian cells.  
 
Two landmark papers which further challenged existing beliefs about microRNA 
function were published by Vasudevan et al and Kedde et al. Vasudevan et al 
proposed that microRNAs could activate translation. They demonstrate that the ARE 
in tumor necrosis factor-alpha mRNA is transformed into a translation activation 
signal upon cell cycle arrest. Its subsequent recruitment of AGO and fragile X mental 
retardation-related protein 1 (FXR1), factors associated with micro-ribonucleoproteins 
(microRNPs), is directed by miR-369-3 (Vasudevan et al, 2007). In contrast, 
translation is repressed by miR369-3 during other cell cycle phases. Furthermore, two 
other microRNAs, Let-7 and the synthetic microRNA mimic cxcr4, similarly enhance 
translation of target mRNAs on cell cycle arrest, yet repress translation in 
proliferating cells (Vasudevan et al, 2007). These results suggest that multiple 
microRNAs and their associated Ago proteins may enhance or repress translation, in a 
cell cycle-dependent manner (Buchan and Parker, 2007). 
  
Based on the intriguing observation that the sequences around the microRNA 
targeting site are highly conserved during evolution, Kedde et al hypothesized that 
these conserved regions may serve as docking platforms for modulators of microRNA 
activity. They demonstrated that the expression of dead end 1 (Dnd1), an 
evolutionarily conserved RBP, inhibited the function of several microRNAs by 
binding to mRNAs and prohibiting microRNA association with their target sites 
(Kedde et al, 2007). This effect is mediated through uridine-rich regions in the 
microRNA-targeted mRNAs, and may occur via physical blockage of microRNA 
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access to its target site or changing the subcellular localization of the target mRNA 
(Ketting, 2007). As the RNA-induced silencing complex (RISC) is only one of the 
numerous mRNA-targeting RBPs, it is perhaps not surprising that the regulation of 
gene expression by microRNAs may be tuned by RBPs that are not a direct part of the 
microRNA complex (Ketting, 2007).  
 
In conclusion, the results of this study, combined with other recently published 
reports, suggest that researchers have barely scratched the surface of understanding 
microRNA biology and function. MicroRNAs, which were previously thought to 
associate solely with the 3’UTRs of several target genes to mediate gene repression, 
have now been shown to have hundreds or possibly thousands of targets. They are 
also able to target genes in their coding regions, 5’UTRs and perhaps even introns, as 
well as induce translational upregulation. These tiny regulators of gene expression 
also appear to be, in turn, regulated by other factors such as RBPs. Shedding greater 
light on these newly discovered facets of microRNA biology will be just one of the 
challenges facing researchers in the near future. 
 
The last 5 years has seen an explosion of information on the function and regulation 
of microRNAs, as well as their mechanism of targeting mRNA cis-elements. Building 
upon the current knowledge base, future research will continue to unravel the 
mysteries of microRNA biology, including the vital role that microRNA-mediated 
gene regulation plays in directing cell fate. As this study and others have 
demonstrated that microRNAs are important modulators of differentiation in ESCs, 
these new insights will likely facilitate the understanding of ESCs and their use as 
models of development and disease, and for potential clinical applications. 
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CHAPTER 8.  MATERIALS AND METHODS    
8.1  Cell culture, transfection & cell-based assays 
8.1.1  Routine cell line maintenance 
 
All cell culture reagents and culture plastics were obtained from Invitrogen/Gibco and 
BD Biosciences, respectively, unless otherwise specified. Cell cultures were 
maintained at 37°C with 5% CO2. mESC lines, E14 (ATCC: CRL-1821) and D3 
(ATCC: CRL-1934), were cultured feeder-free on 0.1% gelatin-coated (Sigma) plates 
in ESC-medium (Dulbecco’s modified Eagle’s medium, 15% heat-inactivated ES-
standard fetal bovine serum (FBS), 100 μM non-essential amino acids, 2 mM L-
glutamine, 55 nM β-mercaptoethanol, 1% (v/v) penicillin/streptomycin and mouse 
leukemia inhibitory factor (mLIF; 103 U/ml, Chemicon). HEK 293T/17 (ATCC: 
CRL-11268) cells were maintained in DMEM supplemented with 10% heat-
inactivated FBS, 2mM L-glutamine and 1% (v/v) penicillin/streptomycin. 
 
8.1.2   Differentiation of mESCs 
 
For RA-induced mESC differentiation, feeder-free mESCs were cultured on 0.1% 
gelatin-coated plates in LIF-deficient ESC-medium supplemented with 100nM all-
trans retinoic acid for up to 6 days. For N2B27-mediated differentiation, feeder-free 
mESCs were cultured on 0.1% gelatin-coated plates in a 1:1 mixture of DMEM/F12 
and Neurobasal medium, together with N2 and B27 supplements as described 
previously (Ying et al., 2003). To form EBs, feeder-free mESCs were trypsinized to a 
single cell suspension and subsequently cultured on uncoated petri dishes in ESC-
medium without mLIF for up to 15 days. Petri dishes were placed on a reciprocal 
shaker to minimize aggregation of EBs. Media were changed every two days for all 
mESC differentiation conditions. 
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8.1.3    Preparation of mouse tissues 
 
(Note: Mouse tissues were isolated by Phil Gaughwin) 
Whole mouse embryos were removed from pregnant C57BL/6J mice euthanized by 
exposure to CO2 at embryonic days (E) 7.5, 11.5, 15.5 and 17.5 (observation of 
vaginal plug recorded as E0.5). To examine tissue-specific expression patterns of 
microRNAs, euthanized adult (at least postnatal day (P) 60) and embryonic (E12.5) 
tissue was obtained by dissection under RNAse-free conditions. Whole embryos and 
embryonic / adult organ derived tissue samples were homogenized in Trizol within 
one hour of tissue collection.  E12.5 whole brain tissue was dissected in ice-cold 
Dulbecco’s Phospate-Buffered Saline (DPBS) to remove meninges and separate the 
hippocampal anlage, cortical sheets, remaining neural tissue rostral to the midbrain-
hindbrain isthmus / boundary (MHB), and tissue caudal to the MHB including 
cervical spinal cord (defined as hippocampus, cortex, midbrain and hindbrain, 
respectively in Fig. 7B). 
 
8.1.4   Transfection  
 
Pre-miR microRNA precursors (Pre-miRs), Anti-miR microRNA inhibitors (Anti-
miRs) and Scrambled oligomer (Scr, AGACUAGCGGUAUCUUUAUCCC) were 
purchased from Ambion. Block-iT fluorescent RNA oligomer (Invitrogen), a FITC-
tagged 25-mer, was used as a surrogate for Pre-miRs and Anti-miRs to optimize 
transfection efficiency. These were transfected into mESCs at a final concentration of 
~100 nM using Lipofectamine 2000 (Invitrogen) as per manufacturer’s instructions. 
For example, for a 12-well transfection, mESCs were seeded at a density of 120,000 
cells per well. After 24 h, 7 μl of Pre-miRs was added to 100 μl of Opti-Mem and 3.5 
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μl of Lipofectamine 2000 was added to 100 μl of Opti-Mem and incubated separately 
for 10 min. These two mixtures were then combined and incubated for a further 20 
min. This final transfection mix was subsequently added to cells in 1 ml of medium. 
1.5 μg of gene-specific shRNA plasmids, non-silencing shRNA plasmid or empty 
vector were transfected into mESCs in 12-well plates and drug selection was 
performed with 1 µg/ml of puromycin (Sigma) 24 h post-transfection for a period of 2 
days.  
 
8.1.5   Immunostaining & Cellomics High Throughput Screening 
 
Cells were fixed in 4% paraformaldehyde, washed twice with DPBS and then 
incubated for 5 min at -20oC in 95% ethanol (v/v in DPBS). Cells were then washed 
thrice with DPBS, blocked for 1 h in 5% normal goat serum in DPBS with 0.1x 
Triton-X100, and incubated overnight with anti-Class III beta-tubulin (Ab18660; 
Abcam, Cambridge, UK) primary antibody at 4ºC. Cells were next washed twice with 
DPBS and incubated for 1 h with the corresponding secondary antibody (Goat anti-
rabbit IgG 568; Molecular Probes). Cells were washed and mounted. 
Immunofluorescence was observed using a Leica microscope, and image analysis was 
conducted using IM50 software. The Alkaline Phosphatase Detection Kit (Chemicon) 
was used to determine Alkaline Phosphatase activity, according to manufacturer’s 
instruction.  
 
Image acquisition and subsequent neurite outgrowth measurements were performed 
using the Cellomics ArrayScan II High Content Screening (HCS) platform 
(Swallowfield, UK). Two separate fluorescent filters at 20× objective magnification 
were used; Channel 1 illuminated Hoechst 33342-labelled nuclei, allowing automated 
 114
focusing upon the cells, and Channel 2 excited objects stained with Alexa Fluor 568-
labelled anti-Class III beta-tubulin. Both images were acquired through a 
535 nm × 35 nm bandwidth dicroic emission filter. Exposure times for each 
wavelength were determined empirically. All images were then analyzed using 
Cellomics neurite outgrowth software, and data analysis for the number of neurons 
per total nucleus count in each field, average intensity of neuronal cell bodies and 
neurites are presented. Data shown were an average of values from 16 random fields 
from 3 replicate wells in two independent experiments.  
 
8.1.6   In situ hybridization 
 
(Note:ISH was performed by Wang Weijia and Liu Rubing) 
For sectioned RNA in situ hybridization, sagittal and transverse sections of outbred 
CD-1 (Charles River) wildtype embryos at stages E3.5 to E14.5 were prepared 
essentially as previously described (Wang et al., 2001). Noon of the vaginal plug date 
was designated as E0.5. Embryo tissues were dissected free, fixed in 4% 
paraformaldehyde overnight, washed in DPBS and dehydrated through graded 
ethanols, followed by two changes of Americlear (Fisher) and embedded in Paraplast 
(Fisher) overnight. Sections of 7 μm were cut and floated onto Plus+ slides (Fisher), 
air dried, and stored at 4°C.  
 
Whole-mount in situ hybridization was performed essentially as previously described 
(Wang et al., 2001; Kloosterman et al., 2006). Embryos were fixed in 4% 
paraformaldehyde overnight, washed in DPBS, and dehydrated through graded 
methanols and stored at –20˚C for up to several months. Before use, embryos were 
rehydrated stepwise from methanol to DPBS+0.1% Tween-20 (PTW) and briefly 
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digested with 10 μg/ml proteinase K. Digoxigenin-labeled RNA probes were 
purchased from Exiqon (www.exiqon.com) and used for both sectioned and 
wholemount RNA in situ and hybridized at 65°C overnight. Following washing in 
PTW, embryos or slides were incubated in a 1:2000 dilution of AP-anti-DIG antibody 
(Boehringer-Mannheim) followed by extensive washing and then staining in Purple 
Precipitating Reagent or NBT/BCIP (Boehringer-Mannheim) at 4°C-30˚C. Stained 
wholemount embryos were photographed in PTW and then stored in 50% ethanol at 
4˚C. Sections were treated with aqueous mounting solution, coverslipped and stored 
at 4˚C prior to photography. 
 
8.1.7   Colony formation assay 
 
E14 mESCs were transfected with Pre-miRs (100 nM) and/or Anti-miRs (100 nM), or 
scrambled RNA oligomer (100 nM) or lipofectamine only (Mock Transfection) in 12-
well culture plates at a density of 5 x 105 cells per well. These cells were subsequently 
trypsinized at 48 h and re-suspended in ESC-medium. Various cell numbers (200, 
400) were plated onto mouse feeder layers in 6-well culture plates to form secondary 
ESC-colonies. After seven days, emerging colonies were stained using Wright-
Giemsa (Sigma) stain and counted. Colony morphology and number provide an 
indication of the number of colony-forming undifferentiated mESCs present in a 
population of cells (Qi et al., 2004).   
 
8.1.8   pOct4/pNanog-Luciferase reporter assays 
 
(Note: pOct4/pNanog-Luc reporter assays were performed by YT and TWL) 
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To perform the pOct4/pNanog-Luciferase assays, feeder free mESC lines, E14 and 
D3, were seeded 24 h before transfection at a density of 2.5 x 104 cells per well in 96-
well culture plates (Costar). Pre-miRs (100 nM), Anti-miRs (100 nM), scrambled 
RNA oligomer (100 nM) or shRNA constructs (1 μg), plus pOct4-Luciferase (75 ng) 
or pNanog-Luciferase (75 ng), and pRL-SV40 (1 ng) (Promega) were co-transfected 
using Lipofectamine 2000 according to manufacturer’s instructions. The pRL-SV40 
plasmid served as an internal control for the normalization of transfection efficiency. 
For the transfection of shRNA constructs, selection with 1 µg/ml of puromycin 
(Sigma) was performed 24 h post-transfection for a period of two days. Firefly and 
Renilla luciferase activities were measured with the Dual-Luciferase® Reporter 
system (Promega) 48 h post-transfection by Centro LB960 Luminometer (Berthold 
Technologies Gmbh & Co.). Data generated were expressed relative to control 
transfection (scrambled oligo for Pre-miRs, non-silencing shRNA for shRNA 
constructs) after internal normalization to Renilla luciferase readings. 
 
8.1.9   microRNA target validation assay 
 
(Note:Target validation assays were performed by YT and AYS) 
HEK 293T cells were seeded 24 h before transfection at a density of 5 x 104 cells/well 
in black-walled 96-well culture plates. 120 ng of miR-375 or miR-296 overexpression 
vectors or empty vector; or 12.5 nM of PmiR-134 or scrambled RNA oligomer; were 
cotransfected with 2 ng of the RLuc-MRE vector with Lipofectamine 2000 as per 
manufacturer’s instructions. Concurrently, additional controls were also performed 
using unpredicted RLuc-MREs (eg. reverse complement of miR-21) vs cognate 
microRNA or predicted RLuc-MRE vs non-cognate microRNAs (eg. miR-21). Non-
cognate microRNA transfections against each MRE also served to determine the false 
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positive rate of Pre-miR transfections against that particular MRE. Forty eight hours 
post-transfection, Firefly and Renilla luciferase activities in cell lysates were 
measured consecutively with the Dual-Luciferase® Reporter system (Promega) by a 
luminometer (Centro LB960; Berthold Technologies Gmbh & Co. KG, Germany, 
http://www.bertholdtech.com). Constitutively expressed Firefly luciferase gene 
activity in psiCHECK-2 served as a normalisation control for transfection efficiency. 
After correction for transfection efficiency, the normalised Renilla luciferase readouts 
were expressed as relative percentage change to that of the scrambled RNA oligomer 
transfection. All luciferase assays were repeated a minimum of three times with 4 
culture replicates each. 
 
8.2   DNA manipulation 
8.2.1   General DNA manipulation techniques  
 
PCR was performed using the BD Advantage 2 PCR kit (BD Biosciences). The 
protocol used to amplify DNA fragments from genomic DNA was as follows:  
10x buffer with Mg     5.0 μl 
dNTP (10mM)     1.0 μl 
Genomic DNA (100ng/μl)    1.5 μl 
H2O     39.5 μl 
Polymerase      1.0 μl 
Forward primer (10 μM)    1.0 μl 
Reverse primer (10 μM)    1.0 μl 
Total       50.0 μl 
 
Annealing was done by mixing 1.5 μl of forward oligo (100 μM), 1.5 μl of reverse 
oligo (100 μM) and 47 μl of annealing buffer. These were vortexed well and annealed 




Restriction digest was carried out for 5-16 h at 37oC, at a ratio of 5 enzyme unit to 1 
μg of DNA. The protocol used to digest psiCHECK-2 vector was as follows:  
Water     28.6 μl 
Vector (1 μg/μl)     4.0 μl 
NEB buffer 3      4.0 μl 
BSA       0.4 μl 
Xho1 (20,000U/ml)     1.0 μl 
Not1 (10,000U/ml)     2.0 μl 
Total     40.0 μl 
 
PCR purification and gel extraction were performed as per manufacturer’s 
instructions, using the QIAquick PCR Purification kit and QIAquick Gel Extraction 
kit respectively (Qiagen). 
 
Ligation was carried out at room temperature for 5 min using the NEB Quick Ligation 
kit (NEB). The typical vector to insert ratio used was 1 molecule of vector to 5 
molecules of insert. The protocol used was as follows:  
Vector (200ng/μl)     0.5  μl 
Insert (25ng/μl)     2.0  μl 
Water       6.5  μl 
2x Ligase buffer   10.0  μl 
T4 DNA Ligase     1.0  μl 
 
Transformation was performed using MAX Efficiency DH5α (Invitrogen) as follows: 
1 μl of ligation mix was added to 25 μl of bacteria, tapped gently and incubated on ice 
for 30 min. The mixture was heat shocked at 42oC for 1 min, then allowed to recover 
on ice for 5 min. 400 μl of SOC medium was added and the transformation mix was 
incubated at 37oC on a shaker for 1 h. 150 μl of this transformation mix was spread on 




Clones carrying the DNA of interest were identified by gene specific PCR. Bacterial 
colonies were first picked into a 96-well plate with 50 μl of LB media containing the 
appropriate antibiotic in each well. This was incubated at 37 oC for 1 h and PCR was 
then performed with the following conditions:  
PCR Supermix   17.5  μl 
Forward primer (10 μM)    1.0  μl 
Reverse primer (10 μM)    1.0  μl  
Bacteria      0.5  μl 
 
Minipreps and maxipreps were performed as per manufacturer’s instructions, using 
the QIAprep Spin Miniprep kit and HiSpeed Plasmid Maxi kit respectively (Qiagen). 
 
8.2.2   pOct4/pNanog-Luciferase reporters 
 
pOct4-Luciferase and pNanog-Luciferase reporters were a kind donation from the lab 
of Ng Huck Hui (Chew et al., 2005). 
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8.2.3   Construction of microRNA overexpression plasmids 
 
To generate the overexpression vector for mmu-miR-375, a 500 bp fragment was 
amplified by PCR from mouse genomic DNA and inserted into a modified pIRES2-




Figure 8.1. Vector map of pIRES2-EGFP. From www.clontech.com. 
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To generate the mmu-miR-296 and mmu-miR-21 overexpression vectors, 500 bp 
fragments were amplified by PCR from mouse genomic DNA and inserted into the 
pLL3.7 lentiviral vector (XhoI and HpaI sites; a kind gift from the Center for Cancer 
Research, MIT).  
 
 
Figure 8.2. Vector map of pLL3.7. From www.sciencegateway.org. 
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8.2.4   Construction of pLuc-MRE plasmids 
 
(Note:pLuc-MRE plasmids were constructed by YT and AYS) 
For pLuc-MRE constructs, the rna22-predicted microRNA response elements (MRE, 
20-30 nt) were synthesized as sense and antisense oligomers, annealed and cloned 
into psiCHECK-2 (Promega) at restriction sites XhoI & NotI, directly 3’ downstream 
of Renilla luciferase.  
 
Figure 8.3. Vector map of psiCHECK-2. From www.promega.com. 
 
To generate the pLuc-Nanog5′UTR construct, the 5′UTR of Nanog was synthesized 
as sense and antisense oligomers, annealed and cloned into psiCHECK-2 at the NheI 
restriction site, directly 5′ upstream of Renilla luciferase. The pLuc-Nanog3’UTR 
construct was generated by cloning the entire Nanog 3’UTR into psiCHECK-2 
(Promega) at the NotI restriction site. To generate the Nanog 3’UTR mutant construct, 
PCR directed mutagenesis was performed with a pair of primers containing the 
mutant MRE sequence (GAGGACGTGTTAACTAGTTTCC). The PCR product was 
subsequently used as a template for full-length PCR. The Nanog 3’UTR mutant was 
also cloned into psiCHECK-2 at the NotI restriction site. 
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8.2.5   Construction of gene-specific RNAi plasmids 
 
(Note:RNAi plasmids were constructed by TWL and AYS) 
Nineteen-base-pair gene-specific regions for RNA interference (RNAi) were designed 
(Reynolds et al.l, 2004, Ui-Tei et al., 2004). Oligonucleotides were cloned into 
pSUPER.puro (BglII & HindIII sites; Oligoengine), which expresses 19-nucleotide 
hairpin-type short hairpin RNAs (shRNAs) with a 9-nucleotide loop, as described 
previously (Geijsen et al., 2004).  
 
Figure 8.4. Vector map of pSuper.puro. From www.oligoengine.com. 
 
To ensure specificity, all sequences were analyzed by BLAST to ensure that they did 
not have significant (>15 nucleotide matches) sequence similarity with any other 
gene. For each target gene, RNAi against four regions of the mRNA were designed 
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and screened, and the construct with the highest mRNA suppression was selected for 
subsequent pOct4-Luciferase studies. The oligonucleotides used were: 
 
LRH1  5'-GATCCCCGTGTGTGGCGATAAAGTGTttcaagagaACACTTTATCGCCACACACTTTTTA-3' 
5'-AGCTTAAAAAGGACCTACACTTATGAGAAtctcttgaaTTCTCATAAGTGTAGGTCCGGG-3' 
FADD  5'-GATCCCCGAATATGTCCCCAGTACTAttcaagagaTAGTACTGGGGACATATTCTTTTTA-3' 
5'-AGCTTAAAAAGAATATGTCCCCAGTACTAtctcttgaaTAGTACTGGGGACATATTCGGG-3' 
Gαo  5'-GATCCCCGGAAGACGGACTCCAAGATttcaagagaATCTTGGAGTCCGTCTTCCTTTTTA-3' 
5'-AGCTTAAAAAGGAAGACGGACTCCAAGATtctcttgaaATCTTGGAGTCCGTCTTCCGGG-3' 




8.2.6   Construction of Nanog-CDS & Sox2-CDS plasmids 
 
(Note:CDS plasmids were constructed by Zhang Jinqiu) 
The wild-type Nanog-CDS and Sox2-CDS were cloned into pcDNA3.1 (Invitrogen) 
at restriction sites BamHI and XhoI using the following primers respectively: 
 
NanogBamHIF  5′-GCGGGATCCACCATGAGTGTGGGTCTTCCTGG-3′ 
NanogXhoIR   5′-CGGCTCGAGTCATATTTCACCTGGTGGAG-3′ 
 
Sox2BamHIF  5′- GCGGGATCCCACCATGTATAACATGATGGAGACGGA-3′ 




Figure 8.5. Vector map of pcDNA3.1. Adapted from www.invitrogen.com. 
 
To generate each CDS mutant construct, PCR directed mutagenesis was performed 
with a pair of primers containing the mutant MRE sequence. The PCR products were 
subsequently used as a template for full-length PCR. The CDS mutants were also 
cloned into pcDNA3.1 (Invitrogen) at restriction sites BamHI and XhoI. The primer 










493-2mutmNanogF2:   
5’-ACTAGCAATGGTCTGATCCAAAAGGGAAGCGCACCAGTGGA-3’ 













8.3   RNA and protein work 
8.3.1   RNA extraction & quantitative PCR 
 
For Northern blot, quantitative PCR and microarray analyses,  total RNA was 
extracted from cells using Trizol reagent (Invitrogen) as per manufacturer’s 
instructions and subsequently column-purified with RNeasy kits (Qiagen). Briefly, 
cell pellets were resuspended in Trizol before addition of chloroform (200 µl of 
chloroform per 1ml of Trizol). Samples were shaken vigorously for 15 s, left to settle 
for 2 min, and centrifuged for 20 min at 13,000 x g. After centrifugation, the aqueous 
layer of each sample was removed and added to an equal volume of 70% ethanol. 
This mixture was then applied to an RNeasy column, and washed with RW1 and RPE 
buffers (Qiagen). The column was centrifuged for an additional 2 min at 13,000 x g to 
remove any remaining ethanol carryover and RNA was eluted in 30-100 µl of RNase-
free water.  
 
For microRNAs, cDNA synthesis  was performed with 50 ng of total RNA according 
to the manufacturer’s instructions (Applied Biosystems). Endogenous microRNA 
levels were measured with inventoried Taqman probes and PCR Master Mix (Applied 
Biosystems). miR-16 was used as an internal control. All amplicons were analyzed 
using ABI Prism 7900HT Sequence Detection System (SDS) 2.2 software. 
 
For coding genes, cDNA synthesis was performed with 1 µg of total RNA at 37oC for 
2 h using the High Capacity cDNA Archive Kit (Applied Biosystems), and 
subsequently diluted 10 times. Endogenous mRNA levels of pluripotency and 
differentiation markers were measured with inventoried Taqman probes and PCR 
Master Mix (Applied Biosystems). Endogenous mRNA levels of LRH1, FADD, and 
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Gαo were measured using SYBR Green PCR Master Mix (Applied Biosystems). β-
actin was used as an internal control. All amplicons were analyzed using ABI Prism 
7900HT Sequence Detection System (SDS) 2.2 software. 
 
Primer sequences for quantitative PCR detection of miR-134 target genes: 
 Forward Reverse 
LRH1 5’ - ctcccccaaacgtgaggaaca - 3’ 5’ - tttcgcacgtgaggagaccg - 3’ 
FADD 5’ - ggcagatctgcaggtggcatt - 3’ 5’ - tccgcagcgccttaaccagt - 3’ 
Gαo 5’ - tgctgggggctggagaatca - 3’ 5’ - cccagagtcgcatcatggca - 3’ 
β-actin 5’ - accaactgggacgacatggagaag – 3’ 5’ - tacgaccagaggcatacagggaca - 3’ 
 
8.3.2   Northern blot 
 
(Note: Northern blots were performed by AYS and YT) 
All microRNAs were probed using α32P-UTP-labeled RNA probes which were 
transcribed in vitro from DNA oligomer templates (Thomson et al., 1999). 5S rRNA 
was probed using γ 32P-end-labeled DNA probe. Both types of probes were 
synthesized using the mirVanaTM microRNA Probe Construction kit (Ambion) and 
subsequently column-purified with mirVanaTM Probe & Marker kit (Ambion) as per 
manufacturer’s recommendations. The specific activity of each probe was routinely 
107 cpm/μg RNA/DNA. 10 μg of total RNA were size-fractionated by 15% TBE-
Urea-PAGE (Invitrogen) and electroblotted onto MagnaProbe nylon membrane (GE 
Osmonics Labstore). The membrane was probed overnight at 42ºC in 6 x SSC, 0.2% 
SDS, 5 x Denhardt’s solution with 32P-labelled RNA probes (106 cpm/ml), washed 
thrice at 30ºC in 6 x SSC, 0.2% SDS, and complexes detected by Phosphorimage 
(GE-Healthcare). 
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8.3.3   Microarray 
 
MicroRNA microarray was performed using a service provider (LC Sciences).  The 
assay started from 2 to 5 µg total RNA sample, which was size fractionated using a 
YM-100 Microcon centrifugal filter (from Millipore) and the small RNAs (< 300 nt) 
isolated were 3’-extended with a poly(A) tail using poly(A) polymerase.  An 
oligonucleotide tag was then ligated to the poly(A) tail for later fluorescent dye 
staining; two different tags were used for the two RNA samples in dual-sample 
experiments.  Hybridization was performed overnight on a µParaflo microfluidic chip 
using a micro-circulation pump (Atactic Technologies). On the microfluidic chip, 
each detection probe consisted of a chemically modified nucleotide coding segment 
complementary to target microRNA (from miRBase, 
http://microrna.sanger.ac.uk/sequences/) or other RNA (control or customer defined 
sequences) and a spacer segment of polyethylene glycol to extend the coding segment 
away from the substrate.  The detection probes were made by synthesis in situ using 
photogenerated reagent (PGR) chemistry.  The hybridization melting temperatures 
were balanced by chemical modifications of the detection probes. Hybridization used 
100 µL 6xSSPE buffer (0.90 M NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) 
containing 25% formamide at 34 °C.  After hybridization, detection used fluorescence 
labeling using tag-specific Cy3 and Cy5 dyes.  Hybridization images were collected 
using a laser scanner (GenePix 4000B, Molecular Device) and digitized using Array-
Pro image analysis software (Media Cybernetics).  Data were analyzed by first 
subtracting the background and then normalizing the signals using a LOWESS filter 
(Locally-weighted Regression).  For two color experiments, the ratio of the two sets 
of detected signals (log2 transformed, balanced) and p-values of the t-test were 
calculated; differentially detected signals were those with less than 0.01 p-values. 
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For the mRNA gene expression microarray, two sample repeats were profiled for all 
treatments. Total RNA was Trizol extracted; then first and second strand cDNA 
synthesis, cRNA Biotin-labelling and cRNA purification were performed 
subsequently using the Illumina TotalPrepRNA Amplification kit (Ambion;#IL1791). 
850 ng labeled cRNA were mixed with Hyb Mix (Hyb E1+Formamide) as according 
to instructions in BeadStation 500X Gene Expression System (Illumina) and used for 
microarray (Illumina Mouse Refseq-8 Array) staining. Hybridization and wash 
procedures were performed using Illumina BeadChip protocols where 34 μl of the 
hybridization mix with labeled cRNA sample was dispensed onto the center of each 
array and allowed to hybridize with rotations in a pre-heated oven for 16-20 h at 55ºC. 
Washes were performed with Wash E1BC solution, Block E1 solution was used for 
blocking, and detection performed by Block E1 solution+Streptavidin-Cy3. Samples 
were scanned using standard Illumina procedures. Total chip data is deposited for 
public assess with GEO repository accession number: GSE4522. The microarray data 
were extracted using the software provided by the manufacturer (BeadStudio). 
 
8.3.4   Protein extraction & Western blot 
 
Cell pellets were washed in chilled DPBS, and incubated for 20 min in ice cold lysis 
buffer (50 mM Tris (pH7.0), 150 mM sodium chloride, 10 mM sodium 
pyrophosphate, 50 mM sodium fluoride, 50 mM sodium β-glycerophosphate, 1 mM 
sodium orthovanadate, 2 mM benzamidine, 1 mM dithiothreitol,  0.5% sodium 
deoxycholate, 0.2% Nonidet P-40) containing freshly added protease inhibitors (0.5 
mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, 2 μg/ml aprotonin). Lysates 
were cleared by centrifugation at 4ºC for 20 min at 12,100 x g, and protein 
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concentrations were determined using Bradford Dye (Bio-Rad). Bovine serum 
albumin (BSA) was used as protein standards. 
 
For Western blot analysis, 10 µg of total protein was size fractionated by SDS-PAGE 
on 10% bis-Tris acrylamide NuPAge gels in 1 x MOPS-SDS running buffer, pH 7.3 
(Invitrogen), at 200 V for 60 min at 4ºC, and transferred to Hybond-P® PVDF 
membrane (GE Healthcare) in 1 x NuPage transfer buffer (Invitrogen) with 10% 
methanol at 40 V for 60 min at 4ºC. The membrane was probed with specific primary 
antibodies (Oct4, sc8628; Sox2, sc17320; BMP4, sc6896; Gata4, sc1237; Nestin, 
sc21248; Gαo, sc387; FADD, sc6036; Santa Cruz Biotechnology;  LRH-1, F4100-44; 
USBiological;  Nanog, AB5731; β-actin, MAB1501; Chemicon) and secondary 
horseradish peroxidase conjugated antibodies (anti-goat HRP, sc2768; anti-rabbit 
HRP, sc2030; anti-mouse, sc2005; Santa Cruz). Antibody-protein complexes were 
identified by ECL-Plus (Amersham) and film.  
 
8.4   Statistical analysis 
Unless otherwise stated, the unpaired Student’s t-test was used to determine statistical 
significance. 
 
(Note: All analysis of Illumina microarray data was performed by Henry Yang from 
the Bioinformatics Institute) 
For microarray data, the Pearson’s correlation was used for the similarity test. 
Dendrograms were drawn using Eisenplots (clustering and treeview tools), with arm 
lengths proportional to the respective correlation coefficients. 
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CHAPTER 10. APPENDICES        
10.1  Gene names & sequences of miR-375 target predictions tested 
Rank ENSEMBL GENE-ID  TESTED TARGET SITE ENSEMBL DESCRIPTION 
1 ENSMUSG00000007617  GAGAAGAGCCAGAACGAACAAG homer homolog 1 
2 ENSMUSG00000047298  TGAATGTGAGCCAGGGAACAAG potassium channel, subfamily V, member 2 
3 ENSMUSG00000014504  ATTTAACTGAGCTGTGAACAAG signal recognition particle 19 
4 ENSMUSG00000028560 TGATGGATGAGCTGGGAACAAA ubiquitin specific protease 1 
5 ENSMUSG00000040265  CCATACTGAGCTGCAGAACAAG dynamin 3 
6 ENSMUSG00000001507  AAACGCAGCCCGAAGGAACAAA integrin alpha 3 
7 ENSMUSG00000011256  ATACAATGTGAGCAAGAACAAG disintegrin and metalloproteinase domain 19  
8 ENSMUSG00000040247  AAGAGAGCCAGAGAAGAACAAA TBC1 domain family, member 10c  
9 ENSMUSG00000026872  TATGCAGGGCTATAAGAACAAA zinc finger homeobox 1b 
10 ENSMUSG00000057093 TCCCCTGCAGCTGTTGAACAAA RIKEN cDNA C030039L03 
11 ENSMUSG00000023088  CATGGGAACCAAAATGAACAAA ATP-binding cassette, sub-family C (CFTR/MRP), member 1  
12 ENSMUSG00000035051  CCATTGTTAGCTAATGAACAAA expressed sequence AW494914  
13 ENSMUSG00000053870 TGGTAGTGATGCTGTGAACAAA fucose-1-phosphate guanylyltransferase  
14 ENSMUSG00000049928  AGAGTGAGCCATGATGAACAAG glucagon-like peptide 2 receptor  
15 ENSMUSG00000021870  CCACTGAGCTATTGGGAACAAG sarcolemma associated protein  
16 ENSMUSG00000044081  CATGTTAAGCGCGAAGAACAAG RIKEN cDNA 4930441O14 gene  
17 ENSMUSG00000031958  CAGAAAAAGTTGAAAGAACAAA lactate dehydrogenase D 
18 ENSMUSG00000042156  GTAACACAGTGCCGAGAACAAA Zinc finger protein DZIP1  
19 ENSMUSG00000025956  TTAGAGCTGCTCAAGGAACAAA RIKEN cDNA 2310038H17 gene  
 164 
20 ENSMUSG00000050295  TCTGAGTTGGCACATGAACAAA forkhead box C1 
21 ENSMUSG00000038022  CGAGCTGGAGGCAAAGAACAAG NM_177883, NM_177883.2 
22 ENSMUSG00000042074  AGCACGCAGAAGAAAGAACAAA Mus musculus 12 days embryo eyeball cDNA 
23 ENSMUSG00000057522 GTGTCTGACTGAGCAGAACAAA speckle-type POZ protein  
24 ENSMUSG00000030722  CACCTTTGTGCCGGAGAACAAG nuclear factor of activated T-cells, calcineurin-dependent 2 interacting protein  
25 ENSMUSG00000030319 CACTCAGGTCGTAGTGAACAAA cullin-associated and neddylation-dissociated 2 
26 ENSMUSG00000021820  AGCCAGCTGAGAAGAGAACAAA calcium/calmodulin-dependent protein kinase II gamma  
27 ENSMUSG00000022865  CCTCTAAGAGTCAGTGAACAAA coxsackievirus and adenovirus receptor  
28 ENSMUSG00000033542  GTCTTCTGAGCTCATGAACAAG Rho guanine nucleotide exchange factor (GEF) 5 
29 ENSMUSG00000030678  CTGGAGCCAGAGGCAGAACAAG MYC-associated zinc finger protein  
30 ENSMUSG00000025907  TTAAAAGCTGGCACTGAACAAA RB1-inducible coiled-coil 1 
31 ENSMUSG00000018470  AGTAGCGATTCGCATGAACAAA potassium voltage-gated channel, shaker-related subfamily, beta member 3  
32 ENSMUSG00000033342 ACACGATGATAAAACGAACAAG RIKEN cDNA 4833424O15 gene  
33 ENSMUSG00000052917  CCAGCCGAAGGTGATGAACAAA SUMO1/sentrin specific protease 7 
34 ENSMUSG00000047261 TCAATGTGATGGAATGAACAAA growth associated protein 43  
35 ENSMUSG00000001829  GAAACATGCAGCGGAGAACAAG suppressor of K+ transport defect 3  
36 ENSMUSG00000045817  GTTGTGATGCGGAAAGAACAAA zinc finger protein 36, C3H type-like 2 
37 ENSMUSG00000031021  GATGTGGGCAGCTTTGAACAAG RIKEN cDNA 2310004K06 gene  
38 ENSMUSG00000033420 AAGTCGTGATGGGCAGAACAAA anthrax toxin receptor 1  
39 ENSMUSG00000026782  CTGGTGATGCTAGAAGAACAAG abl-interactor 2 
40 ENSMUSG00000020057 CACGCATAAATGGATGAACAAG RIKEN cDNA 1200002N14 gene  
41 ENSMUSG00000055044  ATGGCGGAGTGAAGGAACAAAC PDZ and LIM domain 1  
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42 ENSMUSG00000023828 TCCAGGAAGCAGGATGAACAAA solute carrier family 22  
43 ENSMUSG00000031174 CCTGAGTTTGTGAATGAACAAG retinitis pigmentosa GTPase regulator  
44 ENSMUSG00000034998  CTAAGGCAGCTGGAGGAACAAG forkhead box N2  
 
 
10.2  Gene names & sequences of miR-296 target predictions tested 
Rank ENSEMBL GENE-ID  TESTED TARGET SITE ENSEMBL DESCRIPTION 
1 ENSMUSG00000037904  CCTTCAGGATAAAGGGGCCCT Ankyrin repeat domain 9. 
2 ENSMUSG00000033751  AGGGAGGAGATGCTGGGGCCC papillomavirus L2 interacting nuclear protein 1. 
3 ENSMUSG00000059810  GATTGCAGTTAGGAGGGGCCC regulator of G-protein signaling 3; C2 membrane binding, PDZ protein/protein interaction, ATP/GTP binding domains. 
4 ENSMUSG00000047415  CGGAGAGATGTCAGGGGCCCT Sphingosylphosphorylcholine receptor (G protein-coupled receptor 68). 
5 ENSMUSG00000024146  GACTGAGAGCCATGGGGCCCA postsynaptic protein Cript; CRIPT protein. 
6 ENSMUSG00000026754 TGTGTTGTGGCTGTGGGGCCC Golgi autoantigen, golgin subfamily A member 1 (Golgin-97). 
7 ENSMUSG00000063931 CACTCAGTGAGACTGGGCCCT Xaa-Pro dipeptidase (X-Pro dipeptidase) (Proline dipeptidase) (Prolidase) (Imidodipeptidase) (Peptidase 4). 
8 ENSMUSG00000020657  TCCCTGGGAATGAGGGGCCCG Rab-related GTP-binding protein. 
9 ENSMUSG00000030032  CAGTAGGGCTGAGTGGGCCCT D3Mm3e protein. 
10 ENSMUSG00000031393 AGGGAGTGACACCAGGGCCCT Methyl-CpG-binding protein 2 (MeCP-2 protein) (MeCP2). 
11 ENSMUSG00000037531  AAAGGCATGAGGAAGGGTCCT 39s ribosomal protein L47, mitochondrial precursor (L47mt) (MRP-L47) (Fragment). 
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12 ENSMUSG00000032099  TGGATTGTCAGGGTGGGTCCT Seminal vesicle protein 7 precursor (SVS VII) (Caltrin) (Calcium transport inhibitor). 
13 ENSMUSG00000026208  ATGGAAGAGTGGGGGGCCTGA Desmin. 
14 ENSMUSG00000029767  AGGATGTACAGAGGGGGCTCT Calumenin precursor (Crocalbin). 
15 ENSMUSG00000028101  ACTGAGGGATGAGGGGGTCCT Protein inhibitor of activated STAT protein 3. 
16 ENSMUSG00000021483  TGTGCTTGAGGGCTGGGCTCT cell cycle related kinase; CDK-related protein kinase PNQLARE. 
17 ENSMUSG00000046997  ATCTTTAGGAAGCGGGGCCTT SPRY domain-containing SOCS box 4; SPRY domain-containing SOCS box protein SSB-4. 
18 ENSMUSG00000030825  AGGATTCTAGGCAGGGGCTCT dehydrogenase/reductase (SDR family) member 10. 
19 ENSMUSG00000023017  GGGGGCAGCAGGAGGGGCTCT amiloride-sensitive cation channel 2, neuronal; acid sensing ion channel; degenerin 2. 
20 ENSMUSG00000033735  GGGGTGAGGAGGGTGGGCTCT Sepiapterin reductase (SPR). 
21 ENSMUSG00000026764  GGAGTCTGATGGAGGGGTCCT Kinesin heavy chain isoform 5C (Kinesin heavy chain neuron-specific 2). 
22 ENSMUSG00000031958 GGCCTGCTGGGACTGGGCCCT D-lactate dehydrogenase. 
23 ENSMUSG00000039000  GAGGTGGAGGAGAAGGGTCCT ubiquitin protein ligase E3C. 
24 ENSMUSG00000035606 AGAGACAGAGGCCAGGGCCCT kyphoscoliosis. 
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10.3   Gene names & sequences of miR-134 target predictions tested 
Rank ENSEMBL GENE-ID  TESTED TARGET SITE ENSEMBL DESCRIPTION 
1 ENSMUSG00000063613 CTTTTTGTAAGAAACAGTCACA RECORD HAS BEEN REMOVED      
2 ENSMUSG00000041098 TGCCTCTGGCACAGCAGTCACA RECORD HAS BEEN REMOVED      
3 ENSMUSG00000051314 ATCCTCTGTGTCACCAGTCACT G protein-coupled receptor 43.   
4 ENSMUSG00000056069 AGGTTTCAGTTAGCCAGTCACA cDNA sequence BC052328   
5 ENSMUSG00000041977 CTGGCATGTTCAACCAGTCACA Rho guanine nucleotide exchange factor (GEF) 11  
6 ENSMUSG00000027180 ATTACCTGGCAACACAGTCACC F-box only protein 3     
7 ENSMUSG00000028137  GCCTCTCTGCCAGTCAGTCACA trinucleotide repeat containing 4        
8 ENSMUSG00000056131 AACTTTCTGATTAGTAGTCACA phosphoglucomutase 3     
9 ENSMUSG00000050379 CTCAAAGGTGTGATCAGTCACT septin 6         
10 ENSMUSG00000036985 TTTTCTTTGGTCTTTAGTCACC zinc finger, DHHC domain containing 9    
11 ENSMUSG00000018486 TTGGTCAAAGCCAGTCACT Wnt-9b protein precursor (Wnt-15) (Wnt-14b).     
12 ENSMUSG00000030869 CCACACATCTGGCCTAGTCACA NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1  
13 ENSMUSG00000054266 ATCCTGAGGTAACCCAGTCACA serine (or cysteine) proteinase inhibitor, clade B, member 9d; serine protease inhibitor 9.      
14 ENSMUSG00000028980 AGGGCTTTACCAATCAGTCACA hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase).  
15 ENSMUSG00000026398 TGCTGAATGTCAAATAGTCACA Orphan nuclear receptor NR5A2 (Liver receptor homolog LRH-1) 
16 ENSMUSG00000059857 ACTTTATCATTATCCAGTCACA Netrin G1 precursor (Laminet-1).         
17 ENSMUSG00000050244 TGTGCTCTGGGAAGAAGTCACA HEAT repeat containing 1         
18 ENSMUSG00000039981 CACCCCTTTATTACTAGTCACA zinc finger CCCH-type containing 12D     
19 ENSMUSG00000039358  TCTTTTTTCTTAGTCAGTCACA D(1B) dopamine receptor (D(5) dopamine receptor).        
20 ENSMUSG00000037411 AATCGTTTGTGTTCCAGTCACA serine (or cysteine) peptidase inhibitor, clade E, member 1  
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21 ENSMUSG00000025326 TTTGCTTCTAACACCAGTCACA Ubiquitin-protein ligase E3A (Oncogenic protein- associated protein E6-AP).      
22 ENSMUSG00000026227  CCCTCTGAGTCTGTGAGTCACA PREDICTED: hypothetical protein LOC72792         
23 ENSMUSG00000063672  ATCAGCTGGTTAGGGAGTCACA NKX6-3 (Fragment).       
24 ENSMUSG00000052591  CCCCCTGCCTCACACAGTCACA RIKEN cDNA 3110070M22 gene (3110070M22Rik), mRNA         
25 ENSMUSG00000039108  AGCACAGGGTGAGCCAGTCACA cDNA sequence BC040823   
26 ENSMUSG00000003227  GGCGTGTGTCTGTCCAGTCACA Tumor necrosis factor receptor superfamily member EDAR precursor (Anhidrotic ectodysplasin receptor 1)  
27 ENSMUSG00000042448  CCTTGGGTCTACAGAAGTCACA Homeobox protein Hox-D1 (Hox-4.9).       
28 ENSMUSG00000024143  TTAAATGTTCATACCAGTCACA ras homolog gene family, member Q; small GTPase Tc10; ras-like protein.  
29 ENSMUSG00000030556) GTGTGATCTCTTTGCAGTCACA leucine rich repeat containing 28        
30 ENSMUSG00000031392  TGTGTTTGAGTCATGAGTCACA Interleukin-1 receptor-associated kinase 1 (IRAK-1) (IRAK) (Pelle-like protein kinase) (mPLK).   
31 ENSMUSG00000000782 ACTCTGTGGTCAACCAGCCACA transcription factor 7, T-cell specific  
32 ENSMUSG00000027746  AGAAGCTGTTAATATAGTCACA ubiquitin-fold modifier 1        
33 ENSMUSG00000020707  AGCCTGTGGTCAACAAGTCACA RIKEN cDNA 2410006N06; U 2-3-0.  
34 ENSMUSG00000032059  TCAAAGTCTAATCAAAGTCACA disrupted in bipolar disorder 1 homolog (human)  
35 ENSMUSG00000024683) TTTGTGTTCAAGGCCAGTCACA mitochondrial ribosomal protein L16      
36 ENSMUSG00000032440  TAGCACTTGACAATCAGTCACA TGF-beta receptor type II precursor (TGFR-2) (TGF-beta type II receptor).        
37 ENSMUSG00000036523  AACCTTGGGTTATCATGTCACG gene regulated by estrogen in breast cancer protein      
38 ENSMUSG00000030232  CGACTTATTTTAACCGGTTACA AE binding protein 2     
39 ENSMUSG00000024526  ATACTGTAATAAACCAGTCACA Cell death activator CIDE-A (Cell death-inducing DFFA-like effector A).  
40 ENSMUSG00000026069  CCTTATTTGCTTACCAGTCACA interleukin 1 receptor-like 1    
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41 ENSMUSG00000035342  AACCCTCTGTGTCACCGTCACC leucine zipper, putative tumor suppressor 2      
42 ENSMUSG00000036405  GTTGTCTGTGTTAGCTGTCACA RECORD_REMOVED      
43 ENSMUSG00000031847  ACTAGAAGGCTTATTAGTCACA RIKEN cDNA 1700030J22 gene (1700030J22Rik), mRNA         
44 ENSMUSG00000023960  AGCTTCTCACAAGCTAGTCACA ectonucleotide pyrophosphatase/phosphodiesterase 5       
45 ENSMUSG00000021481  TCCTTTATTTGGATCAGTCACA zinc finger protein 346  
46 ENSMUSG00000049624 GCGTGGTACCCAGTCAGTCACA Sialin (Solute carrier family 17 member 5) (Sodium/sialic acid cotransporter).   
47 ENSMUSG00000050700  TACTAACCAGGGACCAGTCACA EMILIN 5 precursor (Elastin microfibril interface located protein 5) (Elastin microfibril interfacer 5).         
48 ENSMUSG00000046807  TTCCTTTGGTTTTAGGGTCACA expressed sequence AI646023      
49 ENSMUSG00000020393  AACCTGTAGGCAGCCAGTCACA Kremen protein 1 precursor (Kringle-containing protein marking the eye and the nose) (Dickkopf receptor).        
50 ENSMUSG00000030609  TTTGTGTATAATGTTAGTCACA interferon stimulated exonuclease gene 20-like 1         
51 ENSMUSG00000001089  GACTTTTGGATAACCAGTTTCA leucine zipper protein 1         
52 ENSMUSG00000026788  AGACTCATGTTCCCCAGTCACA Zinc finger protein 297B.        
53 ENSMUSG00000031077  AACTGTCCTGTGGCAAGTCACA FADD protein (FAS-associating death domain-containing protein) (Mediator of receptor induced toxicity).  
54 ENSMUSG00000000127 TAGGACTCTGTCCTCAGTCACC fer (fms/fps related) protein kinase, testis specific 2.     
55 ENSMUSG00000024983  GGGCCGTGATGACTCAGTCACA vesicle transport through interaction with t-SNAREs homolog 1A (yeast)   
56 ENSMUSG00000025203  CAAGAGTTGAACTTGAGTCACA stearoyl-Coenzyme A desaturase 2         
57 ENSMUSG00000042365  GTGGTGCTAGCCTGCAGTCACA RIKEN cDNA A530023G15 gene       
58 ENSMUSG00000021932  GTGCATGGGTCACCGAGTCACA RIKEN cDNA 2610207P08 gene (2610207P08Rik), mRNA         
59 ENSMUSG00000054667  GTCACAGGTACAAATAGTCACA insulin receptor substrate 4.    
60 ENSMUSG00000024535  GCCAGCCTCTGCTTCAGTCACA sorting nexing 24.       
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61 ENSMUSG00000031924  ATGCTGGGATAGCGAAGTCACA cytochrome b5 outer mitochondrial membrane precursor.    
62 ENSMUSG00000021266  CACCCTGTCAAATCAAGTCACA Tryptophanyl-tRNA synthetase (Tryptophan--tRNA ligase) (TrpRS).  
63 ENSMUSG00000025036  AGTAACGTTCAGTCCAGTCACA Sideroflexin 2.  
64 ENSMUSG00000034341  GCAGACTGTCAGTCCAGTCACA WW domain binding protein 2 (WBP-2).     
65 ENSMUSG00000028057  TTCTTTTCTGGCAACTGTCACA Ras-like without CAAX 1  
66 ENSMUSG00000027887 TCCATCTCCTCAGACAGTCACA Mitsugumin 29.   
67 ENSMUSG00000000276  AAATCTGCTGGTCACAGTCACA Diacylglycerol kinase, epsilon (Diglyceride kinase) (DGK-epsilon) (DAG kinase epsilon).  
68 ENSMUSG00000055436) AATCCCTTTGTCACCAGTCACT splicing factor, arginine/serine-rich 11         
69 ENSMUSG00000027430 CCATTTCCATCATTGAGTCACA histidyl tRNA synthetase 2       
70 ENSMUSG00000031443  GGGGCTGGGCAGTGCAGTCACA coagulation factor VII   
71 ENSMUSG00000021756  TGCCTCTAAGGACAAAGTCACA interleukin 6 signal transducer  
72 ENSMUSG00000048773  TTAATTCTGGTGACAAGTCACG Peptidyl-tRNA hydrolase 2, mitochondrial precursor (PTH 2).  
73 ENSMUSG00000003154  GCATCTGGTGGGCCAGTGTATG forkhead box J2  
74 ENSMUSG00000005686 CCAAGCTCCTGATCCAGTCACA AMP deaminase 3 (AMP deaminase isoform E) (AMP deaminase H-type) (Heart-type AMPD).      
75 ENSMUSG00000028657 TGGTCTTGAACTCACAGTCACA Palmitoyl-protein thioesterase 1 precursor (Palmitoyl- protein hydrolase 1).     
76 ENSMUSG00000042201 TCCATCTGGTGCATGGGTCACA RIKEN cDNA C530024P05 gene (C530024P05Rik), mRNA         
77 ENSMUSG00000047910  TGTGGGCACTCAATGAGTCACA protocadherin beta 16.   
78 ENSMUSG00000047091  GTAACTGAGTCAATTAGTTAAG PDZ domain containing 6  
79 ENSMUSG00000042129  GGCTGCAGTTAACCAGTATATA Ras association (RalGDS/AF-6) domain family 4    
80 ENSMUSG00000002881  CCACAGGCTCTAAGCAGTCACA NGFI-A binding protein 1 (EGR-1 binding protein 1).      
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81 ENSMUSG00000046598  ACCTTCTCCTGAGCCAGTCACA 3-hydroxybutyrate dehydrogenase (heart, mitochondrial); D-beta-hydroxybutyrate dehydrogenase.    
82 ENSMUSG00000005649  AGAGAGTGTCCCACTAGTCACA Calcium-binding protein CaBP5.   
83 ENSMUSG00000060733  AGCTTTCTGTAGCCAGTCACCA inositol polyphosphate multikinase       
84 ENSMUSG00000024044  CTACACTGTCAACTGTGTCACA erythrocyte protein band 4.1-like 3      
85 ENSMUSG00000054843  CCCTATCTGCAACACAGTCACA attractin like 1         
86 ENSMUSG00000032030  CGACTCTATTTTGCCAGTCACA Cullin homolog 5 (CUL-5).        
87 ENSMUSG00000041774  ATCTCCTGGAACTAGAGTCACA Ubiquitin-conjugating enzyme E2L 3.      
88 ENSMUSG00000042642 CCTTCACCAAGGATGGGTCACA RFad1, flavin adenine dinucleotide synthetase, homolog (yeast)   
89 ENSMUSG00000019803  GCCATAGGGTCAGCGAGTCACA Orphan nuclear receptor NR2E1 (Nuclear receptor TLX) (Tailless homolog) (Tll) (mTll).    
90 ENSMUSG00000029670  GAGCTCTGTCAGCTCAGTCGCA inhibitor of growth family, member 3     
91 ENSMUSG00000009418  AAACACCTCTGAGACAGTCACA neuron navigator 1.      
92 ENSMUSG00000038446  CTTGACTCTCTTCCTAGTCACG Pre-mRNA splicing factor PRP17 (Cell division cycle 40 homolog).         
93 ENSMUSG00000031748  TATTTACTGAAGACCAGTCACA Guanine nucleotide-binding protein G(o), alpha subunit 1.    
94 ENSMUSG00000035311  ATATTGGTCATGCTGTGTTATG v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian)         
95 ENSMUSG00000020719  GGGGTCTTGTAGGCTAGTCACA Probable RNA-dependent helicase p68 (DEAD-box protein p68) (DEAD-box protein 5) (DEAD-box RNA helicase DEAD1) (mDEAD1). 
96 ENSMUSG00000040441  CAGCTCTGGCACATCAGCCATG expressed sequence C78409 (C78409), mRNA         
97 ENSMUSG00000022987  CTTTTTGGTGACTGTGTTAATA zinc finger protein 641  
98 ENSMUSG00000033475  GTATGTTCTGTCAGCTAGTCAC RIKEN cDNA 1110002E23 gene (1110002E23Rik), mRNA         
99 ENSMUSG00000003119  CTCTAATCAATTCTGAGTCACA CDC2-related protein kinase 7; protein kinase for splicing component.    
100 ENSMUSG00000048982  ACAGTGAGGTGACCAGTTACAA glycoprotein hormone beta 5      
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101 ENSMUSG00000001444 CTCTGCCCGAACTACAGTCACG T-box 21; T-box transcription factor.    
102 ENSMUSG00000041598  TGCCTCTGGCCAGCAGTACACA CDC42 effector protein (Rho GTPase binding) 4    
103 ENSMUSG00000041936  CGGCACTTGTGACCCAGTCACA agrin.   
104 ENSMUSG00000058900  CTAATTTGGGTAAACAGTTATA regulator of sex limited protein-Slp 1   
105 ENSMUSG00000008730  CACTCTCATGGCAACCAGTACA homeodomain interacting protein kinase 1         
106 ENSMUSG00000051147  GGGCCCAAGAAAACCAGTCACA Arylamine N-acetyltransferase 2 (Arylamide acetylase 2) (N-acetyltransferase type 2) (NAT-2).    
107 ENSMUSG00000025577  TTTACTGGTTACGTCAGTCCCA chromobox homolog 2 (Drosophila Pc class)        
108 ENSMUSG00000018209  TCCTGTGGGGCTGGTAGTCACA serine/threonine kinase 4; STE20-like kinase MST1; Yeast Sps1/Ste20-related kinase 3 (S. cerevisiae).    
109 ENSMUSG00000043468  TCTCTGCTGGTACAGCAGTCAA a disintegrin and metallopeptidase domain 30     
110 ENSMUSG00000053870  TACACTGGTAGCTATGTACACA fucose-1-phosphate guanylyltransferase   
111 ENSMUSG00000022772 GTGCTGTGGAAAGCCAGTCACA SUMO/sentrin specific protease 5.        
112 ENSMUSG00000050890  GGGACTGGTAATCACTGTCACA PDLIM1 interacting kinase 1 like         
113 ENSMUSG00000026078  CCAGTCTGGTTTGCATAGTTAC phosducin-like 3         
114 ENSMUSG00000053838) AGCAGAATCTGTCGTAGTCACA NudC domain containing 3         
115 ENSMUSG00000017652  GCACGGGTGTCAGCCTGTCACA CD40 antigen     
116 ENSMUSG00000048458 CTTGGCTTGTGGACCAGTCATA RIKEN cDNA 6530418L21 gene (6530418L21Rik), mRNA         
117 ENSMUSG00000026383 TCCTACTGAGTCACTAGTTACA erythrocyte protein band 4.1-like 5      
118 ENSMUSG00000049699 CTAGCTGAGTCTGGCAGTCACA Urocortin II precursor (Ucn II).         
119 ENSMUSG00000027164  GCCTTGCCCTCTTCCAGTCACA TNF receptor associated factor 6.        
120 ENSMUSG00000053004  GACTGTGTGGCTTCTAGTCACA Histamine H1 receptor.   
121 ENSMUSG00000038827  CTTTCAAGTTGTATTAGTTACT cDNA sequence BC026590   
122 ENSMUSG00000028654  TTCTCTGCCGGCCTGAGTCACA L-myc proto-oncogene protein.    
123 ENSMUSG00000051412  GCCAACTATTAGCCTAGTCATG synaptobrevin like 1     
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124 ENSMUSG00000045854  AGAGCTGTATTAAAGGGTCACA RIKEN cDNA 2610208E05 gene (2610208E05Rik), mRNA         
125 ENSMUSG00000038879  TGAGAGGCTCAGCTATGTTATA NIPA-like domain containing 2    
126 ENSMUSG00000055538  CCTGGCATGTCACATGGTCGCA RIKEN cDNA 2310047A01 gene (2310047A01Rik), mRNA         
127 ENSMUSG00000059994  TACTTCTGAGTCACTGTCATCA Fc receptor-like 1       
128 ENSMUSG00000021867  AGACCCTCTGGTTACTATTATT Adult male small intestine cDNA, RIKEN full-length enriched library, clone:2010100M18  
129 ENSMUSG00000026163  CTCTATCCCAGCTTAGGTCACA sphingosine kinase type 1-interacting protein    
130 ENSMUSG00000032202  TGTCTGTATTTAAGCAGTCACA Ras-related protein Rab-27A.     
131 ENSMUSG00000026585  GTCCTTTGGACAATACAGTCCA kinesin-associated protein 3     
132 ENSMUSG00000051803 CGTGACTGTCAGCCAGTCAGCA No description</p>       
133 ENSMUSG00000028266  TGTCTGCAGTAGACCAGTCACC LIM domain transcription factor LMO4 (LIM-only protein 4) (LMO-4) (Breast tumor autoantigen).    
134 ENSMUSG00000044313  CCAGGCCGTCAGCTAGCTCACC cDNA sequence BC037703   
135 ENSMUSG00000046275 TTCTTCTCATCTCCTAGTCACA tumor suppressor candidate 5 (Tusc5), mRNA       
136 ENSMUSG00000057784  TACTATTTTCAACCAGTTACTA RECORD_REMOVED      
137 ENSMUSG00000030168  GACTCTGGTTCAACATAGCACA adiponectin receptor 2   
138 ENSMUSG00000028572  AGTTCATGTGCAGCGAGTCACA Hook homolog 1.  
139 ENSMUSG00000025781  AAACTTGGTCCACTGAGTTACA ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1     
140 ENSMUSG00000001021 CATCTCTGCTCAGCCATGTGCA S100 calcium binding protein A3  
141 ENSMUSG00000063888  AGACATTCTGGCAGCTAGTATA ribosomal protein L7-like 1      
142 ENSMUSG00000028868  AAGTGACTCTCTCAAGGTCACA WAS protein family, member 2     
143 ENSMUSG00000021712  ATGCTTATGGTTAACAGTTACT tripartite motif protein 23      
144 ENSMUSG00000030560  CTCACAGAGTGATTTAGTCACA cathepsin C      
145 ENSMUSG00000034101 ACTGTCTGTTCAGCAGTCAGCA catenin (cadherin associated protein), delta 1   
146 ENSMUSG00000031285 GTTCTACCCCTGTTCAGTCACA Doublecortin (Lissencephalin-X) (Lis-X) (Doublin).       
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147 ENSMUSG00000047694 GAAAACGTGTTAACTAGTTTCA Yip1 domain family, member 6     
148 ENSMUSG00000047139 ATACTTTGGTTATCCATTCATA CD24a antigen    
149 ENSMUSG00000049076 ATTCAGAGTTAGCTACGTCACT centaurin, beta 2        
150 ENSMUSG00000046541 AACCAGGAATGAACCAGTCACA zinc finger protein 526.         
151 ENSMUSG00000026489 AAGTCTGGTTAATTAGGTGATA chaperone, ABC1 activity of bc1 complex like (S. pombe)  
152 ENSMUSG00000047462 AATTCTCTGGTGATTAGTAGCA RIKEN cDNA A530099J19 gene (A530099J19Rik), mRNA         
153 ENSMUSG00000024844 TTTTTTGGCAAAAACAGTCACT Barrier-to-autointegration factor (Breakpoint cluster region protein 1) (LAP2-binding protein 1).        
154 ENSMUSG00000021303 AGTGTCACAAGCCTAAGTTATG guanine nucleotide binding protein (G protein), gamma 4 subunit  
155 ENSMUSG00000042579 TCTCCTGGCTCAGCTGTCACCA RIKEN cDNA 4632404H12 gene (4632404H12Rik), mRNA         
156 ENSMUSG00000038736 AATCTTTCTTTCTCTAGTCACA chronic myelogenous leukemia tumor antigen 66.   
157 ENSMUSG00000045885 TGGGTCTGGAGCTCGGCTCACA No description</p>       





10.4     Luciferase results for predicted neural MREs 
Relative Luciferase Activity (134 vs Scr) No Gene 293T Neuro2As 
1 Acvr1c 1.32 1.06 
2 Akt3 0.68 1.09 
3 Aph1b 0.75 0.89 
4 Bmp15 0.73 1.13 
5 Bmp2k 0.75 0.79 
6 Bmp8b 0.33 0.49 
7 Bmper 0.68 1.08 
8 Bmpr1b 0.73 1.04 
9 Chrdl1 0.27 0.16 
10 Chrdl1 0.32 0.36 
11 Chrdl1 0.44 0.39 
12 Chrdl1 0.75 0.89 
13 Ctnnb1 0.72 1.01 
14 Dpp8 0.67 1.01 
15 Dpp8 0.72 1.04 
16 Dpp8 0.71 0.92 
17 Dcx 0.19 0.30 
18 Dpp8 0.98 1.10 
19 Dtx4 0.39 0.57 
20 E2f1 0.77 1.04 
21 E2f3 0.73 1.01 
22 Efnb2 0.59 1.04 
23 Egfr 1.23 0.88 
24 Fzd6 0.65 0.74 
25 Gab1 0.93 0.84 
26 Hhip 0.53 1.17 
27 Hoxa1 1.04 1.09 
28 Hoxb13 0.79 0.91 
29 Hoxc10 0.47 0.51 
30 Zfp42 0.79 1.03 
31 Myb 0.66 1.34 
32 Mybl2 0.83 0.90 
33 Notch1 0.75 1.09 
34 Ntn2l 1.13 1.35 
35 Otx2 0.76 1.16 
36 Sema3c 0.97 1.17 
37 Sfrp2 0.91 0.85 
38 Shh 0.87 1.28 
39 Smad3 0.92 1.07 
40 Smad5 1.03 0.96 
41 Tcf12 0.61 0.65 
42 Tcf4 0.97 1.17 
43 Tcf7 1.12 0.91 
44 Tgfb2 0.85 1.07 
45 Tgfbr1 1.10 0.86 
46 Tgfbr3 0.59 1.21 
47 Tgfbr3 0.68 0.92 
48 134 RC 0.07 0.03 
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10.5  Summary of rna22’s predictions for four model genomes 
 
(adapted from Table 1 of Miranda et al., 2006)
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